These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
Title of each class:
|
Trading Symbol:
|
Name of each exchange on which registered:
|
|
Common stock, represented by CHESS Units of Foreign Securities
|
JHX
|
New York Stock Exchange*
|
|
CHESS Units of Foreign Securities
|
JHX
|
New York Stock Exchange*
|
|
American Depositary Shares, each representing one unit of CHESS Units of Foreign Securities
|
JHX
|
New York Stock Exchange
|
|
* Listed, not for trading, but only in connection with the registered American Depositary Shares, pursuant to the requirements of the U.S. Securities and Exchange Commission
|
||
|
Large accelerated filer
|
|
☒
|
|
Accelerated filer
|
|
☐
|
|
Non-accelerated filer
|
|
☐
|
|
Emerging growth company
|
|
☐
|
|
US GAAP
|
|
☒
|
|
International Financial Reporting Standards as issued by the International Accounting
Standards Board
|
|
☐
|
|
Other
|
|
☐
|
|
|
|
|
|
Page(s)
|
|
|
|
|
|
Page(s)
|
|
PART 1
|
|
|
Item 1. Identity of Directors, Senior Management and Advisers
|
Not applicable
|
|
Item 2. Offer Statistics and Expected Timetable
|
Not applicable
|
|
Item 3. Key Information
|
|
|
A. Selected Financial Data
|
2-3
|
|
B. Capitalization and Indebtedness
|
Not applicable
|
|
C. Reasons for the Offer and Use of Proceeds
|
Not applicable
|
|
D. Risk Factors
|
171-188
|
|
Item 4. Information on the Company
|
|
|
A. History and Development of the Company
|
4-5; 17-18; 212
|
|
B. Business Overview
|
6-13
|
|
C. Organizational Structure
|
5; 14
|
|
D. Property, Plants and Equipment
|
15-18; 114
|
|
Item 4A. Unresolved Staff Comments
|
None
|
|
Item 5. Operating and Financial Review and Prospects
|
|
|
A. Operating Results
|
95-110
|
|
B. Liquidity and Capital Resources
|
111-115
|
|
C. Research and Development, Patents and Licenses, etc.
|
12
|
|
D. Trend Information
|
115
|
|
E. Off-Balance Sheet Arrangements
|
115-116
|
|
F. Tabular Disclosure of Contractual Obligations
|
116
|
|
G. Safe Harbor
|
89-90
|
|
Item 6. Directors, Senior Management and Employees
|
|
|
A. Directors and Senior Management
|
19-29
|
|
B. Compensation
|
30-68
|
|
C. Board Practices
|
24-29; 69-88
|
|
D. Employees
|
193
|
|
E. Share Ownership
|
58-61; 64-68
|
|
Item 7. Major Shareholders and Related Party Transactions
|
|
|
A. Major Shareholders
|
216-218
|
|
B. Related Party Transactions
|
80
|
|
C. Interests of Experts and Counsel
|
Not Applicable
|
|
Item 8. Financial Information
|
|
|
A. Consolidated Statements and Other Financial Information
|
117-169; 201-202
|
|
B. Significant Changes
|
None
|
|
Item 9. The Offer and Listing
|
|
|
A. Offer and Listing Details
|
193-196
|
|
B. Plan of Distribution
|
Not Applicable
|
|
C. Markets
|
194-195
|
|
D. Selling Shareholders
|
Not Applicable
|
|
|
|
|
|
|
|
E. Dilution
|
Not Applicable
|
|
F. Expenses of the Issue
|
Not Applicable
|
|
|
|
|
A. Share Capital
|
Not Applicable
|
|
B. Memorandum and Articles of Association
|
197-204
|
|
C. Material Contracts
|
204
|
|
D. Exchange Controls
|
204-205
|
|
E. Taxation
|
205-211
|
|
F. Dividends and Paying Agents
|
Not Applicable
|
|
G. Statement by Experts
|
Not Applicable
|
|
H. Documents on Display
|
212
|
|
I. Subsidiary Information
|
Not Applicable
|
|
|
213-215
|
|
|
|
|
A. Debt Securities
|
Not Applicable
|
|
B. Warrants and Rights
|
Not Applicable
|
|
C. Other Securities
|
Not Applicable
|
|
D. American Depositary Shares
|
195-196
|
|
|
|
|
|
None
|
|
|
None
|
|
|
191-192
|
|
|
83
|
|
|
81-82
|
|
|
170
|
|
|
None
|
|
|
None
|
|
|
None
|
|
|
69-88
|
|
|
16-17
|
|
|
|
|
|
Not Applicable
|
|
|
117-169
|
|
|
223-228
|
|
|
|
(Millions of US dollars)
|
||||||||||||||||||
|
Consolidated Statement of Operations Data
|
|
2019
|
|
2018
|
|
2017
|
|
2016
|
|
2015
|
||||||||||
|
Net sales
|
|
$
|
2,506.6
|
|
|
$
|
2,054.5
|
|
|
$
|
1,921.6
|
|
|
$
|
1,728.2
|
|
|
$
|
1,656.9
|
|
|
Income from operations
1
|
|
228.8
|
|
|
146.1
|
|
|
276.5
|
|
|
244.4
|
|
|
291.3
|
|
|||||
|
Net income
1
|
|
$
|
228.8
|
|
|
$
|
146.1
|
|
|
$
|
276.5
|
|
|
$
|
244.4
|
|
|
$
|
291.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
(Millions of US dollars)
|
||||||||||||||||||
|
Consolidated Balance Sheet Data
|
|
2019
|
|
2018
|
|
2017
|
|
2016
|
|
2015
|
||||||||||
|
Total assets
|
|
$
|
4,032.6
|
|
|
$
|
2,351.0
|
|
|
$
|
2,012.7
|
|
|
$
|
2,029.4
|
|
|
$
|
2,036.4
|
|
|
Net assets
|
|
974.4
|
|
|
(221.5
|
)
|
|
(212.2
|
)
|
|
(225.2
|
)
|
|
(202.6
|
)
|
|||||
|
Common stock
|
|
$
|
230.0
|
|
|
$
|
229.5
|
|
|
$
|
229.1
|
|
|
$
|
231.4
|
|
|
$
|
231.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
(Millions)
|
||||||||||||||||||
|
Shares
|
|
2019
|
|
2018
|
|
2017
|
|
2016
|
|
2015
|
||||||||||
|
Basic weighted average number of common shares
|
|
441.9
|
|
|
441.2
|
|
|
442.7
|
|
|
445.3
|
|
|
445.0
|
|
|||||
|
Diluted weighted average number of common shares
|
|
443.0
|
|
|
442.3
|
|
|
443.9
|
|
|
447.2
|
|
|
446.4
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
|
|
(US dollar)
|
||||||||||||||||||
|
Earnings Per Share
|
|
2019
|
|
2018
|
|
2017
|
|
2016
|
|
2015
|
||||||||||
|
Income from operations per common share – basic
|
|
$
|
0.52
|
|
|
$
|
0.33
|
|
|
$
|
0.62
|
|
|
$
|
0.55
|
|
|
$
|
0.65
|
|
|
Net income per common share – basic
|
|
0.52
|
|
|
0.33
|
|
|
0.62
|
|
|
0.55
|
|
|
0.65
|
|
|||||
|
Income from operations per common share – diluted
|
|
0.52
|
|
|
0.33
|
|
|
0.62
|
|
|
0.55
|
|
|
0.65
|
|
|||||
|
Net income per common share – diluted
|
|
0.52
|
|
|
0.33
|
|
|
0.62
|
|
|
0.55
|
|
|
0.65
|
|
|||||
|
Dividends declared per share
|
|
0.40
|
|
|
0.38
|
|
|
0.39
|
|
|
0.58
|
|
|
0.60
|
|
|||||
|
Dividends paid per share
|
|
$
|
0.40
|
|
|
$
|
0.38
|
|
|
$
|
0.39
|
|
|
$
|
0.58
|
|
|
$
|
0.88
|
|
|
Other Financial Data
|
|
2019
|
|
2018
|
|
2017
|
|
2016
|
|
2015
|
||||||||||
|
Cash Flow (Millions of US dollars)
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Net cash provided by operating activities
2
|
|
$
|
287.6
|
|
|
$
|
302.0
|
|
|
$
|
382.5
|
|
|
$
|
222.9
|
|
|
$
|
186.3
|
|
|
Net cash used in investing activities
2
|
|
(848.0
|
)
|
|
(239.0
|
)
|
|
(109.0
|
)
|
|
(66.6
|
)
|
|
(277.7
|
)
|
|||||
|
Net cash provided by (used in) financing activities
2
|
|
$
|
364.2
|
|
|
$
|
60.6
|
|
|
$
|
(210.0
|
)
|
|
$
|
(121.2
|
)
|
|
$
|
(39.0
|
)
|
|
Volume (million square feet)
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
North America Fiber Cement
|
|
2,308.1
|
|
|
2,238.8
|
|
|
2,215.4
|
|
|
1,969.2
|
|
|
1,821.5
|
|
|||||
|
Asia Pacific Fiber Cement
3
|
|
546.1
|
|
|
494.7
|
|
|
448.2
|
|
|
449.6
|
|
|
456.2
|
|
|||||
|
Asia Pacific Fiber Cement excluding
4
|
|
546.1
|
|
|
494.7
|
|
|
448.2
|
|
|
439.8
|
|
|
414.6
|
|
|||||
|
Europe Building Products
5
|
|
815.8
|
|
|
34.0
|
|
|
39.0
|
|
|
31.3
|
|
|
28.2
|
|
|||||
|
Net Sales (Millions of US dollars)
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
North America Fiber Cement
|
|
$
|
1,676.9
|
|
|
$
|
1,578.1
|
|
|
$
|
1,493.4
|
|
|
$
|
1,335.0
|
|
|
$
|
1,224.7
|
|
|
Asia Pacific Fiber Cement
3
|
|
446.8
|
|
|
425.4
|
|
|
370.6
|
|
|
341.9
|
|
|
380.4
|
|
|||||
|
Asia Pacific Fiber Cement excluding
4
|
|
446.8
|
|
|
425.4
|
|
|
370.6
|
|
|
336.8
|
|
|
354.3
|
|
|||||
|
Europe Building Products
5
|
|
368.3
|
|
|
36.3
|
|
|
41.2
|
|
|
37.5
|
|
|
38.0
|
|
|||||
|
Other Businesses
|
|
$
|
14.6
|
|
|
$
|
14.7
|
|
|
$
|
16.4
|
|
|
$
|
13.8
|
|
|
$
|
13.8
|
|
|
|
|
2019
|
|
2018
|
|
2017
|
|
2016
|
|
2015
|
||||||||||
|
Average sales price per unit (per thousand square feet)
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
North America Fiber Cement
|
|
$
|
718
|
|
|
$
|
698
|
|
|
$
|
665
|
|
|
$
|
669
|
|
|
$
|
666
|
|
|
Asia Pacific Fiber Cement
3
|
|
724
|
|
|
762
|
|
|
758
|
|
|
709
|
|
|
788
|
|
|||||
|
Asia Pacific Fiber Cement excluding
4
|
|
724
|
|
|
762
|
|
|
758
|
|
|
713
|
|
|
804
|
|
|||||
|
Europe Building Products
5
|
|
$
|
354
|
|
|
$
|
950
|
|
|
$
|
977
|
|
|
$
|
986
|
|
|
$
|
1,163
|
|
|
1
|
Income from operations and net income include the following: asbestos adjustments, Asbestos Injuries Compensation Fund (“AICF”) selling, general and administrative (“SG&A”) expenses, AICF interest income (expense), loss on early debt extinguishment, Fermacell acquisition costs, product line discontinuation, non-recurring stamp duty, New Zealand weathertightness claims and related tax adjustments.
|
|
|
|
(Millions of US dollars)
|
||||||||||||||||||
|
Other Financial Data
|
|
2019
|
|
2018
|
|
2017
|
|
2016
|
|
2015
|
||||||||||
|
Asbestos adjustments (expense) benefit
|
|
$
|
(22.0
|
)
|
|
$
|
(156.4
|
)
|
|
$
|
40.4
|
|
|
$
|
5.5
|
|
|
$
|
33.4
|
|
|
AICF SG&A expenses
|
|
(1.5
|
)
|
|
(1.9
|
)
|
|
(1.5
|
)
|
|
(1.7
|
)
|
|
(2.5
|
)
|
|||||
|
AICF interest income (expense)
|
|
2.0
|
|
|
1.9
|
|
|
(1.1
|
)
|
|
(0.3
|
)
|
|
1.4
|
|
|||||
|
Loss on early debt extinguishment
|
|
(1.0
|
)
|
|
(26.1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
|
Fermacell acquisition costs
|
|
—
|
|
|
(10.0
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
|
Product line discontinuation
|
|
(29.5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
|
Non-recurring stamp duty
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(4.2
|
)
|
|||||
|
New Zealand weathertightness claims
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(0.5
|
)
|
|
4.3
|
|
|||||
|
Tax adjustments
|
|
$
|
(19.7
|
)
|
|
$
|
47.3
|
|
|
$
|
(9.9
|
)
|
|
$
|
(1.5
|
)
|
|
$
|
37.5
|
|
|
2
|
Net cash provided by operating activities, net cash used in investing activities and net cash provided by (used in) financing activities have been revised for fiscal years 2015, 2016, 2017 and 2018 to reflect the impact of Accounting Standards Update ("ASU") 2016-18. See Note 2 to our consolidated financial statements in Section 2 for details on ASU 2016-18.
|
|
3
|
Asia Pacific Fiber Cement segment includes all fiber cement products manufactured in Australia, New Zealand and the Philippines and sold in Australia, New Zealand, Asia, the Middle East and various Pacific Islands.
|
|
4
|
Excludes the Australian Pipes business which we sold in the first quarter of fiscal year 2016.
|
|
5
|
Europe Building Products segment includes the newly acquired Fermacell business and fiber cement products manufactured in the United States that are sold in Europe.
|
|
|
|
(Millions of US dollars)
|
||||||||||
|
|
|
2019
|
|
2018
|
|
2017
|
||||||
|
North America Fiber Cement
|
|
$
|
1,676.9
|
|
|
$
|
1,578.1
|
|
|
$
|
1,493.4
|
|
|
Asia Pacific Fiber Cement
|
|
446.8
|
|
|
425.4
|
|
|
370.6
|
|
|||
|
Europe Building Products
|
|
368.3
|
|
|
36.3
|
|
|
41.2
|
|
|||
|
Other Businesses
|
|
14.6
|
|
|
14.7
|
|
|
16.4
|
|
|||
|
Total Net Sales
|
|
$
|
2,506.6
|
|
|
$
|
2,054.5
|
|
|
$
|
1,921.6
|
|
|
•
|
Our fiber cement products exhibit resistance to the damaging effects of moisture, fire, impact and termites compared to natural and engineered wood and wood-based products;
|
|
•
|
Competing products do not duplicate fiber cement aesthetics and the characteristics necessary for effectively accepting paint applications;
|
|
•
|
Our fiber cement products provide the ability to imprint designs that closely resemble the patterns and profiles of traditional building materials such as wood and stucco;
|
|
•
|
The surface properties of our products provide an effective paint-holding finish, especially when compared to natural and engineered wood products, allowing for greater periods of time between necessary maintenance and repainting; and
|
|
•
|
Compared to masonry construction, fiber cement is lightweight, physically flexible and can be cut using readily available tools, making our products more appealing across a broad range of architectural styles, be it of timber or steel-framed construction.
|
|
Name of Company
|
|
Jurisdiction of
Establishment
|
|
Jurisdiction of
Tax Residence
|
|
Fermacell B.V.
|
|
Netherlands
|
|
Netherlands
|
|
James Hardie Spain S.L.U.
|
|
Spain
|
|
Spain
|
|
Fermacell Schraplau GmbH
|
|
Germany
|
|
Germany
|
|
James Hardie 117 Pty Ltd
|
|
Australia
|
|
Australia
|
|
James Hardie Australia Pty Ltd
|
|
Australia
|
|
Australia
|
|
James Hardie Building Products Inc.
|
|
United States
|
|
United States
|
|
James Hardie Europe B.V.
|
|
Netherlands
|
|
Netherlands
|
|
James Hardie Europe GmbH
|
|
Germany
|
|
Germany
|
|
James Hardie Finance Holdings 1 Limited
|
|
Bermuda
|
|
Ireland
|
|
James Hardie Europe Holdings 1 GmbH
|
|
Germany
|
|
Germany
|
|
James Hardie Europe Holdings 2 GmbH
|
|
Germany
|
|
Germany
|
|
James Hardie Holdings Limited
|
|
Ireland
|
|
Ireland
|
|
James Hardie International Finance Designated Activity Company
|
|
Ireland
|
|
Ireland
|
|
James Hardie International Group Limited
|
|
Ireland
|
|
Ireland
|
|
James Hardie International Holdings Limited
|
|
Ireland
|
|
Ireland
|
|
James Hardie New Zealand Limited
|
|
New Zealand
|
|
New Zealand
|
|
James Hardie NL1 B.V.
|
|
Netherlands
|
|
Netherlands
|
|
James Hardie NL2 B.V.
|
|
Netherlands
|
|
Netherlands
|
|
James Hardie NZ Holdings Limited
|
|
New Zealand
|
|
New Zealand
|
|
James Hardie North America, Inc
|
|
United States
|
|
United States
|
|
James Hardie NV
|
|
Netherlands
|
|
Netherlands
|
|
James Hardie Philippines Inc
|
|
Philippines
|
|
Philippines
|
|
James Hardie Research (Holdings) Pty Ltd
|
|
Australia
|
|
Australia
|
|
James Hardie Research Pty Ltd
|
|
Australia
|
|
Australia
|
|
JH Research USA, LLC
|
|
United States
|
|
United States
|
|
James Hardie Technology Holdings 1 Limited
|
|
Ireland
|
|
Ireland
|
|
James Hardie Technology Holdings 2 Limited
|
|
Ireland
|
|
Ireland
|
|
James Hardie Technology Limited
|
|
Bermuda
|
|
Ireland
|
|
James Hardie U.S. Investments Sierra Inc.
|
|
United States
|
|
United States
|
|
RCI Holdings Pty Ltd
|
|
Australia
|
|
Australia
|
|
Plant Location
|
|
Owned /
Leased
|
|
Nameplate Capacity
(mmsf)
1
|
|
|
United States fiber cement
2
|
|
|
|
|
|
|
Cleburne, Texas
|
|
Owned
|
|
666
|
|
|
Peru, Illinois
|
|
Owned
|
|
560
|
|
|
Plant City, Florida
|
|
Owned
|
|
600
|
|
|
Pulaski, Virginia
|
|
Owned
|
|
600
|
|
|
Reno, Nevada
|
|
Owned
|
|
300
|
|
|
Tacoma, Washington
|
|
Owned
|
|
500
|
|
|
Waxahachie, Texas
|
|
Owned
|
|
360
|
|
|
Fontana, California
|
|
Owned
|
|
250
|
|
|
Summerville, South Carolina
|
|
Owned
|
|
190
|
|
|
Asia Pacific fiber cement
|
|
|
|
|
|
|
Australia
|
|
|
|
|
|
|
Rosehill, New South Wales
|
|
Owned
|
|
180
|
|
|
Carole Park, Queensland
|
|
Owned
|
3
|
160
|
|
|
New Zealand
|
|
|
|
|
|
|
Auckland
|
|
Leased
|
4
|
75
|
|
|
Philippines
|
|
|
|
|
|
|
Cabuyao City
|
|
Owned
|
5
|
172
|
|
|
Europe fiber gypsum
|
|
|
|
|
|
|
Münchehof, Germany
|
|
Owned
|
|
441
|
|
|
Orejo, Spain
|
|
Owned
|
|
275
|
|
|
Wijchen, the Netherlands
|
|
Owned
|
|
273
|
|
|
Siglingen, Germany
|
|
Owned
|
|
154
|
|
|
Other
|
|
|
|
|
|
|
Calbe, Germany
|
|
Owned
|
6
|
41
|
|
|
Schraplau, Germany
|
|
Owned
|
7
|
N/A
|
|
|
1
|
The calculated annual nameplate capacity in the United States, Europe and Asia Pacific is based on management’s historical experience with our production process and is calculated assuming continuous operation, 24 hours per day, seven days per week, producing 5/16” medium density product at a targeted operating speed. No accepted industry standard exists for the calculation of our fiber cement, fiber gypsum and cement bonded board manufacturing facility nameplate, design and utilization capacities.
|
|
2
|
In the fourth quarter of fiscal year 2018, we announced a Greenfield capacity project in Prattville, Alabama with an expected completion date in the first half of fiscal year 2021. This project will add an additional nameplate 600 mmsf to our manufacturing capacity. This incremental capacity is not included in the table above.
|
|
3
|
In the fourth quarter of fiscal year 2018, we announced an A$28.5 million (US$22.8 million) Brownfield expansion project at our Carole Park, Queensland facility with an expected commissioning date in the first quarter of fiscal year 2021. This incremental capacity is not included in the table above.
|
|
4
|
We exercised our option to renew the Auckland leases for a further term of 10 years prior to the leases’ expiry on 22 March 2016. The Auckland leases now expire on 22 March 2026, at which time we have an option to renew them for a further term of 10 years expiring in March 2036. There is no option to purchase at the expiration of the leases.
|
|
5
|
The land on which our Philippines fiber cement plant is located is owned by Ajempa Holding Inc. (“Ajempa”), a related party. Ajempa is 40% owned by our operating entity, James Hardie Philippines Inc., and 60% owned by the James Hardie Philippines Retirement Fund. James Hardie Philippines Inc. owns 100% of the fixed assets on the land owned by Ajempa.
|
|
6
|
Our Calbe, Germany plant produces cement bonded boards.
|
|
7
|
Our Schraplau, Germany facility is a raw materials processing facility for our fiber gypsum plants. As a result, no annual nameplate capacity is available.
|
|
|
|
(Millions of US dollars)
|
||||||||||
|
|
|
2019
|
|
2018
|
|
2017
|
||||||
|
North America Fiber Cement
|
|
$
|
246.8
|
|
|
$
|
182.5
|
|
|
$
|
76.1
|
|
|
Asia Pacific Fiber Cement
|
|
24.7
|
|
|
18.4
|
|
|
24.2
|
|
|||
|
Europe Building Products
|
|
26.0
|
|
|
—
|
|
|
0.2
|
|
|||
|
Other Businesses
|
|
1.5
|
|
|
2.0
|
|
|
0.7
|
|
|||
|
R&D and Corporate
|
|
2.1
|
|
|
0.8
|
|
|
0.7
|
|
|||
|
Total Capital Expenditures
|
|
$
|
301.1
|
|
|
$
|
203.7
|
|
|
$
|
101.9
|
|
|
Project Description
|
|
Approximate
Investment
(US millions)
|
|
Investment
to date
(US millions)
|
|
Project
Start Date
|
|
Expected
Commission
Date
|
|
Expected
Nameplate Capacity
Increase
1
(mmsf)
|
||||
|
Prattville Greenfield expansion
|
|
$
|
240.0
|
|
|
$
|
149.4
|
|
|
Q4FY18
|
|
FY21
|
|
600
|
|
Tacoma Greenfield expansion
2
|
|
187.0
|
|
|
149.5
|
|
|
Q4 FY17
|
|
FY19
|
|
300
|
||
|
Carole Park Brownfield expansion
|
|
22.8
|
|
|
13.1
|
|
|
Q4FY18
|
|
FY21
|
|
88
|
||
|
North America ColorPlus
®
expansion
3
|
|
TBD
|
|
|
$
|
8.8
|
|
|
TBD
|
|
TBD
|
|
N/A
|
|
|
1
|
The expected nameplate capacity increase is based on management’s historical experience with our production process and is calculated assuming continuous operation, 24 hours per day, seven days per week, producing 5/16” medium density product at a targeted operating speed. It does not take into account factors such as product mix with varying thickness and density, batch size, plant availability and production speeds.
|
|
2
|
In fiscal year 2015, we purchased land and buildings of US$28.3 million on land adjacent to our existing Tacoma facility. In the fourth quarter of fiscal year 2017, we began the planning and design of our Tacoma Greenfield expansion project on this new site. In fiscal year 2019, we completed the construction of a new sheet machine line. The additional nameplate capacity of 300 mmsf has been included in our manufacturing capacity table above. As part of our Tacoma Greenfield expansion project, we are also adding new ColorPlus
®
and finishing lines which we expect to complete in the first half of fiscal year 2020.
|
|
3
|
In fiscal year 2019, we purchased land and building for US$8.8 million for the future expansion of our ColorPlus
®
products. Further investment amounts will be disclosed when the additional investments required for this project are approved by management.
|
|
Project Description
|
|
Total
Investment
(US Millions)
|
|
Fiscal Year of
Expenditure
|
||
|
Plant City SM4 - 3rd operating sheet machine
|
|
$
|
71.2
|
|
|
FY14 - FY17
|
|
Cleburne - 3rd sheet machine
|
|
40.8
|
|
|
FY14 - FY17
|
|
|
Waxahachie lease buyout
|
|
16.5
|
|
|
FY17
|
|
|
Summerville recommissioning
|
|
15.7
|
|
|
FY17 - FY18
|
|
|
Philippines capacity expansion
|
|
$
|
18.0
|
|
|
FY16 - FY19
|
|
Jack Truong BS, PhD
Chief Executive Officer
Age 56
|
|
|
Dr Jack G. Truong joined James Hardie as President of International Operations in April 2017. Dr Truong was announced CEO successor and appointed President and Chief Operating Officer with the responsibility of running the Company's global business in September 2018. He was officially appointed CEO in January 2019.
Dr Truong’s ability to anticipate global market trends and deliver profitable revenue growth is evidenced by his extensive multinational and multisector business experience. Prior to James Hardie, Dr Truong was the President and Chief Executive Officer of leading home appliance manufacturer, Electrolux North America Inc, a $5+ billion revenue and 14,000+ employee business at the time of his leadership.
|
|
Before joining Electrolux, Dr Truong enjoyed a successful 22-year career at 3M Company, where he held senior leadership roles throughout the United States, Europe and Asia-Pacific, including Vice President and General Manager of the Global Construction and Home Improvements Division and Global Office Supplies Division.
As an engineer and inventor himself – earning his PhD in chemical engineering from the Rensselaer Polytechnic Institute in New York – Dr Truong is the recipient of 11 U.S. patents and several international patents. Dr Truong also enjoys giving time to philanthropic causes and professional industry associations, receiving multiple accolades for his humanitarian work and business accomplishments.
|
|
|
Matthew Marsh BA, MBA
Chief Financial Officer and Executive Vice President – Corporate
Age 44
|
|
|
Matthew Marsh joined James Hardie as Chief Financial Officer (“CFO”) in June 2013. As CFO he oversees the Company’s overall financial activities, including accounting, tax, treasury, performance and competitor analysis, internal audit and financial operations.
Effective 16 October 2015, Mr Marsh’s role was expanded to include the role of Executive Vice President – Corporate. In this role, Mr Marsh continues his oversight of the Company’s overall financial management in addition to the oversight of James Hardie’s information systems, legal and compliance, and investor and media relations functions.
|
|
After a 16-year career at General Electric Company (“GE”), Mr Marsh brings a strong background in financial management. Before joining James Hardie, Mr Marsh most recently served as CFO of GE Healthcare’s IT business. Prior to being named CFO of GE Healthcare IT, Mr Marsh oversaw the finance operations for GE Healthcare’s US Healthcare Systems and US Diagnostic Imaging businesses.
Prior to those appointments, Mr Marsh traveled globally with the GE Internal Audit Staff gaining extensive experience in several industries including appliances, information services, distribution and supply, aviation, plastics, financial services, capital markets and healthcare, across more than twenty countries. Mr Marsh has graduated from GE’s Financial Management Program (FMP).
Mr Marsh has a Bachelor of Arts in Economics and Public Affairs from Syracuse University, USA and an MBA from University of Chicago’s Booth School of Business, USA.
|
|
|
Sean Gadd BEng, MBA
Executive Vice President, North America Commercial
Age 46
|
|
|
Sean Gadd joined James Hardie in 2004 as a Regional Engineering Manager for the Asia Pacific business, and progressed to Plant Manager for both the Carole Park and Rosehill facilities in Australia. Mr Gadd then moved to the US in 2006 to take the role of Manufacturing Manager for Trim and various manufacturing facilities across the US.
In 2009, Mr Gadd ran the US trim business for James Hardie with responsibility for both Manufacturing and Sales, followed by a brief assignment leading Supply Chain. In 2012, Mr Gadd was promoted to the role of Vice President of Sales for Western USA and Canada. Over the next year, his role was expanded to include the Midwest and Northeast of the USA.
|
|
Mr Gadd was appointed Executive General Manager in September 2013 with full responsibility for the Northern Division. In October 2015, he was appointed Executive Vice President, Markets and Segments, North America with responsibility for Strategic Marketing and Development. In December 2018, Mr Gadd was appointed Executive Vice President, North America Commercial with responsibility for sales, products, segments and marketing.
Mr Gadd has a Bachelor of Engineering in Manufacturing Management and an executive MBA from the Australian Graduate School of Management, Australia.
|
|
|
Ryan Kilcullen BSc, MS
Executive Vice President – Operations
Age 38
|
|
|
Ryan Kilcullen joined James Hardie in 2007 as a PcI/PdI Engineer. Since then, he has worked for the Company in various manufacturing and supply chain roles including Process Engineer, Production Manager, and Supply Chain Engineer. In 2012, he became Supply Chain Manager, ColorPlus
®
Business Unit, responsible for the end-to-end design and performance of our ColorPlus
®
product line supply chain. In 2013, he became responsible for North American Supply Chain operations, with responsibilities that included Procurement, Network Planning, Production Planning, Transportation, Distribution Management, Customer Service, and Inside Sales. In June 2015, he was appointed Vice President – Central Operations, responsible for the Company’s Supply Chain Operations and Centralized Manufacturing functions.
|
|
In August 2016, he was appointed Executive Vice President – Operations, responsible for the Company’s Supply Chain, Manufacturing, Engineering and Environmental, Health & Safety Operations.
Mr Kilcullen has a Bachelor of Science in Industrial Engineering from Rensselaer Polytechnic Institute and a Master of Engineering in Logistics from Massachusetts Institute of Technology.
|
|
|
Conrad Groenewald B.Tech, MDP, MBA
General Manager, Asia Pacific
Age 46
|
|
|
Conrad Groenewald joined James Hardie in January 2015 as General Manager, Asia Pacific.
As General Manager for Asia Pacific based in Sydney, Australia, Mr Groenewald has responsibility for running the Company’s business across Australia, New Zealand, the Philippines and the rest of SE Asia.
Before joining James Hardie, Mr Groenewald held senior executive roles with the shared services entity of NSW Health, HealthShare NSW; initially as the Chief Operating Officer and then moving into the role of Chief Executive Officer. During his time in this role, he was responsible for setting the strategic direction of HealthShare NSW, while ensuring that the 7,000 staff provided professional services to the NSW
|
|
Health department’s back of the house services.
After graduating in 1995, Mr Groenewald started his career as a Process Engineer at Mondi Paper (part of Anglo American Group) in South Africa. There he progressed through the business to Production Manager, and eventually Operations Manager, prior to emigrating to Australia in 2002. In Australia, Mr Groenewald joined Visy Industries where he spent almost 10 years in Senior Operations Management roles across various divisions throughout Australia.
Mr Groenewald has an MBA from The Open University UK, an MDP Business Administration and Management from UNISA, and has a Chemical Engineering qualification and Bachelor of Technology in Pulp and Paper from Durban University of Technology.
|
|
|
Jörg Brinkmann MS, PhD
General Manager, Europe
Age 40
|
|
|
Dr Jörg Brinkmann joined James Hardie as General Manager, Europe in April 2018 as part of the Fermacell GmbH acquisition. In this role he is responsible for running the Company’s European activities, which are headquartered in Düsseldorf, Germany.
Before joining James Hardie, Dr Brinkmann held several German as well as international leadership roles in Sales and Marketing at the Xella Group (the former owner of the Fermacell business) starting in 2005. In 2014 he was appointed CEO of the former Fermacell Company with responsibility for the entire business. Under his leadership, the company achieved significant profitable growth.
|
|
Dr Brinkmann holds a Masters degree (“Diplom-Kaufmann”) from the University of Duisburg-Essen as well as a PhD from the University of Hohenheim, Germany.
|
|
|
Joe Blasko BSFS, JD
General Counsel and Chief Compliance Officer
Age 52
|
|
|
Joe Blasko joined James Hardie as General Counsel and Chief Compliance Officer in June 2011.
Before joining James Hardie, Mr Blasko was Assistant General Counsel, and later, the General Counsel at Liebert Corporation, an Emerson Network Power Systems company and wholly-owned subsidiary of Emerson Electric Co. In his four years with Liebert/Emerson, Mr Blasko was responsible for establishing the legal department in Columbus, Ohio, managing and overseeing all legal matters and working closely with the executive management team. In this role, Mr Blasko also had global responsibilities which required expertise across multiple jurisdictions.
|
|
From 2004 to 2006, Mr Blasko was Associate General Counsel at The Scotts Miracle-Gro Company, serving as the effective “general counsel” to numerous corporate divisions within the organization. From 1997 to 2004, Mr Blasko gained considerable regulatory and litigation expertise working at Vorys, Sater, Seymour and Pease LLP in Ohio.
Mr Blasko has a Juris Doctor from Case Western Reserve University in Cleveland, Ohio, USA and a Bachelor of Science in Foreign Service from Georgetown University, USA, with a specialty in International Relations, Law and Organizations.
|
|
|
Jason Miele BA
Vice President, Investor and Media Relations
Age 42
|
|
|
Jason Miele was appointed to the position of Vice President – Investor and Media Relations in February 2017. Mr Miele has responsibility for overseeing the Company’s investor relations strategy and successful interface with external audiences, communicating the Company’s business strategy and its financial performance to various stakeholders including shareholders, investment analysts, and the financial media.
Mr Miele has 20 years of relevant professional experience, including 12 years of experience with James Hardie, where he has served in various finance and operational support roles, most recently as James Hardie’s Group Controller, a position he held from 2013 to 2017.
|
|
Mr Miele has a Bachelor’s Degree from the University of California at Santa Barbara, where he graduated with a degree in Business Economics with an emphasis in Accounting.
|
|
|
Michael Hammes BS, MBA
Age 77
|
|
|
Michael Hammes was elected as an independent non-executive director of James Hardie in February 2007. He was appointed Chairman of the Board in January 2008 and is a member of the Remuneration Committee and the Nominating and Governance Committee.
Experience
: Mr Hammes has extensive commercial experience at a senior executive level. He has held a number of executive positions in the medical products, hardware and home improvement, and automobile sectors, including CEO and Chairman of Sunrise Medical, Inc. (2000-2007), Chairman and CEO of Guide Corporation (1998-2000), Chairman and CEO of Coleman Company, Inc. (1993-1997), Vice Chairman of Black & Decker Corporation (1992-1993) and various senior executive roles with Chrysler Corporation (1986-1990) and Ford Motor Company (1966-1986).
|
|
Directorships of listed companies in the past five years
:
Former
– Director of Navistar International Corporation (1996-2017); Director of DynaVox Mayer-Johnson (2010-2016).
Other
: Resident of the United States.
Last elected
: August 2018
Term expires
: August 2021
|
|
|
Brian Anderson BS, MBA, CPA
Age 68
|
|
|
Brian Anderson was appointed as an independent non-executive director of James Hardie in December 2006. He is Chairman of the Audit Committee and a member of the Remuneration Committee.
Experience
: Mr Anderson has extensive financial and business experience at both executive and board levels. He has held a variety of senior positions, with thirteen years at Baxter International, Inc., including Corporate Vice President of Finance, Senior Vice President and CFO (1997-2004) and, more recently, Executive Vice President and CFO of OfficeMax, Inc. (2004-2005). Earlier in his career, Mr Anderson was an Audit Partner of Deloitte & Touche LLP (1986-1991).
|
|
Directorships of listed companies in the past five years
:
Current
– Director of Stericycle Inc. (since 2017); Director of PulteGroup (since 2005); Director of W.W. Grainger, Inc. (since 1999).
Former
– Chairman (2010-2016) and Director (2005-2016) of A.M. Castle & Co.; Lead Director of W.W. Grainger, Inc. (2011-2014).
Other
: Member of the Governing Board of the Center for Audit Quality (since 2016); resident of the United States.
Last elected
: August 2017
Term expires
: August 2020
|
|
|
Russell Chenu BCom, MBA
Age 69
|
|
|
Russell Chenu was appointed as a non-executive director of James Hardie in August 2014. He is a member of the Remuneration Committee and the Nominating and Governance Committee.
Experience
: Mr Chenu joined James Hardie as Interim CFO in October 2004 and was appointed CFO in February 2005. He was elected to the Company’s Managing Board at the 2005 Annual General Meeting, re-elected in 2008 and continued as a member of the Managing Board until it was dissolved in June 2010. As CFO, he was responsible for accounting, treasury, taxation, corporate finance, information technology and systems, and procurement. Mr Chenu retired as CFO in November 2013.
|
|
Mr Chenu is an experienced corporate and finance professional who held senior finance and management positions with a number of Australian publicly-listed companies. In a number of these senior roles, he was engaged in significant strategic business planning and business change, including several turnarounds, new market expansions and management leadership initiatives.
Mr Chenu has a Bachelor of Commerce from the University of Melbourne and an MBA from Macquarie Graduate School of Management, Australia.
Directorships of listed companies in the past five years
:
Current
– Director of Reliance Worldwide Corporation Limited (since 2016); Director of CIMIC Group Limited (since 2014); Director of Metro Performance Glass Limited (since 2014).
Other
: Resident of Australia.
Last elected:
August 2017
Term expires
: August 2020
|
|
|
Andrea Gisle Joosen MSc, BSc
Age 55
|
|
|
Andrea Gisle Joosen was appointed as an independent non-executive director of James Hardie in March 2015. She is a member of the Audit Committee.
Experience
: Ms Gisle Joosen is an experienced former executive with extensive experience in marketing, brand management and business development across a range of different consumer businesses. Her former roles include Chief Executive of Boxer TV Access AB in Sweden and Managing Director (Nordic region) of Panasonic, Chantelle AB and Twentieth Century Fox. Her early career involved several senior marketing roles with Procter & Gamble and Johnson & Johnson.
|
|
Directorships of listed companies in the past five years
:
Current
– Director of BillerudKorsnas AB (since 2015); Director of Dixons Carphone plc (since 2014); Director of ICA Gruppen AB (since 2010).
Former
–Director of Mr Green AB (2015 - 2019); Director of Dixons Retail plc (2013-2014).
Other
: Director of Acast AB (since June 2018); Director of Neopitch AB (since 2004); resident of Sweden.
Last elected
: August 2018
Term expires
: August 2021
|
|
|
David D. Harrison BA, MBA, CMA
Age 71
|
|
|
David Harrison was appointed as an independent non-executive director of James Hardie in May 2008. He is Chairman of the Nominating and Governance Committee and a member of the Audit Committee.
Experience
: Mr Harrison is an experienced company director with a finance background, having served in corporate finance roles, international operations and information technology for 22 years with Borg Warner/General Electric Co. His previous experience includes 10 years at Pentair, Inc., as Executive Vice President and CFO (1994-1996 and 2000-2007) and Vice President and CFO roles at Scotts, Inc. and Coltec Industries, Inc. (1996-2000).
|
|
Directorships of listed companies in the past five years:
Current
– Director of National Oilwell Varco (since 2003).
Other
: Resident of the United States.
Last elected
: August 2016
Term expires
: August 2019
|
|
|
Persio V. Lisboa BS
Age 53
|
|
|
|
|
|
Persio Lisboa was appointed as an independent non-executive director of James Hardie in February 2018. He is Chairman of the Remuneration Committee.
Experience
: Mr Lisboa has extensive senior executive experience. He currently serves as Executive Vice President & Chief Operating Officer at Navistar, Inc. (Navistar), a leading manufacturer of commercial trucks, buses, defense vehicles and engines, since March 2017. Prior to holding this position, Mr Lisboa served as President, Operations of Navistar from November 2014 to March 2017. Prior to that, Mr Lisboa served as Senior Vice President, Chief Procurement Officer of Navistar from December 2012 to November 2014, as Vice President, Purchasing and Logistics and Chief Procurement Officer of Navistar from October 2011 to November 2012,
|
|||
|
and as Vice President, Purchasing and Logistics of Navistar from August 2008 to October 2011. Prior to these positions, Mr Lisboa held various management positions within Navistar’s North American and South American operations. Mr Lisboa began his career at Maxion International Motores Brasil, followed by a move to International Engines Argentina S.A., and then to MWM-International South America.
|
||||
|
Directorships of listed companies in the past five years
:
Former
- Director of Broadwind Energy, Inc. (2016-2018).
Other:
Resident of the United States.
Last elected
: August 2018
Term expires
: August 2021
|
||||
|
Alison Littley BA, FCIPS
Age 56
|
|
|
Alison Littley was appointed as an independent non-executive director of James Hardie in February 2012. She is a member of the Audit Committee and the Remuneration Committee.
Experience
: Ms Littley has substantial experience in multinational manufacturing and supply chain operations, and she brings a strong international leadership background building effective management teams and third party relationships. She has held a variety of positions, most recently as Chief Executive of Buying Solutions, a UK Government Agency responsible for procurement of goods and services on behalf of UK government and public sector bodies (2006-2011). She has previously held senior management roles in Diageo plc (1999-2006) and Mars, Inc. (1981-1999).
|
|
Directorships of listed companies in the past five years
:
Current
- Norcros plc (since May 2019); Headlam Group plc (since January 2019).
Other:
Director of Osborne Group Holdings Limited (since September 2018); Director of Rosewood Group Holdings Limited (since September 2018); Director of Weightmans LLP (since 2013); resident of the United Kingdom.
Last elected
: August 2018
Term expires
: August 2019
|
|
|
Anne Lloyd, BS
Age 57
|
|
|
Anne Lloyd was appointed as an independent non-executive director of James Hardie in November 2018. She is a member of the Audit Committee.
Experience
: Ms Lloyd, an experienced corporate and finance executive, served as Chief Financial Officer of Martin Marietta Materials, Inc. a leading supplier of aggregates and heavy building materials, for over 12 years from June 2005 until her retirement in August 2017. She joined Martin Marietta in 1998 as Vice President and Controller and was promoted to Chief Accounting Officer in 1999. She was subsequently appointed Treasurer (2006-2013) and promoted to Executive Vice President in 2009. Earlier in her career, Ms Lloyd spent 14 years with Ernst & Young LLP (1984-1998), latterly as
|
|
a senior manager and client service executive for the natural resources, mining, insurance and healthcare industries.
Directorships of listed companies in the past five years
:
Current
- Director of Insteel Industries, Inc (since April 2019); Director of Highwoods Properties, Inc. (since 2018).
Former
- Director of Terra Nitrogen Company, L.P. (2009-2018).
Other:
Resident of the United States.
Last elected
: Ms Lloyd will be standing for election at the August 2019 Annual General Meeting.
|
|
|
Rada Rodriguez MSc
Age 60
|
|
|
Rada Rodriguez was appointed as an independent non-executive director of James Hardie in November 2018. She is a member of the Nominating and Governance Committee.
Experience:
Ms Rodriguez has served as Chief Executive Officer of Schneider Electric GmbH, part of Schneider Electric Group, a global energy management and automation company, for 9 years and has been Senior Vice President, Corporate Alliances since 2017. Since joining the company in 1999, she has held a progression of senior roles including Head of International Research and Development for Schneider Electric Sweden, and Senior Vice President and Zone President, Central and Eastern Europe.
|
|
Prior to joining Schneider Electric GmbH, she worked at Lexel Group (later acquired by Schneider) and before that she worked for 5 years at Colasit Scandinavia AB, a Swiss industrial machinery manufacturer. She started her career with K-Konsult AB, a Swedish technical consulting firm with a focus on installation technology where she worked for 5 years as a design engineer.
Directorships of listed companies in the past five years:
Former
– Director of Eltel AB (2015-2017).
Other
: Director of ZVEI (since 2014); resident of Germany.
Last elected
: Ms Rodriguez will be standing for election at the August 2019 Annual General Meeting.
|
|
|
Rudolf van der Meer M.Ch.Eng
Age 74
|
|
|
Rudy van der Meer was appointed as an independent non-executive director of James Hardie in February 2007. He is a member of the Nominating and Governance Committee.
Experience
: Mr van der Meer is an experienced former executive, with considerable knowledge of international business and the building and construction sector. During his 32-year association with Akzo Nobel N.V., he held a number of senior positions including CEO of Coatings (2000-2005), CEO of Chemicals (1993-2000), and member of the five person Executive Board (1993-2005).
|
|
Directorships of listed companies in the past five years:
Current
– Director of LyondellBasell Industries N.V. (since 2010).
Other
: Former Chairman of the Supervisory Board of VGZ Health Insurance (2011-2017); resident of the Netherlands.
Last elected
: August 2017
Term expires
: August 2019
|
|
|
•
|
Dr Jack Truong, CEO (from 31 January 2019);
|
|
•
|
Louis Gries, Former CEO (through 31 January 2019);
|
|
•
|
Matthew Marsh, CFO and Executive Vice President - Corporate;
|
|
•
|
Sean Gadd, Executive Vice President - North America Commercial;
|
|
•
|
Joseph Blasko, General Counsel and Chief Compliance Officer; and
|
|
•
|
Zean Nielsen, Former Executive Vice President - Sales.
|
|
1
|
Please see the “Glossary of Abbreviations and Definitions” in Section 4 of this Annual Report for a reconciliation of non-GAAP financial measures used in this Remuneration Report to the most directly comparable US GAAP financial measure.
|
|
•
|
Dr Truong’s fixed and variable compensation were increased in conjunction with his transition to the role of CEO (see page 52 for further details).
|
|
•
|
A base salary increase for Mr Marsh was made to continue to align his compensation package with our CEO succession plan and our need to retain key senior executives through the CEO transition process.
|
|
•
|
A base salary increase for Mr Gadd was made to properly align his compensation with the increase in his role scope and accountability that occurred during fiscal year 2019.
|
|
•
|
There were no changes to Mr Gries’ fixed or variable compensation. Mr Gries’ base salary, target short-term incentive (“STI”), and target long-term incentive (“LTI”) remained the same in fiscal year 2019 as they were for fiscal year 2018.
|
|
•
|
No changes were made to the operation or components of the company performance plan (“CP Plan”) or individual performance plan (“IP Plan”) for our annual STI program for fiscal year 2019, other than to establish new targets which align with our strategic initiatives as we do every year. A complete description of the performance hurdles applicable for fiscal year 2019 for the CP Plan is set out in the section titled “Incentive Arrangements” later in this Remuneration Report.
|
|
•
|
No changes were made to the design of the LTI Plan for fiscal year 2019. The LTI plan remains similar to the fiscal year 2018 plan with updated financial targets. A complete description of the LTI program, including the applicable performance hurdles is set out in the section titled “Incentive Arrangements” later in this Remuneration Report.
|
|
Summary of Fiscal Year 2019 Senior Executive Officer Target Compensation
|
|||||||||||
|
Senior Executive Officer
|
FY2019 Annual Base Salary (US$)
|
|
FY2019 STI Target Value (US$)
|
|
FY2019 LTI Target Value (US$)
|
|
FY2019 Total Target Compensation (US$)
|
||||
|
J Truong*
|
678,658
|
|
|
589,767
|
|
|
1,950,000
|
|
|
3,218,425
|
|
|
L Gries
|
950,000
|
|
|
1,187,500
|
|
|
4,000,000
|
|
|
6,137,500
|
|
|
M Marsh
|
630,000
|
|
|
472,500
|
|
|
1,200,000
|
|
|
2,302,500
|
|
|
S Gadd
|
550,000
|
|
|
330,000
|
|
|
800,000
|
|
|
1,680,000
|
|
|
J Blasko
|
437,750
|
|
|
262,650
|
|
|
500,000
|
|
|
1,200,400
|
|
|
Z Nielsen
|
525,000
|
|
|
315,000
|
|
|
1,000,000
|
|
|
1,840,000
|
|
|
Compensation Practices We Employ
|
|||
|
ü
|
Retain independent compensation advisers reporting directly to the Remuneration Committee
|
û
|
Prohibition on hedging of stock held by executives and directors
|
|
ü
|
Pay for performance model, with approximately 85% of our CEO’s total target compensation being performance-based “at risk” compensation and an average of approximately 70% total target compensation being performance-based “at risk” compensation for our other Senior Executive Officers
|
û
|
Limited employment agreements and severance arrangements
|
|
ü
|
Circuit breaker on annual STI awards to ensure that no annual incentive awards are paid unless minimum US growth and corporate performance levels are achieved
|
û
|
Limited change-in-control benefits
|
|
ü
|
Set robust share ownership requirements for all directors and Senior Executive Officers
|
û
|
No dividends paid on unvested equity awards
|
|
ü
|
Broad clawback policy on performance-based compensation
|
û
|
Limited perquisites and other benefits
|
|
ü
|
Set performance-based vesting conditions for all equity grants to Senior Executive Officers
|
û
|
No annual time-based LTI equity grants to Senior Executive Officers
|
|
ü
|
Provide the Remuneration Committee with ability to exercise “negative” discretion when determining the vesting and payout of our LTI programs
|
û
|
No excessive retirement or deferred compensation arrangements
|
|
Acuity Brands, Inc
|
Louisiana-Pacific Corp
|
Quanex Building Products Corp
|
|
American Woodmark Corp
|
Martin Marietta Materials, Inc
|
Simpson Manufacturing Co., Inc
|
|
Apogee Enterprises, Inc
|
Masco Corporation
|
Trex Co., Inc
|
|
Armstrong World Industries, Inc
|
Mohawk Industries, Inc
|
USG Corp
|
|
Eagle Materials, Inc
|
Mueller Water Products, Inc
|
Valmont Industries, Inc
|
|
Fortune Brands Home & Security
|
NCI Building Systems, Inc
|
Vulcan Materials Co
|
|
Lennox International, Inc
|
Owens Corning
|
Watsco, Inc
|
|
•
|
our historical performance;
|
|
•
|
our Peer Group;
|
|
•
|
the goals in our STI and LTI variable remuneration plans; and
|
|
•
|
the key objectives and measures the Board expects to see achieved, which are set forth in what is referred to as the “Scorecard” and further discussed later in this Remuneration Report.
|
|
Duration
|
Plan Name
|
Amount
|
Form Incentive Paid
|
|
STI (1 year)
|
IP Plan
|
20% of STI Target
|
Cash
|
|
|
CP Plan
|
80% of STI Target
|
Cash
|
|
LTI (3 years)
|
Long Term Incentive Plan 2006 (“LTIP”)
|
25% of LTI Target
|
ROCE RSUs
|
|
|
|
25% of LTI Target
|
TSR RSUs
|
|
|
|
50% of LTI Target
|
Cash (Scorecard LTI)
|
|
•
|
Matrix Factor = capped at 2.0x
|
|
•
|
Matrix Factor
plus
Interiors Factor = capped at 2.3x
|
|
•
|
“Wood-look” Factor = capped at 1.25x
|
|
•
|
the US business performing well above target on the Return Measure;
|
|
•
|
the US business performing below target on the Growth Measure;
|
|
•
|
the US business performing below target on the Interiors Factor and “Wood-look” Factor;
|
|
•
|
Asia Pacific performing above target on the Growth Measure;
|
|
•
|
Asia Pacific performing above target on the Return Measure due to higher returns in Australia, partially offset by below target returns in New Zealand and the Philippines; and
|
|
•
|
Europe performing at target with a successful integration and retaining key business leaders with no business interruption.
|
|
•
|
ROCE RSUs are used as they are an indicator of high capital efficiency required over time;
|
|
•
|
Relative TSR RSUs are used as they are an indicator of our performance relative to our US peer companies; and
|
|
•
|
Scorecard LTI is an indicator of each Senior Executive Officer’s contribution to achieving our long-term strategic goals.
|
|
|
ROCE RSUs
|
|
TSR RSUs
|
|
Scorecard LTI Units
|
|
|
L Gries
|
122,211
|
|
226,709
|
|
366,634
|
|
|
J Truong
|
55,938
|
|
106,058
|
|
196,372
|
|
|
M Marsh
|
36,663
|
|
68,013
|
|
109,990
|
|
|
S Gadd
|
24,442
|
|
45,342
|
|
73,327
|
|
|
J Blasko
|
15,276
|
|
28,339
|
|
45,829
|
|
|
Z Nielsen
|
30,553
|
|
56,677
|
|
91,659
|
|
|
•
|
tie the reward’s value to share price which provides alignment with shareholder interests;
|
|
•
|
promote that we earn appropriate returns on capital invested;
|
|
•
|
reward performance that is under management’s direct influence and control; and
|
|
•
|
focus management on capital efficiency as the necessary precondition for the creation of additional shareholder value.
|
|
Fiscal Years 2017-2019 ROCE
|
Fiscal Years 2018-2020 ROCE
|
Fiscal Years 2019-2021 ROCE
|
Amount of Target to Vest
|
|
< 24.0%
|
< 25.0%
|
< 24.0%
|
0.0x
|
|
≥ 24.0%, but < 26.0%
|
≥ 25.0%, but < 27.0%
|
≥ 24.0%, but < 26.0%
|
0.5x
|
|
≥ 26.0%, but < 28.5%
|
≥ 27.0%, but < 29.5%
|
≥ 26.0%, but < 27.5%
|
1.0x
|
|
≥ 28.5%, but < 29.5%
|
≥ 29.5%, but < 30.5%
|
≥ 27.5%, but < 28.5%
|
1.5x
|
|
≥ 29.5%
|
≥ 30.5%
|
>
28.5%
|
2.0x
|
|
ROCE Performance Level
|
Amount of Target to Vest
|
|
< 24.0%
|
0.0x
|
|
≥ 24.0%, but < 26.0%
|
0.5x
|
|
≥ 26.0%, but < 28.5%
|
1.0x
|
|
≥ 28.5%, but < 29.5%
|
1.5x
|
|
≥ 29.5%
|
2.0x
|
|
Performance against Peer Group
|
Amount of Target to Vest
|
|
< 40
th
Percentile
|
0.0x
|
|
40
th
Percentile
|
0.5x
|
|
> 40
th
, but < 60
th
Percentile
|
Sliding Scale
|
|
60
th
Percentile
|
1.0x
|
|
> 60
th
, but < 80
th
Percentile
|
Sliding Scale
|
|
≥ 80
th
Percentile
|
2.0x
|
|
Performance against Peer Group
|
Amount of Target to Vest
|
|
< 40
th
Percentile
|
0.0x
|
|
40
th
Percentile
|
0.5x
|
|
> 40
th
, but < 60
th
Percentile
|
Sliding Scale
|
|
60
th
Percentile
|
1.0x
|
|
> 60
th
, but < 80
th
Percentile
|
Sliding Scale
|
|
≥ 80
th
Percentile
|
2.0x
|
|
•
|
allows the Remuneration Committee to set targets for and reward executives on a balance of longer-term financial, strategic, business, customer and organizational development goals which it believes are important contributors to long-term creation of shareholder value;
|
|
•
|
ties the reward’s value to our share price over the medium-term; and
|
|
•
|
allows flexibility to apply rewards across different countries, while providing Senior Executive Officers with liquidity to pay tax or other material commitments at a time that coincides with vesting of shares (via the other components of the LTI Plan) as payment is in cash.
|
|
Performance Measure/Rationale
|
Performance Metric/Results
|
Board Assessment for the Three-year Period
|
|
Grow exterior cladding market share and maintain category share in the US business
A key strategy for the Company is to maximize its market share growth/retention of the exterior cladding market for new housing starts and for repair & remodel markets.
|
Goal:
PDG above market. Our performance against ‘wood-look’ competition.
Result
: Average annual PDG performance for the three year period of 2.8% was well below the Board target. Growth above vinyl but below close alternatives also did not meet Board expectations.
.
|
Performance below expectations
|
|
Interiors Market Strategy Implementation
|
Goal:
Growth above market of 2% per annum.
Result:
Interiors volume growth averaged negative 7% per annum during the three year period, not meeting the Board requirement.
|
Performance below expectations
|
|
Build US organizational and leadership capability in support of the 35/90 growth target
The amount of growth that 35/90 entails requires lower turnover levels and an increase in management depth and organizational capability.
|
Goal:
Continued focus on turnover, driving the North American turnover to below 15% by the end of the three year period. Execute a successful succession plan. Successful recruitment, hiring and onboarding of business leaders and development of bench strength.
Result:
Succession plan successfully executed resulting in appointment of Dr Jack Truong as CEO on 31 January 2019. Significant improvements in the hiring of key talent at the executive level and Average annual turnover of 18.9% did not meet the Board target. Demonstrated improvement in the critical areas of leadership development, recruitment and onboarding of bench strength talent and employee engagement.
|
Performance met expectations
|
|
|
|
|
|
|
|
|
|
Performance Measure/Rationale
|
Performance Metric/Results
|
Board Assessment for the Three-year Period
|
|
Safety
The safety of our employees is an essential objective of the Company.
|
Goal
: Incident Rate (“IR”) of 2.0 or below and severity rate (“SR”) of 20.0 or below.
Result:
The global manufacturing IR and SR decreased from 1.5 & 25.6 during fiscal years 2014-16 to 1.1 & 19.4 during fiscal years 2017-19.
Implemented Zero Harm strategy during the three year period and now completed second year of Zero Harm Safety Culture Initiatives.
Despite the significant progress noted, management acknowledges the fatality in the Carole Park plant in 2017.
|
Performance met expectations
|
|
Pursue organic growth in all APAC markets and grow Scyon and new products to a greater proportion of APAC business.
|
Goal
: James Hardie Australia ("JHA") annual growth above market of 4% while maintaining category share. James Hardie New Zealand ("JHNZ") annual growth above market of 3% while maintaining category share. Significant growth of Scyon product line.
Result:
JHA average annual growth above market of 7% and category share expansion significantly beat the Board requirement while expanding category share.
JHNZ average annual growth above market of 4% while maintaining category share exceeded the Board requirement.
Scyon Revenue Growth of over 50% significantly exceeded Board targets.
|
Performance exceeded expectations
|
|
|
|
|
|
|
|
|
|
Performance Measure/Rationale
|
Performance Metric/Results
|
Board Assessment for the Three-year Period
|
|
Manufacturing effectiveness and sourcing efficiency
The Company operates a national US network of manufacturing facilities.
|
Goal
: Commercial-in-confidence metrics for product efficiency, process efficiency, material yield and service level metric used to assess whether manufacturing and supply chain is effectively supporting our product leadership strategy.
Result
: Exceeded the process efficiency metric each of the three years.
Exceeded the product efficiency target one of the three years and the three year average product efficiency metric met the expectations.
Material Yield metric did not meet expectations.
Service level metric improved each year during the period after working out of the capacity constrained position of fiscal year 2017.
Successfully executed start-up and commissioning of 4 new lines representing 20% additional capacity to support the product leadership strategy.
Defined and launched Lean manufacturing initiative in fiscal year 2019.
|
Performance met expectations
|
|
Define a clear vision and strategy for non-fiber cement business.
|
Goal
: Define a clear vision and strategy for non-fiber cement business.
Result
: Acquisition of Fermacell during the period provides significant growth opportunity leveraging non-fiber cement technology products (fiber gypsum). Further, the acquisition also provides significant growth opportunity for fiber cement in Europe, providing a third region of significance for the Company. Further, the Company made the decision to discontinue its windows operations to ensure proper level of focus on core growth opportunities
.
|
Performance met expectations
|
|
|
Base Salary
|
Target STI
|
|||||
|
Name
|
Fiscal Year 2019 (US$)
|
Fiscal Year 2020 (US$)
|
Fiscal Year 2019 (US$)
|
Fiscal Year 2020 (US$)
|
|||
|
J Truong
|
800,000
|
|
800,000
|
|
100
|
%
|
No change
|
|
M Marsh
|
630,000
|
|
642,600
|
|
75
|
%
|
No change
|
|
S Gadd
|
550,000
|
|
561,000
|
|
60
|
%
|
No change
|
|
J Blasko
|
437,500
|
|
450,883
|
|
60
|
%
|
No change
|
|
Z Nielsen
|
525,000
|
|
N/A
|
|
N/A
|
|
N/A
|
|
|
APAC
|
Europe
|
North America
|
|
PDG
|
1% - 6%
|
N/A
|
3% - 6%
|
|
Organic revenue growth
|
N/A
|
5% - 12%
|
N/A
|
|
EBIT Margin
|
20% - 25%
|
11% - 15%
|
21% - 26%
|
|
Lean - Cumulative over 3 Years
|
US$19 million
|
US$20 million
|
US$100 million
|
|
Zero Harm
|
- Safe Start Implementation
- Driver/Fleet Safety Program
- DART rate: 0.20
|
- Replicate Systems from NA and APAC
- Safe Start Implementation
|
- 5S World Class Facilities
- Energy Control Program
- DART rate: 0.20
|
|
Innovation
|
Commercial-in-confidence metrics for products and process efficiencies
|
Deliver a commercially viable portfolio of fiber cement products for the EU market
|
Commercial-in-confidence metrics for products and process efficiencies
|
|
People & Culture
|
- Turnover: 12%
- Talent Management
- Leadership Competencies
|
- Turnover: 8%
- Talent Management
- Leadership Competencies
|
- Turnover: 15%
- Talent Management
- Leadership Competencies
|
|
Environment, Social & Governance ("ESG")
|
Fiscal Year 2020: Establish team to globally drive ESG reporting improvement
Fiscal Year 2021: Deliver ESG Report
Fiscal Year 2022: ESG Report shows improvement across areas management flagged in Fiscal Year 2021 report
|
||
|
•
|
The Employment Agreement is effective 31 January 2019 providing for service as CEO.
|
|
•
|
Dr Truong is an employee-at-will and either he or the Company may terminate his employment at any time or any reason.
|
|
•
|
Base salary at an initial annual rate of US$800,000, subject to annual review and approval by the Remuneration Committee.
|
|
•
|
Participation in the Company’s annual STI and LTI Plans, with a minimum STI target of 100% of his annual base salary, as established by the Company’s Board.
|
|
•
|
Participation in the Company’s benefit, health and welfare plans and certain fringe benefits made generally available to Senior Executive Officers in accordance with his agreement and Company policies.
|
|
•
|
In the event that Dr Truong’s employment is terminated by the Company for any reason other than for “Cause”, or if Dr Truong voluntarily terminates his employment for “Good Reason”, in addition to those benefits that would be considered standard for any employee at termination (
i.e.
, unpaid base salary, accrued vacation, unreimbursed business expenses and the payment of any earned but unpaid annual incentive award) Dr Truong will be entitled to receive the following benefits:
|
|
◦
|
An aggregate amount equal to the sum of: (i) two times Dr Truong’s base salary plus (ii) two times Dr Truong’s target annual incentive, payable in substantially equal periodic installments over the two year period following the date of termination;
|
|
◦
|
An amount, if any, with respect to the annual incentive award opportunity for the fiscal year in which termination of employment occurs, as determined under the terms and conditions of annual incentive program(s) then in-effect;
|
|
◦
|
All outstanding equity awards will be subject to the terms and conditions of the applicable equity incentive plan and any corresponding award agreement(s); provided, however, that (i) if the date of termination occurs prior to 21 August 2022, any service-based vesting criteria on the long-term incentive awards granted to Dr Truong on 21 August 2017 that were designated as retention awards will be deemed satisfied in full (but any performance criteria then still applicable to those awards will remain in effect);
|
|
◦
|
Monthly payments for a period of up to 24 months following the date of termination equal to the premium Dr Truong would be required to pay for continuation coverage under the Company’s health benefit plans; and
|
|
◦
|
The Company will provide Dr Truong with reasonable professional outplacement services for a period of up to 24 months following the date of termination.
|
|
•
|
Executive Employment Agreement renewed effective as of 14 October 2010 providing for service as Chief Executive Officer.
|
|
•
|
Mr Gries is an employee-at-will and either he or the Company may terminate his employment at any time or any reason.
|
|
•
|
Base salary at an initial annual rate of US$950,000, subject to annual review and approval by the Remuneration Committee.
|
|
•
|
Participation in the Company’s annual STI and LTI Plans, with a minimum STI target of 100% of his annual base salary, as established by the Company’s Board.
|
|
•
|
Participation in the Company’s benefit, health and welfare plans and certain fringe benefits made generally available to Senior Executive Officers in accordance with his agreement and Company policies.
|
|
•
|
Provisions concerning consequences of termination of employment under specified circumstances, including: (i) termination by the Company for cause; (ii) termination by reason of death or disability; (iii) retirement; (iv) termination by the Company without cause or by Mr Gries with good reason; or (v) termination by Mr Gries without good reason.
|
|
•
|
In the event that Mr Gries’ employment is terminated by the Company for any reason other than for cause, or if Mr Gries voluntarily terminates his employment for good reason, the Company shall pay to Mr Gries, in addition to any compensation or reimbursements he would otherwise be entitled to up to the date of termination: (i) an amount equal to 150% of his then current base salary; (ii) an amount equal to 150% of his average annual STI bonus actually paid, calculated based on the three full fiscal years immediately preceding the year of termination; (iii) his prorated bonus; (iv) no pro rata forfeiture of his unvested RSUs/Scorecard LTI grants - these will vest in accordance with the terms and timing of the specific grants; and (v) continuation of health and medical benefits at the Company’s expense for the duration of the consultation agreement referenced below, provided that Mr Gries signs the Company’s release of claims without revocation and has been and continues to remain in compliance with his confidentiality and noncompetition obligations as set forth in this agreement.
|
|
•
|
In the event of Mr Gries’ retirement after the age of 65, or prior to age 65 with the approval of the Board, his then unvested RSUs and awards will not be forfeited and will be held through the applicable testing periods.
|
|
•
|
In the event that Mr Gries’ employment is terminated for any reason other than by the Company for cause or due to his death, in addition to any severance payment he may be entitled to as set forth above, the Company and Mr Gries each agree to enter into a consulting arrangement for a minimum of two years, as long as Mr Gries adheres to certain non-competition and confidentiality provisions and executes a release of claims following the effective date of termination. Under the consulting agreement, Mr Gries will receive his annual target STI bonus and annual base salary in exchange for his consulting services and non-compete.
|
|
•
|
The Company may terminate the consulting arrangement and its obligations to make any further payments to Mr Gries in the event that Mr Gries willfully fails or refuses to carry out any material reasonable directions of the Board or the CEO or commits any willful act, which could include a violation of his covenant not to compete, or is convicted of a crime. In the event that the Company deems such conduct as reason for the Company to terminate Mr Gries for cause, Mr Gries shall not be entitled to payment of any compensation, including the lapse of his unvested RSUs and awards
.
|
|
•
|
Effective 15 May 2016, the Company entered into an employment agreement with Mr Marsh (the “Marsh Agreement”), which has an initial term of three years and automatic one year renewals thereafter unless either Mr Marsh or the Company notifies the other party at least 90 days before the expiration date that the Marsh Agreement is not to be renewed. In the event that the Company is the party that determines not to renew, such non-renewal shall be treated as a termination without “Cause” (as defined in the Marsh Agreement) and subject to the termination without “Cause” provisions of the Marsh Agreement.
|
|
•
|
The Marsh Agreement provides for a base salary of not less than US$560,000, or such greater amount as may be established by the Remuneration Committee, for Mr Marsh. The base salary shall be reviewed annually for increase in the discretion of the Remuneration Committee. Additionally, Mr Marsh shall be eligible for an annual STI award with payout opportunities that are commensurate with his position and duties, with a minimum target annual STI award opportunity of not less than 70% of the current base salary. Mr Marsh shall also be eligible to participate in our annual LTI plan on terms commensurate with his position and duties, with a minimum annual target LTI award opportunity of not less than US$1,200,000.
|
|
•
|
Mr Marsh shall be eligible for participation in our employee benefit, health and welfare plans and certain fringe benefits made generally available to Senior Executive Officers in accordance with Company policies.
|
|
•
|
The Marsh Agreement contains provisions concerning the consequences of termination of employment under specified circumstances, including: (i) termination by the Company for Cause; (ii) termination by reason of death or disability; (iii) termination by the Company without Cause or by Mr Marsh with “Good Reason” (as defined in the Marsh Agreement); or (iv) termination by Mr Marsh without Good Reason. In particular, in the event the Company terminates Mr Marsh without Cause or Mr Marsh voluntarily terminates for Good Reason, Mr Marsh shall be entitled to: (i) a lump-sum amount equal to his unpaid base salary through and including the date of termination, as well as accrued, unused vacation pay and unreimbursed business expenses; (ii) a payment for any earned but unpaid annual incentive award for a completed calendar year prior to the date of termination; (iii) salary continuation for the two year period following the date of termination, provided the aggregate amount of such continuation payments shall be equal to the sum of (A) two times the base salary plus (B) one times the annual incentive award opportunity, as then in effect; (iv) an amount, if any, with respect to the annual incentive award opportunity for the year in which such termination of employment occurs, as determined under the terms and conditions of the Company’s annual incentive program(s); (v) all outstanding equity awards will remain subject to the terms and conditions of the applicable equity incentive plan and any corresponding award agreement(s); (vi) monthly payments for a period of 18 months equal to the premium Mr Marsh would be required to pay for COBRA continuation coverage under James Hardie’s health benefit plans, determined using the COBRA premium rate in effect for the level of coverage that Mr Marsh has in place immediately prior to termination; and (vii) the Company will assist Mr Marsh in finding other employment opportunities by providing to him, at James Hardie’s limited expense, reasonable professional outplacement services through the provider of James Hardie’s choice for a period of up to 24 months.
|
|
•
|
Pursuant to the confidentiality, non-competition and non-solicitation provisions of the Marsh Agreement, for a period of 24 months following any termination of Mr Marsh’s employment, Mr Marsh shall be prohibited from: (i) directly or indirectly acting, engaging in, have a financial or other interest in, or otherwise serving as an employee, agent, partner, shareholder, director, or consultant for certain designated competitors of the Company; and (ii) employing or retaining or soliciting for employment any person who is an employee or consultant of the Company or soliciting suppliers or customers of the Company or inducing any such person to terminate his, her, or its relationship with the Company.
|
|
(US dollars)
|
|
Primary
|
|
Post-
employment
|
|
Equity Awards
|
|
Other
|
TOTAL
|
||||||||||||||
|
Name
|
|
Base Pay
1
|
|
STI
Award
2
|
|
Other
Benefits
3
|
|
401(k)
|
|
Ongoing Vesting
4
|
|
Mark-to
Market
5
|
|
Relocation
Allowances,
and Other
Nonrecurring
6
|
|||||||||
|
J Truong
7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Fiscal Year 2019
|
|
679,396
|
|
|
949,362
|
|
|
46,902
|
|
|
17,226
|
|
|
1,412,235
|
|
|
(337,627
|
)
|
|
30,528
|
|
2,798,022
|
|
|
Fiscal Year 2018
|
|
576,923
|
|
|
718,515
|
|
|
44,685
|
|
|
24,508
|
|
|
621,741
|
|
|
39,814
|
|
|
302,355
|
|
2,328,541
|
|
|
L Gries
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Fiscal Year 2019
|
|
950,000
|
|
|
1,453,500
|
|
|
142,152
|
|
|
17,259
|
|
|
6,041,539
|
|
|
(2,125,994
|
)
|
|
—
|
|
6,478,456
|
|
|
Fiscal Year 2018
|
|
950,000
|
|
|
902,500
|
|
|
99,201
|
|
|
16,200
|
|
|
5,891,642
|
|
|
213,689
|
|
|
—
|
|
8,073,232
|
|
|
M Marsh
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Fiscal Year 2019
|
|
621,923
|
|
|
578,340
|
|
|
77,524
|
|
|
16,915
|
|
|
2,158,119
|
|
|
(731,729
|
)
|
|
—
|
|
2,721,092
|
|
|
Fiscal Year 2018
|
|
589,231
|
|
|
319,200
|
|
|
73,023
|
|
|
16,754
|
|
|
1,947,188
|
|
|
111,348
|
|
|
—
|
|
3,056,744
|
|
|
S Gadd
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Fiscal Year 2019
|
|
525,289
|
|
|
373,200
|
|
|
47,548
|
|
|
17,210
|
|
|
1,389,526
|
|
|
(467,763
|
)
|
|
100,000
|
|
1,985,010
|
|
|
Fiscal Year 2018
|
|
475,231
|
|
|
130,200
|
|
|
58,888
|
|
|
17,474
|
|
|
1,300,430
|
|
|
51,661
|
|
|
150,000
|
|
2,183,884
|
|
|
J Blasko
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Fiscal Year 2019
|
|
434,317
|
|
|
321,484
|
|
|
59,065
|
|
|
16,677
|
|
|
688,153
|
|
|
(240,355
|
)
|
|
—
|
|
1,279,341
|
|
|
Fiscal Year 2018
|
|
419,615
|
|
|
206,550
|
|
|
53,235
|
|
|
16,477
|
|
|
691,901
|
|
|
30,025
|
|
|
—
|
|
1,417,803
|
|
|
Z Nielsen
9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Fiscal Year 2019
|
|
376,923
|
|
|
—
|
|
|
45,748
|
|
|
3,808
|
|
|
506,476
|
|
|
(212,519
|
)
|
|
411,590
|
|
1,132,026
|
|
|
Fiscal Year 2018
|
|
298,077
|
|
|
300,000
|
|
|
24,263
|
|
|
—
|
|
|
621,741
|
|
|
39,814
|
|
|
266,667
|
|
1,550,562
|
|
|
TOTAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Fiscal Year 2019
|
|
3,587,848
|
|
|
3,675,886
|
|
|
418,939
|
|
|
89,095
|
|
|
12,196,048
|
|
|
(4,115,987
|
)
|
|
542,118
|
|
16,393,947
|
|
|
Fiscal Year 2018
|
|
3,309,077
|
|
|
2,576,965
|
|
|
353,295
|
|
|
91,413
|
|
|
11,074,643
|
|
|
486,351
|
|
|
719,022
|
|
18,610,766
|
|
|
1
|
Base pay for fiscal years 2019 and 2018 includes salary paid to Senior Executive Officers for the 26 bi-weekly paychecks received during the fiscal years.
|
|
2
|
For further details on STI awards paid for fiscal years 2019, see “Incentive Arrangements” above in this Remuneration section. Amounts reflect actual STI awards to be paid in June 2019 and paid in June 2018, for fiscal years 2019 and 2018, respectively.
|
|
3
|
Includes the aggregate amount of all other benefits received in the year indicated. Examples of benefits that may be received include medical and life insurance benefits, car allowances, membership in executive wellness programs, and financial planning and tax services.
|
|
4
|
Includes equity award expense for grants of Scorecard LTI awards, relative TSR RSUs and ROCE RSUs. Relative TSR RSUs are valued using a Monte Carlo simulation method. ROCE RSUs and Scorecard LTI awards are valued based on the Company’s share price at each balance sheet date adjusted for the fair value of estimated dividends as well as the Remuneration Committee’s current expectation of the amount of the RSUs or awards which will vest. The fair value of equity awards granted are included in compensation over the periods in which the equity awards vest. For ROCE RSUs and Scorecard LTI awards, this amount excludes adjustments to the equity award expense in previous fiscal years resulting from changes in the Company’s share price, which is disclosed separately in the Equity Awards “Mark-to-Market” column.
|
|
5
|
The amount included in this column is the equity award expense in relation to ROCE RSUs and Scorecard LTI awards resulting from changes in fair market value of the US dollar share price during the fiscal years 2019 and 2018 as well as adjustments to performance ratings based on review by the Board of Directors. During fiscal year 2019, there was a 26.6% decrease in our share price from US$17.53 to US$12.87. During fiscal year 2018, there was an 11.5% appreciation in our share price from US$15.72 to US$17.53.
|
|
6
|
Includes the aggregate of non-recurring payments or other benefits received in the year indicated. Examples include one-time signing bonus or other limited payments connected to initial retention, one-time discretionary bonus payments, relocation allowances and costs and severance payments.
|
|
7
|
J Truong's base pay includes US$34,289 in fiscal year 2019, which is allocated for tax purposes to his services on the Company’s Board. Dr Truong was elected to the Board on 31 January 2019.
|
|
8
|
L Gries' base pay includes US$172,016 and US$196,876 in fiscal years 2019 and 2018, respectively, which is allocated for tax purposes to his services on the Company’s Board. Mr Gries resigned from the Board on 31 January 2019.
|
|
9
|
Mr Nielsen left the Company during fiscal year 2019. The amount in the Relocation Allowances and Other Nonrecurring column includes severance paid to Mr Nielsen following his exit from the Company.
|
|
|
Scorecard LTI
1
(US dollars)
|
||||||||||||
|
|
FY2019
|
FY2020
|
FY2021
|
FY2022
|
FY2023
|
TOTAL
|
|
||||||
|
J Truong
|
203,118
|
|
389,982
|
|
388,917
|
|
148,108
|
|
—
|
|
1,130,125
|
|
|
|
L Gries
|
498,288
|
|
806,962
|
|
804,757
|
|
—
|
|
—
|
|
2,110,007
|
|
|
|
M Marsh
|
130,528
|
|
211,385
|
|
210,808
|
|
80,280
|
|
—
|
|
633,001
|
|
|
|
S Gadd
|
87,018
|
|
140,922
|
|
140,537
|
|
53,520
|
|
—
|
|
421,997
|
|
|
|
J Blasko
|
54,385
|
|
88,075
|
|
87,834
|
|
33,449
|
|
—
|
|
263,743
|
|
|
|
Z Nielsen
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
|
|
973,337
|
|
1,637,326
|
|
1,632,853
|
|
315,357
|
|
—
|
|
4,558,873
|
|
|
|
|
ROCE RSUs
2
(US dollars)
|
||||||||||||
|
|
FY2019
|
FY2020
|
FY2021
|
FY2022
|
FY2023
|
TOTAL
|
|
||||||
|
J Truong
|
83,494
|
|
140,933
|
|
140,548
|
|
53,524
|
|
—
|
|
418,499
|
|
|
|
L Gries
|
215,924
|
|
349,682
|
|
348,726
|
|
—
|
|
—
|
|
914,332
|
|
|
|
M Marsh
|
56,559
|
|
91,596
|
|
91,346
|
|
34,786
|
|
—
|
|
274,287
|
|
|
|
S Gadd
|
37,707
|
|
61,065
|
|
60,898
|
|
23,191
|
|
—
|
|
182,861
|
|
|
|
J Blasko
|
23,566
|
|
38,164
|
|
38,060
|
|
14,494
|
|
—
|
|
114,284
|
|
|
|
Z Nielsen
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
|
|
417,250
|
|
681,440
|
|
679,578
|
|
125,995
|
|
—
|
|
1,904,263
|
|
|
|
|
Relative TSR RSUs
3
(US dollars)
|
||||||||||||
|
|
FY2019
|
FY2020
|
FY2021
|
FY2022
|
FY2023
|
TOTAL
|
|
||||||
|
J Truong
|
166,036
|
|
278,952
|
|
278,190
|
|
105,941
|
|
—
|
|
829,119
|
|
|
|
L Gries
|
467,460
|
|
757,037
|
|
754,968
|
|
—
|
|
—
|
|
1,979,465
|
|
|
|
M Marsh
|
122,453
|
|
198,309
|
|
197,767
|
|
75,314
|
|
—
|
|
593,843
|
|
|
|
S Gadd
|
81,635
|
|
132,206
|
|
131,844
|
|
50,209
|
|
—
|
|
395,894
|
|
|
|
J Blasko
|
51,022
|
|
82,629
|
|
82,404
|
|
31,381
|
|
—
|
|
247,436
|
|
|
|
Z Nielsen
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
|
|
|
888,606
|
|
1,449,133
|
|
1,445,173
|
|
262,845
|
|
—
|
|
4,045,757
|
|
|
|
1
|
Represents annual SG&A expense for Scorecard LTI granted in August 2018, September 2018 and January 2019. The fair value of each award is adjusted for changes in our common stock price at each balance sheet date, adjusted for the fair value of estimated dividends, until the final scorecard rating is applied in August 2021 at which time the final values are based on the Company’s share price and the senior executive’s scorecard rating at the time of each respective vesting.
|
|
2
|
Represents annual SG&A expense for the ROCE RSUs granted in August 2018 and September 2018. The fair value of each RSU is adjusted for changes in JHI plc’s common stock price at each balance sheet date adjusted for the fair value of estimated dividends, until August 2021 when ROCE results are known and the Remuneration Committee makes a determination on the amount of negative discretion to be applied and some, all or none of the awards become vested.
|
|
3
|
Represents annual SG&A expense for the relative TSR RSUs granted in August and September 2018 with fair market value estimated using the Monte Carlo option-pricing method.
|
|
Name
|
Grant Date
|
Release Date
|
Holding and Unvested at 1 April 2018
|
|
Granted
|
|
Total Value at Grant
1
(US$)
|
|
Vested
|
|
Lapsed
|
|
Holding and Unvested at 30 April 2019
|
|
Fair Value per RSU
2
(US$)
|
|
||
|
J Truong
|
21-Aug-17
3
|
21-Aug-20
|
61,726
|
|
61,726
|
|
$
|
471,019
|
|
—
|
|
—
|
|
61,726
|
|
$
|
7.6308
|
|
|
|
21-Aug-17
4
|
21-Aug-20
|
34,110
|
|
34,110
|
|
$
|
484,086
|
|
—
|
|
—
|
|
34,110
|
|
$
|
14.1919
|
|
|
|
21-Aug-17
6
|
21-Aug-20
|
61,726
|
|
61,726
|
|
$
|
471,019
|
|
—
|
|
—
|
|
61,726
|
|
$
|
7.6308
|
|
|
|
21-Aug-17
7
|
21-Aug-20
|
34,110
|
|
34,110
|
|
$
|
484,086
|
|
—
|
|
—
|
|
34,110
|
|
$
|
14.1919
|
|
|
|
17-Aug-18
3
|
17-Aug-21
|
—
|
|
56,677
|
|
$
|
494,864
|
|
—
|
|
—
|
|
56,677
|
|
$
|
8.7313
|
|
|
|
17-Aug-18
4
|
17-Aug-21
|
—
|
|
30,553
|
|
$
|
444,375
|
|
—
|
|
—
|
|
30,553
|
|
$
|
14.5444
|
|
|
|
6-Sep-18
3
|
17-Aug-21
|
—
|
|
49,381
|
|
$
|
334,255
|
|
—
|
|
—
|
|
49,381
|
|
$
|
6.7689
|
|
|
|
6-Sep-18
4
|
17-Aug-21
|
—
|
|
25,385
|
|
$
|
343,817
|
|
—
|
|
—
|
|
25,385
|
|
$
|
13.5441
|
|
|
L Gries
|
16-Sep-14
3,5
|
16-Sep-17
|
162,717
|
|
260,346
|
|
$
|
1,883,812
|
|
(62,561
|
)
|
(100,156
|
)
|
—
|
|
$
|
7.2358
|
|
|
|
16-Sep-15
3
|
16-Sep-18
|
292,514
|
|
292,514
|
|
$
|
2,448,459
|
|
(76,419
|
)
|
—
|
|
216,095
|
|
$
|
8.3704
|
|
|
|
16-Sep-15
4
|
16-Sep-18
|
254,480
|
|
254,480
|
|
$
|
3,227,875
|
|
(178,136
|
)
|
(76,344
|
)
|
—
|
|
$
|
12.6842
|
|
|
|
16-Sep-16
3
|
16-Sep-19
|
218,159
|
|
218,159
|
|
$
|
2,334,585
|
|
—
|
|
—
|
|
218,159
|
|
$
|
10.7013
|
|
|
|
16-Sep-16
4
|
16-Sep-19
|
194,626
|
|
194,626
|
|
$
|
3,045,566
|
|
—
|
|
—
|
|
194,626
|
|
$
|
15.6483
|
|
|
|
21-Aug-17
3
|
21-Aug-20
|
246,902
|
|
246,902
|
|
$
|
1,884,060
|
|
—
|
|
—
|
|
246,902
|
|
$
|
7.6308
|
|
|
|
21-Aug-17
4
|
21-Aug-20
|
136,441
|
|
136,441
|
|
$
|
1,936,357
|
|
—
|
|
—
|
|
136,441
|
|
$
|
14.1919
|
|
|
|
17-Aug-18
3
|
17-Aug-21
|
—
|
|
226,709
|
|
$
|
1,979,464
|
|
—
|
|
—
|
|
226,709
|
|
$
|
8.7313
|
|
|
|
17-Aug-18
4
|
17-Aug-21
|
—
|
|
122,211
|
|
$
|
1,777,486
|
|
—
|
|
—
|
|
122,211
|
|
$
|
14.5444
|
|
|
M Marsh
|
16-Sep-14
3
|
16-Sep-17
|
24,242
|
|
38,787
|
|
$
|
280,655
|
|
(8,339
|
)
|
(15,903
|
)
|
—
|
|
$
|
7.2358
|
|
|
|
16-Sep-15
3
|
16-Sep-18
|
65,816
|
|
65,816
|
|
$
|
550,906
|
|
(17,194
|
)
|
—
|
|
48,622
|
|
$
|
8.3704
|
|
|
|
16-Sep-15
4
|
16-Sep-18
|
57,258
|
|
57,258
|
|
$
|
726,272
|
|
(40,080
|
)
|
(17,178
|
)
|
—
|
|
$
|
12.6842
|
|
|
|
16-Sep-16
3
|
16-Sep-19
|
65,448
|
|
65,448
|
|
$
|
700,379
|
|
—
|
|
—
|
|
65,448
|
|
$
|
10.7013
|
|
|
|
16-Sep-16
4
|
16-Sep-19
|
58,388
|
|
58,388
|
|
$
|
913,673
|
|
—
|
|
—
|
|
58,388
|
|
$
|
15.6483
|
|
|
|
21-Aug-17
3
|
21-Aug-20
|
74,071
|
|
74,071
|
|
$
|
565,221
|
|
—
|
|
—
|
|
74,071
|
|
$
|
7.6308
|
|
|
|
21-Aug-17
4
|
21-Aug-20
|
40,932
|
|
40,932
|
|
$
|
580,903
|
|
—
|
|
—
|
|
40,932
|
|
$
|
14.1919
|
|
|
|
21-Aug-17
6
|
21-Aug-20
|
74,071
|
|
74,071
|
|
$
|
565,221
|
|
—
|
|
—
|
|
74,071
|
|
$
|
7.6308
|
|
|
|
21-Aug-17
7
|
21-Aug-20
|
40,932
|
|
40,932
|
|
$
|
580,903
|
|
—
|
|
—
|
|
40,932
|
|
$
|
14.1919
|
|
|
|
17-Aug-18
3
|
17-Aug-21
|
—
|
|
68,013
|
|
$
|
593,842
|
|
—
|
|
—
|
|
68,013
|
|
$
|
8.7313
|
|
|
|
17-Aug-18
4
|
17-Aug-21
|
—
|
|
36,663
|
|
$
|
533,241
|
|
—
|
|
—
|
|
36,663
|
|
$
|
14.5444
|
|
|
S Gadd
|
16-Sep-14
3
|
16-Sep-17
|
24,242
|
|
38,787
|
|
$
|
280,655
|
|
(8,339
|
)
|
(15,903
|
)
|
—
|
|
$
|
7.2358
|
|
|
|
16-Sep-15
3
|
16-Sep-18
|
47,533
|
|
47,533
|
|
$
|
397,870
|
|
(12,417
|
)
|
—
|
|
35,116
|
|
$
|
8.3704
|
|
|
|
16-Sep-15
4
|
16-Sep-18
|
41,353
|
|
41,353
|
|
$
|
524,530
|
|
(28,947
|
)
|
(12,406
|
)
|
—
|
|
$
|
12.6842
|
|
|
|
16-Sep-16
3
|
16-Sep-19
|
35,451
|
|
35,451
|
|
$
|
379,372
|
|
—
|
|
—
|
|
35,451
|
|
$
|
10.7013
|
|
|
|
16-Sep-16
4
|
16-Sep-19
|
31,627
|
|
31,627
|
|
$
|
494,909
|
|
—
|
|
—
|
|
31,627
|
|
$
|
15.6483
|
|
|
|
21-Aug-17
3
|
21-Aug-20
|
49,380
|
|
49,380
|
|
$
|
376,809
|
|
—
|
|
—
|
|
49,380
|
|
$
|
7.6308
|
|
|
|
21-Aug-17
4
|
21-Aug-20
|
27,288
|
|
27,288
|
|
$
|
387,269
|
|
—
|
|
—
|
|
27,288
|
|
$
|
14.1919
|
|
|
|
21-Aug-17
6
|
21-Aug-20
|
49,380
|
|
49,380
|
|
$
|
376,809
|
|
—
|
|
—
|
|
49,380
|
|
$
|
7.6308
|
|
|
|
21-Aug-17
7
|
21-Aug-20
|
27,288
|
|
27,288
|
|
$
|
387,269
|
|
—
|
|
—
|
|
27,288
|
|
$
|
14.1919
|
|
|
|
17-Aug-18
3
|
17-Aug-21
|
—
|
|
45,342
|
|
$
|
395,895
|
|
—
|
|
—
|
|
45,342
|
|
$
|
8.7313
|
|
|
|
17-Aug-18
4
|
17-Aug-21
|
—
|
|
24,442
|
|
$
|
355,494
|
|
—
|
|
—
|
|
24,442
|
|
$
|
14.5444
|
|
|
J Blasko
|
16-Sep-14
3
|
16-Sep-17
|
14,545
|
|
23,272
|
|
$
|
168,392
|
|
(5,003
|
)
|
(9,542
|
)
|
—
|
|
$
|
7.2358
|
|
|
|
16-Sep-15
3
|
16-Sep-18
|
29,251
|
|
29,251
|
|
$
|
244,843
|
|
(7,641
|
)
|
—
|
|
21,610
|
|
$
|
8.3704
|
|
|
|
16-Sep-15
4
|
16-Sep-18
|
25,448
|
|
25,448
|
|
$
|
322,788
|
|
(17,813
|
)
|
(7,635
|
)
|
—
|
|
$
|
12.6842
|
|
|
|
16-Sep-16
3
|
16-Sep-19
|
24,543
|
|
24,543
|
|
$
|
262,642
|
|
—
|
|
—
|
|
24,543
|
|
$
|
10.7013
|
|
|
|
16-Sep-16
4
|
16-Sep-19
|
21,895
|
|
21,895
|
|
$
|
342,620
|
|
—
|
|
—
|
|
21,895
|
|
$
|
15.6483
|
|
|
|
21-Aug-17
3
|
21-Aug-20
|
30,863
|
|
30,863
|
|
$
|
235,509
|
|
—
|
|
—
|
|
30,863
|
|
$
|
7.6308
|
|
|
|
21-Aug-17
4
|
21-Aug-20
|
17,055
|
|
17,055
|
|
$
|
242,043
|
|
—
|
|
—
|
|
17,055
|
|
$
|
14.1919
|
|
|
|
17-Aug-18
3
|
17-Aug-21
|
—
|
|
28,339
|
|
$
|
247,436
|
|
—
|
|
—
|
|
28,339
|
|
$
|
8.7313
|
|
|
|
17-Aug-18
4
|
17-Aug-21
|
—
|
|
15,276
|
|
$
|
222,180
|
|
—
|
|
—
|
|
15,276
|
|
$
|
14.5444
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Name
|
Grant Date
|
Release Date
|
Holding and Unvested at 1 April 2018
|
|
Granted
|
|
Total Value at Grant
1
(US$)
|
|
Vested
|
|
Lapsed
|
|
Holding and Unvested at 30 April 2019
|
|
Fair Value per RSU
2
(US$)
|
|
||
|
Z Nielsen
|
21-Aug-17
3
|
21-Aug-20
|
61,726
|
|
61,726
|
|
$
|
471,019
|
|
—
|
|
(34,567
|
)
|
27,159
|
|
$
|
7.6308
|
|
|
|
21-Aug-17
4
|
21-Aug-20
|
34,110
|
|
34,110
|
|
$
|
484,086
|
|
—
|
|
(19,102
|
)
|
15,008
|
|
$
|
14.1919
|
|
|
|
21-Aug-17
6
|
21-Aug-20
|
61,726
|
|
61,726
|
|
$
|
471,019
|
|
—
|
|
(45,060
|
)
|
16,666
|
|
$
|
7.6308
|
|
|
|
21-Aug-17
7
|
21-Aug-20
|
34,110
|
|
34,110
|
|
$
|
484,086
|
|
—
|
|
(24,901
|
)
|
9,209
|
|
$
|
14.1919
|
|
|
|
17-Aug-18
3
|
17-Aug-21
|
—
|
|
56,677
|
|
$
|
494,864
|
|
—
|
|
(56,677
|
)
|
—
|
|
$
|
8.7313
|
|
|
|
17-Aug-18
4
|
17-Aug-21
|
—
|
|
30,553
|
|
$
|
444,375
|
|
—
|
|
(30,553
|
)
|
—
|
|
$
|
14.5444
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
1
|
Total Value at Grant = Fair Value per RSU multiplied by number of RSUs granted. The number of RSUs granted are at maximum achievement.
|
|
2
|
Fair Value per RSU is estimated on the date of grant using a binomial lattice model that incorporates a Monte Carlo simulation for Relative TSR RSUs. The fair value for ROCE RSUs is the share price on the date of grant, adjusted for the fair value of estimated dividends as the RSU holder is not entitled to dividends over the vesting period.
|
|
3
|
Relative TSR RSUs granted under the LTIP. These RSUs are subject to performance hurdles.
|
|
4
|
ROCE RSUs granted under the LTIP. These RSUs are subject to performance hurdles as well as the potential application of negative discretion.
|
|
5
|
Mr Gries was also granted a cash-settled award (equivalent to 11,164 units) on 16 September 2014. This cash-settled award may vest based on the same vesting criteria as his relative TSR RSU grant and may only vest in the event that his relative TSR RSU grant vests in full. Upon vesting, the award will be settled in cash based on the number of units vested and the fair market value of our shares of common stock as of the relevant vesting date.
|
|
6
|
Special one-time retention grant of Relative TSR RSUs granted under the LTIP. These RSUs are subject to performance hurdles and service-based vesting criteria.
|
|
7
|
Special one-time retention grant of ROCE RSUs granted under the LTIP. These RSUs are subject to performance hurdles and service-based vesting criteria as well as the potential application of negative discretion.
|
|
Name
|
Grant Date
|
Release Date
|
Holding and Unvested at 1 April 2018
|
|
Granted
|
|
Vested
1
|
|
Lapsed
|
|
Holding and Unvested at 30 April 2019
|
|
|
J Truong
|
21-Aug-17
|
21-Aug-20
|
102,331
|
|
102,331
|
|
—
|
|
—
|
|
102,331
|
|
|
|
21-Aug-17
3
|
21-Aug-20
|
102,331
|
|
102,331
|
|
—
|
|
—
|
|
102,331
|
|
|
|
17-Aug-18
|
17-Aug-21
|
—
|
|
91,659
|
|
—
|
|
—
|
|
91,659
|
|
|
|
6-Sep-18
|
17-Aug-21
|
—
|
|
76,155
|
|
—
|
|
—
|
|
76,155
|
|
|
|
31-Jan-19
|
17-Aug-21
|
—
|
|
28,558
|
|
—
|
|
—
|
|
28,558
|
|
|
L Gries
|
16-Sep-15
|
16-Sep-18
|
286,290
|
|
286,290
|
|
(95,334
|
)
|
(190,956
|
)
|
—
|
|
|
|
16-Sep-16
2
|
16-Sep-19
|
218,954
|
|
218,954
|
|
—
|
|
—
|
|
218,954
|
|
|
|
21-Aug-17
|
21-Aug-20
|
409,323
|
|
409,323
|
|
—
|
|
—
|
|
409,323
|
|
|
|
17-Aug-18
|
17-Aug-21
|
—
|
|
366,634
|
|
—
|
|
—
|
|
366,634
|
|
|
M Marsh
|
16-Sep-15
|
16-Sep-18
|
64,415
|
|
64,415
|
|
(23,189
|
)
|
(41,226
|
)
|
—
|
|
|
|
16-Sep-16
2
|
16-Sep-19
|
65,686
|
|
65,686
|
|
—
|
|
—
|
|
65,686
|
|
|
|
21-Aug-17
|
21-Aug-20
|
122,797
|
|
122,797
|
|
—
|
|
—
|
|
122,797
|
|
|
|
21-Aug-17
3
|
21-Aug-20
|
122,797
|
|
122,797
|
|
—
|
|
—
|
|
122,797
|
|
|
|
17-Aug-18
|
17-Aug-21
|
—
|
|
109,990
|
|
—
|
|
—
|
|
109,990
|
|
|
S Gadd
|
16-Sep-15
|
16-Sep-18
|
46,522
|
|
46,522
|
|
(16,747
|
)
|
(29,775
|
)
|
—
|
|
|
|
16-Sep-16
2
|
16-Sep-19
|
35,580
|
|
35,580
|
|
—
|
|
—
|
|
35,580
|
|
|
|
21-Aug-17
|
21-Aug-20
|
81,865
|
|
81,865
|
|
—
|
|
—
|
|
81,865
|
|
|
|
21-Aug-17
3
|
21-Aug-20
|
81,865
|
|
81,865
|
|
—
|
|
—
|
|
81,865
|
|
|
|
17-Aug-18
|
17-Aug-21
|
—
|
|
73,327
|
|
—
|
|
—
|
|
73,327
|
|
|
J Blasko
|
16-Sep-15
|
16-Sep-18
|
28,629
|
|
28,629
|
|
(10,306
|
)
|
(18,323
|
)
|
—
|
|
|
|
16-Sep-16
2
|
16-Sep-19
|
24,632
|
|
24,632
|
|
—
|
|
—
|
|
24,632
|
|
|
|
21-Aug-17
|
21-Aug-20
|
51,165
|
|
51,165
|
|
—
|
|
—
|
|
51,165
|
|
|
|
17-Aug-18
|
17-Aug-21
|
—
|
|
45,829
|
|
—
|
|
—
|
|
45,829
|
|
|
Z Nielsen
|
21-Aug-17
|
21-Aug-20
|
102,331
|
|
102,331
|
|
—
|
|
(57,306
|
)
|
45,025
|
|
|
|
21-Aug-17
3
|
21-Aug-20
|
102,331
|
|
102,331
|
|
—
|
|
(74,702
|
)
|
27,629
|
|
|
|
17-Aug-18
|
17-Aug-21
|
—
|
|
91,659
|
|
—
|
|
(91,659
|
)
|
—
|
|
|
1
|
Represents the number of Scorecard LTI awards vesting after the Remuneration Committee’s application of the Scorecard in respect of fiscal years 2017-2019. A detailed assessment of the reasons for the Scorecard ratings was set out in the fiscal year 2018 Remuneration Report.
|
|
2
|
Scorecard LTI awards in respect of fiscal years 2017-2019 will vest on 16 September 2019. A detailed assessment of the Remuneration Committee’s assessment of management’s performance is set out on pages 46 to 48 of this Remuneration Report.
|
|
3
|
Special one-time retention grant of Scorecard LTI awards granted under the LTIP, which are also subject to service-based vesting criteria.
|
|
Position
|
|
Fiscal Year
2019 (US$)
|
|
|
Chairman
|
|
420,794
|
|
|
Board member
|
|
205,734
|
|
|
Audit Committee Chair
|
|
20,000
|
|
|
Remuneration Committee Chair
|
|
20,000
|
|
|
Nominating & Governance Committee Chair
|
|
20,000
|
|
|
Ad-hoc Board sub-committee attendance
1
|
|
3,000
|
|
|
(US dollars)
|
|
|
|
|
|
|
|
|
||||
|
Name
|
|
Primary
Directors’ Fees
1
|
|
Other Payments
2
|
|
Other Benefits
3
|
|
TOTAL
|
||||
|
M Hammes
|
|
|
|
|
|
|
|
|
||||
|
Fiscal Year 2019
|
|
426,794
|
|
|
447,059
|
|
|
30,509
|
|
|
904,362
|
|
|
Fiscal Year 2018
|
|
426,936
|
|
|
604,100
|
|
|
94,308
|
|
|
1,125,344
|
|
|
B Anderson
|
|
|
|
|
|
|
|
|
||||
|
Fiscal Year 2019
|
|
231,734
|
|
|
—
|
|
|
14,332
|
|
|
246,066
|
|
|
Fiscal Year 2018
|
|
237,876
|
|
|
—
|
|
|
—
|
|
|
237,876
|
|
|
D Harrison
|
|
|
|
|
|
|
|
|
||||
|
Fiscal Year 2019
|
|
220,734
|
|
|
—
|
|
|
23,673
|
|
|
244,407
|
|
|
Fiscal Year 2018
|
|
209,887
|
|
|
—
|
|
|
10,410
|
|
|
220,297
|
|
|
A Littley
|
|
|
|
|
|
|
|
|
||||
|
Fiscal Year 2019
|
|
214,734
|
|
|
—
|
|
|
—
|
|
|
214,734
|
|
|
Fiscal Year 2018
|
|
205,875
|
|
|
—
|
|
|
—
|
|
|
205,875
|
|
|
J Osborne
|
|
|
|
|
|
|
|
|
||||
|
Fiscal Year 2019
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Fiscal Year 2018
|
|
86,302
|
|
|
—
|
|
|
—
|
|
|
86,302
|
|
|
R van der Meer
|
|
|
|
|
|
|
|
|
||||
|
Fiscal Year 2019
|
|
210,734
|
|
|
—
|
|
|
—
|
|
|
210,734
|
|
|
Fiscal Year 2018
|
|
219,876
|
|
|
—
|
|
|
—
|
|
|
219,876
|
|
|
R Chenu
4
|
|
|
|
|
|
|
|
|
||||
|
Fiscal Year 2019
|
|
211,734
|
|
|
—
|
|
|
—
|
|
|
211,734
|
|
|
Fiscal Year 2018
|
|
214,876
|
|
|
—
|
|
|
—
|
|
|
214,876
|
|
|
A Gisle Joosen
|
|
|
|
|
|
|
|
|
||||
|
Fiscal Year 2019
|
|
214,734
|
|
|
—
|
|
|
—
|
|
|
214,734
|
|
|
Fiscal Year 2018
|
|
199,876
|
|
|
—
|
|
|
—
|
|
|
199,876
|
|
|
S Simms
|
|
|
|
|
|
|
|
|
||||
|
Fiscal Year 2019
|
|
92,558
|
|
|
—
|
|
|
—
|
|
|
92,558
|
|
|
Fiscal Year 2018
|
|
186,957
|
|
|
—
|
|
|
—
|
|
|
186,957
|
|
|
P Lisboa
|
|
|
|
|
|
|
|
|
||||
|
Fiscal Year 2019
|
|
223,799
|
|
|
—
|
|
|
—
|
|
|
223,799
|
|
|
Fiscal Year 2018
|
|
33,146
|
|
|
—
|
|
|
—
|
|
|
33,146
|
|
|
A Lloyd
|
|
|
|
|
|
|
|
|
||||
|
Fiscal Year 2019
|
|
83,859
|
|
|
—
|
|
|
—
|
|
|
83,859
|
|
|
Fiscal Year 2018
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
R Rodriguez
|
|
|
|
|
|
|
|
|
||||
|
Fiscal Year 2019
|
|
78,827
|
|
|
—
|
|
|
—
|
|
|
78,827
|
|
|
Fiscal Year 2018
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Total Compensation for Non-Executive Directors
|
||||||||||||
|
Fiscal Year 2019
|
|
2,210,241
|
|
|
447,059
|
|
|
68,514
|
|
|
2,725,814
|
|
|
Fiscal Year 2018
|
|
2,021,607
|
|
|
604,100
|
|
|
104,718
|
|
|
2,730,425
|
|
|
1
|
Amount includes base, Chairman and Committee Chairman fees, as well as fees for attendance at ad hoc sub-committee meetings.
|
|
2
|
Amount for fiscal year 2019 relates to: (i) a supplemental compensation payment of US$147,059 in relation to income for the year ended 31 December 2017 in circumstances where Irish income taxes levied on director compensation exceeded net income taxes owed on such compensation in their country of tax residence and paid in accordance with the remuneration policy for non-executive directors; and (ii) a US$3
0
0,000 exertion fee in recognition of the additional time commitment and contribution of the Chairman in association with: (i) his active participation in the induction, mentoring, support and assessment of newly recruited senior managers; (ii) the smooth transition of the former CEO and successful onboarding and induction of Dr Truong as both the CEO and as an executive director; and (iii) supporting Dr Truong in continuing the development of the high performance leadership team during the transition phase which is anticipated to continue through fiscal year 2020. A more complete description of the Chairman’s role with regard to management succession planning is contained in Section 1 - Corporate Governance Report of this Annual Report. Amount for fiscal year 2018 relates to a supplemental compensation payment in relation to income from the years ended 31 December 2010 through 31 December 2016 in circumstances where Irish income taxes levied on director compensation exceeded net income taxes owed on such compensation in their country of tax residence and paid in accordance with the remuneration policy for non-executive directors
.
|
|
3
|
Amount includes the cost of non-executive directors’ fiscal compliance in Ireland and other costs connected with Board-related events paid for by the Company.
|
|
4
|
In addition to the compensation set forth above, Mr Chenu continues to receive certain tax services from the Company, and remains eligible for certain tax equalization benefits relative to the vesting of previously granted equity awards, stemming from his prior service as an executive officer of the Company.
|
|
|
Years Ended 31 March
|
||||||
|
(In US dollars)
|
2019
|
|
2018
|
||||
|
Managerial Services
1
|
$
|
6,292,737
|
|
|
$
|
7,876,356
|
|
|
Director Services
2
|
2,725,814
|
|
|
2,927,303
|
|
||
|
|
$
|
9,018,551
|
|
|
$
|
10,803,659
|
|
|
1
|
Includes cash payments, non-cash benefits (examples include medical and life insurance benefits, car allowances, membership in executive wellness programs, financial planning and tax services), 401(k) benefits, and amounts expensed for outstanding equity awards for former CEO L Gries and current CEO J Truong.
|
|
2
|
Includes compensation for all non-executive directors, which includes base, Chairman, Chairman exertion fee, supplemental compensation fee (as described in footnote 2 of the table above which sets out the remuneration for non-executive directors), Committee Chairman fee and cost of non-employee directors’ fiscal compliance in Ireland. It includes costs connected with Board-related events paid for by the Company and it includes a proportion of the former CEO L Gries and current CEO J Truong’s remuneration paid as fees for their service on the JHI plc Board in fiscal years 2019 and 2018.
|
|
Name
|
|
CUFS at
30 April
2019
|
|
CUFS at
30 April
2018
|
|
RSUs at
30 April
2019
|
|
RSUs at
30 April
2018
|
||||
|
J Truong
|
|
—
|
|
|
—
|
|
|
353,668
|
|
|
191,672
|
|
|
L Gries
|
|
547,208
|
|
|
504,507
|
|
|
1,361,143
|
|
|
1,505,839
|
|
|
M Marsh
|
|
104,317
|
|
|
61,251
|
|
|
507,140
|
|
|
501,158
|
|
|
S Gadd
|
|
55,101
|
|
|
55,101
|
|
|
325,314
|
|
|
333,542
|
|
|
J Blasko
|
|
52,213
|
|
|
46,837
|
|
|
159,581
|
|
|
163,600
|
|
|
Z Nielsen
|
|
—
|
|
|
—
|
|
|
68,042
|
|
|
191,672
|
|
|
Name
|
|
CUFS at
30 April
2019
|
|
CUFS at
30 April
2018
|
||
|
M Hammes
1
|
|
44,109
|
|
|
44,109
|
|
|
B Anderson
2
|
|
18,920
|
|
|
18,920
|
|
|
R Chenu
|
|
105,518
|
|
|
105,518
|
|
|
A Gisle Joosen
|
|
3,420
|
|
|
2,480
|
|
|
D Harrison
3
|
|
19,259
|
|
|
19,259
|
|
|
P Lisboa
4
|
|
2,389
|
|
|
—
|
|
|
A Littley
5
|
|
2,045
|
|
|
2,045
|
|
|
A Lloyd
6
|
|
18,000
|
|
|
—
|
|
|
J Osborne
7
|
|
—
|
|
|
—
|
|
|
R Rodriguez
|
|
—
|
|
|
—
|
|
|
S Simms
8
|
|
—
|
|
|
—
|
|
|
R van der Meer
|
|
17,290
|
|
|
17,290
|
|
|
1
|
35,109 CUFS held in the name of Mr and Mrs Hammes and 9,000 CUFS held as American Depositary Shares (“ADSs”) in the name of Mr and Mrs Hammes.
|
|
2
|
7,635 CUFS held in the name of Mr Anderson, 390 CUFS held as ADSs in the name of Mr Anderson and 10,895 CUFS held as ADSs in the name of Mr and Mrs Anderson.
|
|
3
|
2,384 CUFS held in the name of Mr Harrison, 1,000 CUFS held as ADSs in the name of Mr Harrison and 15,875 CUFS held as ADSs in the name of Mr and Mrs Harrison.
|
|
4
|
2,389 CUFS held as ADSs in the name of Mr Lisboa.
|
|
5
|
2,045 CUFS held as ADSs in the name of Ms Littley.
|
|
6
|
18,000 CUFS held as ADSs in the name of Ms Lloyd.
|
|
7
|
Ceased to be a director on 18 August 2017.
|
|
8
|
Resigned from the Board on 24 August 2018.
|
|
•
|
the LTIP; and
|
|
Restricted Stock Units
|
|||||||
|
Grant Type
|
Grant Date
|
Granted
|
|
Vested as of
31 March 2019 |
|
Outstanding as of 31 March 2019
|
|
|
TSR
|
September 2015
|
579,262
|
|
121,982
|
|
367,978
|
|
|
TSR
|
September 2016
|
456,819
|
|
—
|
|
422,684
|
|
|
ROCE
|
September 2016
|
407,539
|
|
—
|
|
377,087
|
|
|
TSR
|
August 2017
|
685,490
|
|
—
|
|
593,827
|
|
|
ROCE
|
August 2017
|
378,809
|
|
—
|
|
328,154
|
|
|
TSR - Retention
|
August 2017
|
246,903
|
|
—
|
|
201,843
|
|
|
ROCE - Retention
|
August 2017
|
136,440
|
|
—
|
|
111,539
|
|
|
TSR
|
August 2018
|
663,738
|
|
—
|
|
567,387
|
|
|
ROCE
|
August 2018
|
357,797
|
|
—
|
|
305,857
|
|
|
TSR
|
September 2018
|
49,381
|
|
—
|
|
49,381
|
|
|
ROCE
|
September 2018
|
25,385
|
|
—
|
|
25,385
|
|
|
|
|
Total Outstanding
|
|
3,351,122
|
|
||
|
Scorecard LTI
|
|||
|
Grant Type
|
Grant Date
|
Granted and Outstanding as of 31 March 2019
|
|
|
Scorecard
|
September 2016
|
424,224
|
|
|
Scorecard
|
August 2017
|
984,463
|
|
|
Scorecard - Retention
|
August 2017
|
334,622
|
|
|
Scorecard
|
August 2018
|
917,576
|
|
|
Scorecard
|
September 2018
|
76,155
|
|
|
Scorecard
|
January 2019
|
28,558
|
|
|
|
|
2,765,598
|
|
|
Restricted Stock Units
|
||||||
|
Grant Date
|
Granted
|
|
Vested as of
31 March 2019 |
|
Outstanding as of 31 March 2019
|
|
|
December 2016
|
297,388
|
|
123,308
|
|
108,342
|
|
|
December 2017
|
320,909
|
|
75,554
|
|
204,957
|
|
|
February 2018
|
3,926
|
|
982
|
|
2,396
|
|
|
December 2018
|
545,185
|
|
3,475
|
|
522,083
|
|
|
March 2019
|
72,608
|
|
—
|
|
72,608
|
|
|
|
Total Outstanding
|
|
910,386
|
|
||
|
•
|
Generally, in the United States, an audit committee of a public company is directly responsible for appointing the company’s independent registered public accounting firm, with such appointment being subsequently ratified by shareholders. Under Irish law, the independent registered public accounting firm is directly appointed by the shareholders where there is a new appointment. Otherwise, the appointment is deemed to continue unless the firm retires, is asked to retire or is unable to perform their duties; and
|
|
•
|
NYSE rules require each issuer to have an audit committee, a compensation committee (equivalent to a remuneration committee) and a nominating committee composed entirely of independent directors. As a foreign private issuer, the Company does not have to comply with this requirement; however, the Board committee charters reflect Australian and Irish practices, in that such Board committees have a majority of independent directors, unless a higher number or percentage is mandated.
|
|
•
|
appointing, removing and assessing the performance and remuneration of the CEO and CFO;
|
|
•
|
succession planning for the Board and senior management and defining the Company’s management structure and responsibilities;
|
|
•
|
approving the overall strategy for the Company, including the business plan and annual operating and capital expenditure budgets;
|
|
•
|
ensuring that the Company has in place an appropriate risk management framework and that the risk appetite and tolerances are set at an appropriate level;
|
|
•
|
convening and monitoring the operation of shareholder meetings and approving matters to be submitted to shareholders for their consideration;
|
|
•
|
approving annual and periodic reports, results announcements and related media releases, and notices of shareholder meetings;
|
|
•
|
approving the dividend policy and interim dividends and, when appropriate, making recommendations to shareholders regarding the annual dividend;
|
|
•
|
reviewing the authority levels of the CEO and management;
|
|
•
|
approving the remuneration framework for the Company;
|
|
•
|
overseeing corporate governance matters for the Company;
|
|
•
|
approving corporate-level Company policies;
|
|
•
|
considering management’s recommendations on various matters which are above the authority levels delegated to the CEO or management; and
|
|
•
|
any other matter which the Board considers appropriate to be approved by the Board.
|
|
•
|
Audit Committee;
|
|
•
|
Remuneration Committee; and
|
|
•
|
Nominating and Governance Committee.
|
|
|
|
Board
|
|
Audit
|
|
Remuneration
|
|
Nominating &
Governance
|
||||||||||||||
|
Name
|
|
H
|
|
A
|
|
Member
|
|
H
|
|
A
|
|
Member
|
|
H
|
|
A
|
|
Member
|
|
H
|
|
A
|
|
M Hammes
|
|
5
|
|
5
|
|
•
|
|
4
|
|
4
|
|
•
|
|
6
|
|
6
|
|
•
|
|
5
|
|
5
|
|
B Anderson
|
|
5
|
|
4
|
|
C
|
|
5
|
|
5
|
|
•
|
|
6
|
|
5
|
|
|
|
|
|
|
|
R Chenu
|
|
5
|
|
5
|
|
|
|
|
|
|
|
•
|
|
6
|
|
6
|
|
•
|
|
5
|
|
5
|
|
D Harrison
|
|
5
|
|
5
|
|
•
|
|
5
|
|
5
|
|
|
|
|
|
|
|
C
|
|
4
|
|
4
|
|
A Gisle Joosen
|
|
5
|
|
5
|
|
•
|
|
5
|
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
P Lisboa
|
|
5
|
|
5
|
|
|
|
|
|
|
|
C
|
|
4
|
|
4
|
|
•
|
|
4
|
|
4
|
|
A Littley
|
|
5
|
|
5
|
|
•
|
|
5
|
|
5
|
|
•
|
|
6
|
|
5
|
|
|
|
|
|
|
|
A Lloyd
|
|
1
|
|
1
|
|
•
|
|
1
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
R Rodriguez
|
|
1
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
|
1
|
|
1
|
|
S Simms
|
|
2
|
|
1
|
|
|
|
|
|
|
|
•
|
|
3
|
|
2
|
|
•
|
|
2
|
|
1
|
|
R van der Meer
1
|
|
5
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
|
5
|
|
2
|
|
A
|
Number of meetings attended during the time the director held office or was a member of the Board committee during the fiscal year. Non-committee members may also attend Board committee meetings from time to time; these attendances are not shown.
|
|
1
|
Mr van der Meer was unable to attend some meetings due to illness.
|
|
Level
|
|
Percentage of female
employees
|
|
Percentage of employees with
diversity characteristics
|
|
James Hardie Board
1
|
|
40% (4 of 10)
|
|
60% (6 of 10)
|
|
US BUSINESS
2
|
||||
|
Senior leadership positions
3
|
|
16% (28 of 171)
|
|
30% (52 of 171)
|
|
All management positions
|
|
17% (68 of 396)
|
|
30% (117 of 396)
|
|
Total workforce
|
|
13% (331 of 2,634)
|
|
38% (989 of 2,634)
|
|
NON-US BUSINESSES
4
|
||||
|
Senior leadership positions
3
|
|
10% (3 of 30)
|
|
|
|
All management positions
|
|
20% (51 of 252)
|
|
|
|
Total workforce
|
|
17% (362 of 2,130)
|
|
|
|
1
|
Includes gender and race diversity characteristics for the Board. CEO is reported with US Business Senior leadership positions.
|
|
2
|
Includes US employees with diversity characteristics including gender, race or national origin.
|
|
3
|
Senior Leaders are defined as individuals at senior manager and director level and above who participate in the Company and Individual Performance (CIP) Plan.
|
|
4
|
Race/national origin diversity characteristics vary between countries and are therefore not captured in aggregate for Non-US businesses.
|
|
•
|
diversity characteristics in excess of 30%; and
|
|
•
|
women in excess of 20% among non-executive directors.
|
|
Objectives
|
FY19 Actions and Outcomes
|
FY20 Plans
|
|
To promote a culture of diversity (which includes gender, skills, experience, and other elements that reflect a broad representation of individuals with various backgrounds)
|
•
North American employees and leaders completed “Creating a Harassment Free Workplace” training in FY19.
•
Created operating committee of the top 45 global leaders to drive collaboration and best practice sharing to achieve strategic business, which is comprised of 16% women.
•
International Women’s Day events and recognition occurred across all of the Asia-Pacific region during the week of 8 March 2019.
•
Became members of the National Association of Women in Construction (NAWIC) and attended the NAWIC awards in Australia.
•
Held events for Lunar / Chinese New Year, Diwali, Waitangi Day, and several other culturally significant holidays to celebrate the diverse backgrounds of our people.
•
In both the Philippines and New Zealand, the management teams have nearly 50/50 splits between males and females.
|
•
Global initiatives will continue in FY20. Objectives are to align and refine our culture, define employee value proposition; address performance management, grow and develop talent, & improve our hiring processes.
•
The Asia-Pacific region will continue to celebrate International Women’s Day and diverse holidays through FY20.
•
Asia-Pacific region will be analyzing the results of their recently conducted culture survey to understand cultural strengths and opportunities in terms of diversity and inclusion. Analysis will also be undertaken to identify differences across gender and other areas of diversity and taking actions to build a more inclusive workplace as needed.
|
|
To ensure that recruitment and selection processes are based on merit
|
•
For FY19, results for North America’s Engineering Development Program (EDP) recruits, 7 out of 14 (50%) hires were either women or have diversity characteristics.
•
James Hardie Ambassador Program (HAP) for the North American Repair & Remodel segment was implemented to create product awareness and preference in targeted neighborhoods. Hardie Ambassadors hired in FY19 totaled 15 employees, of which 9 (60%) were women and/or have diversity characteristics.
•
As of the end of FY19 total new hires in North America were 19% female, with 22 out of 52 (42%) open Leadership roles filled by women.
•
First female leader recruited onto the Asia-Pacific Senior Leadership Team (Director, People & Performance).
•
Made a conscious effort to balance shortlists by gender for key externally sourced roles.
•
Created and leveraged recruitment videos highlighting a diverse workforce which are now being shared externally as a recruitment tool.
•
Showcasing diverse talent on LinkedIn to attract more diverse talent into the organization.
|
•
Recruitment of diverse candidates for management roles continues to be a focus for FY20.
•
We plan to continue the EDP and HAP initiatives and maintain or enhance the diversity characteristics of the program participants.
•
Standardized assessments and interview methodology strategies will be implemented to enhance selection processes in recruiting talent.
|
|
To provide talent management and development opportunities which provide equal opportunities for all current employees
|
•
In North America, we ran two groups of employees through our Leadership Fundamentals program in FY19, which were intended to provide our new leaders with the skills to build and manage high-performing and diverse teams. 30% of our Leadership Fundamentals attendees in FY19 were women (12 of 40 attendees).
•
Diversity and Inclusion training was conducted with senior leaders in Australia. This included a session that placed the leaders in the shoes of various minority personas virtually so that they could recognize and understand the adjustments they could make to be more inclusive and focused on the actions necessary to enhance diversity.
•
In Australia we are participating in a company-wide women’s mentorship program. Some of our senior leaders are mentors and some of our emerging talent are mentees.
|
•
Rolling out global talent and organizational review processes to identify strengths, gaps and future succession.
•
Launching the Women’s Initiative Network (WIN) group in North America to build cross- functional networks among women in leadership roles. WIN will have an Executive Leadership Team ("ELT") sponsor to champion the program.
|
|
Objectives
|
FY19 Actions and Outcomes
|
FY20 Plans
|
|
To reward and remunerate fairly
|
•
Annually, management conducts an employee wage benchmarking study to ensure remuneration is aligned with the Company remuneration philosophy. In FY19, the study included all corporate and plant locations.
•
The Workplace Gender Equality Act (WGEA) report is submitted to the Australian government on an annual basis. The WGEA confirmed that JH Australia is compliant with the Workplace Gender Equality Act 2012 (Act).
|
•
Review, evaluate and propose updated salary compensation structure to ensure alignment with market.
•
Conducting benefits conjoint to better understand our global population’s preferences and needs.
•
Will continue to conduct the WGEA gender pay review and analysis. We will extend this across the entire Asia-Pacific region to identify any gender pay gaps. Management will then establish an action plan to address identified opportunities to close the gaps.
|
|
To provide flexible work practices
|
•
Flexible working arrangements continued to be discussed with each employee and individual arrangements are offered as job requirements permit.
|
•
Paid Time-Off (PTO) leave to be reviewed and evaluated, with updated program proposed to better align with market and current best practices in FY20.
•
Developing a refreshed leave and flexible work policy, Hardie Flex, which will encompass ways to offer our people flexibility as well as enhanced leave options.
|
|
Executive Leadership
|
Board Experience
|
Succession Planning
|
Governance
|
|
Strategy
|
Financial Acumen
|
Corporate Finance
|
Risk Management
|
|
Global Experience
|
Health, Safety and
Environmental
|
Human Resources and
Executive Remuneration
|
Manufacturing
|
|
Market Experience
|
|
|
|
|
•
|
identifying and recommending to the Board individuals qualified to become directors;
|
|
•
|
overseeing the evaluation of the Board and senior management and formulating succession plans for the CEO, CFO and senior executives;
|
|
•
|
assessing the independence of each director;
|
|
•
|
reviewing the conduct of the AGM; and
|
|
•
|
performing a leadership role in shaping the Company’s culture and corporate governance policies.
|
|
•
|
provides leadership to the Board;
|
|
•
|
chairs Board and shareholder meetings;
|
|
•
|
facilitates Board discussions;
|
|
•
|
monitors, evaluates and assesses the performance of the Board and Board committees; and
|
|
•
|
is a member of and attends meetings of the Remuneration and Nominating and Governance committees.
|
|
•
|
overseeing the Company’s financial reporting process and reports on the results of its activities to the Board;
|
|
•
|
reviewing with management and the external auditor the Company’s annual and quarterly financial statements and reports to shareholders; discussing earnings releases as well as information and earnings guidance provided to analysts;
|
|
•
|
reviewing and assessing the Company’s risk management strategy, policies and procedures and the adequacy of the Company’s policies, processes and frameworks for managing risk;
|
|
•
|
exercising general oversight of the appointment and provision of all external audit services to the Company, the remuneration paid to the external auditor, and the performance of the Company’s internal audit function;
|
|
•
|
reviewing the adequacy and effectiveness of the Company’s internal compliance and control procedures;
|
|
•
|
reviewing the Company’s compliance with legal and regulatory requirements; and
|
|
•
|
establishing procedures for complaints regarding accounting, internal accounting controls and auditing matters, including any complaints from whistle-blowers.
|
|
•
|
the financial statements, and other financial information included in this Annual Report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this Annual Report; and
|
|
•
|
this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Annual Report.
|
|
•
|
understand the Company’s strategy and assess the quality of its management;
|
|
•
|
examine the Company’s financial position and the strength of its growth prospects; and
|
|
•
|
receive any news or information that might reasonably be expected to materially affect the price or market for the Company securities.
|
|
•
|
making management briefings and presentations accessible via a live webcast and/or teleconference following the release of quarterly and annual results;
|
|
•
|
audio webcasts of other management briefings and the annual shareholder meeting;
|
|
•
|
a comprehensive investor relations website that displays all announcements and notices (promptly after they have been cleared by the ASX), major management and investor road show presentations;
|
|
•
|
site visits and briefings on strategy for investment analysts;
|
|
•
|
regular engagement with institutional shareholders to discuss a wide range of governance issues;
|
|
•
|
an email alert service to advise shareholders and other interested parties of announcements and other events; and
|
|
•
|
equality of access for shareholders and investment analysts to briefings, presentations and meetings and equality of media access to the Company, on a reasonable basis.
|
|
•
|
attend the AGM either in person or by proxy;
|
|
•
|
speak at the AGM; and
|
|
•
|
exercise voting rights, including at the AGM, subject to their instructions on the Voting Instruction Form.
|
|
•
|
the Company’s principal strategic, operational and financial risks are identified and assessed;
|
|
•
|
the Company’s risk appetite for each risk is considered;
|
|
•
|
effective systems are in place to monitor and manage risks; and
|
|
•
|
reporting systems, internal controls and arrangements for monitoring compliance with laws and regulations are adequate.
|
|
•
|
engagement with members of the Risk Management Committee, at least quarterly, to assess the key strategic, operations, reporting and compliance risks facing the Company, the level of risk and the processes implemented to manage each of these key risks over the upcoming twelve months;
|
|
•
|
quarterly reporting to executive management, the Audit Committee, and annual reporting to the Board, of the Risk Management Committee’s assessment regarding the key strategic, operations, reporting and compliance risks facing the Company;
|
|
•
|
a program for the Audit Committee to review in detail each year the Company’s general risk tolerance and all items identified by the Risk Management Committee as high focus risks;
|
|
•
|
quarterly meetings of the Financial Statements Disclosure Committee to review all quarterly and annual financial statements and results;
|
|
•
|
an internal audit department with a direct reporting line to the Chairman of the Audit Committee;
|
|
•
|
regular monitoring of the liquidity and status of the Company’s finance facilities;
|
|
•
|
maintaining an appropriate global insurance program;
|
|
•
|
maintaining policies and procedures in relation to treasury operations, including the use of financial derivatives and issuing procedures requiring significant capital and recurring expenditure approvals; and
|
|
•
|
implementing and maintaining training programs in relation to legal and regulatory compliance issues such as trade practices/antitrust, insider trading, foreign corrupt practices and anti-bribery, employment law matters, trade secrecy and intellectual property protection.
|
|
•
|
administers and makes recommendations on the Company’s incentive compensation and equity-based remuneration plans;
|
|
•
|
reviews the remuneration of directors;
|
|
•
|
reviews the remuneration framework for the Company; and
|
|
•
|
makes recommendations to the Board on the Company’s recruitment, retention and termination policies and procedures for senior management.
|
|
•
|
statements about the Company’s future performance;
|
|
•
|
projections of the Company’s results of operations or financial condition;
|
|
•
|
statements regarding the Company’s plans, objectives or goals, including those relating to strategies, initiatives, competition, acquisitions, dispositions and/or its products;
|
|
•
|
expectations concerning the costs associated with the suspension or closure of operations at any of the Company’s plants and future plans with respect to any such plants;
|
|
•
|
expectations concerning the costs associated with the significant capital expenditure projects at any of the Company’s plants and future plans with respect to any such projects;
|
|
•
|
expectations regarding the extension or renewal of the Company’s credit facilities including changes to terms, covenants or ratios;
|
|
•
|
expectations concerning dividend payments and share buy-backs;
|
|
•
|
statements concerning the Company’s corporate and tax domiciles and structures and potential changes to them, including potential tax charges;
|
|
•
|
statements regarding tax liabilities and related audits, reviews and proceedings;
|
|
•
|
statements regarding the possible consequences and/or potential outcome of legal proceedings brought against us and the potential liabilities, if any, associated with such proceedings;
|
|
•
|
expectations about the timing and amount of contributions to AICF, a special purpose fund for the compensation of proven Australian asbestos-related personal injury and death claims;
|
|
•
|
expectations concerning the adequacy of the Company’s warranty provisions and estimates for future warranty-related costs;
|
|
•
|
statements regarding the Company’s ability to manage legal and regulatory matters (including, but not limited to, product liability, environmental, intellectual property and competition law matters) and to resolve any such pending legal and regulatory matters within current estimates and in anticipation of certain third-party recoveries; and
|
|
•
|
statements about economic conditions, such as changes in the US economic or housing market conditions or changes in the market conditions in the Asia Pacific region, the levels of new home construction and home renovations, unemployment levels, changes in consumer income, changes or stability in housing values, the availability of mortgages and other financing, mortgage and other interest rates, housing affordability and supply, the levels of foreclosures and home resales, currency exchange rates, and builder and consumer confidence.
|
|
US$ Millions
|
|
FY19
|
|
FY18
|
|
Change %
|
|||||
|
Net sales
|
|
$
|
2,506.6
|
|
|
$
|
2,054.5
|
|
|
22
|
|
|
Cost of goods sold
|
|
(1,675.6
|
)
|
|
(1,324.3
|
)
|
|
(27
|
)
|
||
|
Gross profit
|
|
831.0
|
|
|
730.2
|
|
|
14
|
|
||
|
|
|
|
|
|
|
|
|||||
|
Selling, general and administrative expenses
|
|
(403.6
|
)
|
|
(311.3
|
)
|
|
(30
|
)
|
||
|
Research and development expenses
|
|
(37.9
|
)
|
|
(33.3
|
)
|
|
(14
|
)
|
||
|
Asset impairments
|
|
(15.9
|
)
|
|
—
|
|
|
|
|
||
|
Asbestos adjustments
|
|
(22.0
|
)
|
|
(156.4
|
)
|
|
86
|
|
||
|
Operating income
|
|
351.6
|
|
|
229.2
|
|
|
53
|
|
||
|
|
|
|
|
|
|
|
|||||
|
Net interest expense
|
|
(50.1
|
)
|
|
(29.5
|
)
|
|
(70
|
)
|
||
|
Loss on early debt extinguishment
1
|
|
(1.0
|
)
|
|
(26.1
|
)
|
|
96
|
|
||
|
Other income
|
|
0.1
|
|
|
0.7
|
|
|
(86
|
)
|
||
|
Income before income taxes
|
|
300.6
|
|
|
174.3
|
|
|
72
|
|
||
|
Income tax expense
|
|
(71.8
|
)
|
|
(28.2
|
)
|
|
|
|
||
|
Net income
|
|
$
|
228.8
|
|
|
$
|
146.1
|
|
|
57
|
|
|
|
|
|
|
|
|
|
|||||
|
1
|
Readers are referred to Note 10 of our 31 March 2019 consolidated financial statements for further information related to long-term debt.
|
|
|
|
FY19
|
|
FY18
|
|
Change
|
|||
|
Volume (mmsf)
|
|
2,308.1
|
|
|
2,238.8
|
|
|
3
|
%
|
|
Average net sales price per unit (per msf)
|
|
US$718
|
|
US$698
|
|
3
|
%
|
||
|
|
|
|
|
|
|
|
|||
|
Fiber cement net sales (US$ millions)
|
|
1,676.9
|
|
|
1,578.1
|
|
|
6
|
%
|
|
Gross profit
|
|
|
|
|
|
3
|
%
|
||
|
Gross margin (%)
|
|
|
|
|
|
(0.9 pts)
|
|||
|
Operating income (US$ millions)
|
|
382.5
|
|
|
381.9
|
|
|
—
|
|
|
US$ Operating income margin (%)
|
|
22.8
|
|
|
24.2
|
|
|
(1.4 pts)
|
|
|
Operating income excluding product line discontinuation
1
(US$ millions)
|
|
387.9
|
|
|
381.9
|
|
|
2
|
%
|
|
Operating income margin excluding product line discontinuation
1
(%)
|
|
23.1
|
|
|
24.2
|
|
|
(1.1 pts)
|
|
|
|
|
|
|
|
|
|
|||
|
1
|
Excludes product line discontinuation expenses of US$5.4 million for fiscal year 2019. These expenses include asset impairments of US$3.0 million, and a one-time charge of US$2.4 million to cost of goods sold associated with our decision to discontinue our MCT product line, as well as certain excess and obsolete ColorPlus
®
color palettes.
|
|
Higher average net sales price
|
2.0
|
pts
|
|
Higher start up costs
|
(0.1
|
pts)
|
|
Higher production and other costs
|
(2.8
|
pts)
|
|
Total percentage point change in gross margin
|
(0.9
|
pts)
|
|
|
|
FY19
|
|
FY18
|
|
Change
|
|||
|
Volume (mmsf)
|
|
546.1
|
|
|
494.7
|
|
|
10
|
%
|
|
Average net sales price per unit (per msf)
|
|
US$724
|
|
US$762
|
|
(5
|
%)
|
||
|
|
|
|
|
|
|
|
|||
|
Net Sales (US$ millions)
|
|
446.8
|
|
|
425.4
|
|
|
5
|
%
|
|
US$ Gross profit
|
|
|
|
|
|
(6
|
%)
|
||
|
US$ Gross margin (%)
|
|
|
|
|
|
(3.9 pts)
|
|||
|
Operating income (US$ millions)
|
|
99.8
|
|
|
108.1
|
|
|
(8
|
%)
|
|
US$ Operating income margin (%)
|
|
22.3
|
|
|
25.4
|
|
|
(3.1 pts)
|
|
|
|
|
FY19
|
|
FY18
|
|
Change
|
|||
|
Volume (mmsf)
|
|
546.1
|
|
|
494.7
|
|
|
10
|
%
|
|
Average net sales price per unit (per msf)
|
|
A$992
|
|
A$985
|
|
1
|
%
|
||
|
|
|
|
|
|
|
|
|||
|
Net Sales (A$ millions)
|
|
612.2
|
|
|
549.7
|
|
|
11
|
%
|
|
A$ Gross profit
|
|
|
|
|
|
FLAT
|
|
||
|
A$ Gross margin (%)
|
|
|
|
|
|
(4.0 pts)
|
|
||
|
Operating income (A$ millions)
|
|
136.5
|
|
|
139.8
|
|
|
(2
|
%)
|
|
A$ Operating income margin (%)
|
|
22.3
|
|
|
25.4
|
|
|
(3.1 pts)
|
|
|
Higher average net sales price
|
0.3
|
pts
|
|
Higher production costs
|
(4.3
|
pts)
|
|
Total percentage point change in gross margin
|
(4.0
|
pts)
|
|
|
|
FY19
|
|
FY18
|
|
Change
|
|||
|
Volume (mmsf)
|
|
815.8
|
|
|
34.0
|
|
|
|
|
|
Average net sales price per unit (per msf)
|
|
US$354
|
|
US$950
|
|
(63
|
%)
|
||
|
|
|
|
|
|
|
|
|||
|
Fiber cement net sales (US$ millions)
|
|
35.8
|
|
|
36.3
|
|
|
(1
|
%)
|
|
Fiber gypsum net sales
1
(US$ millions)
|
|
332.5
|
|
|
—
|
|
|
|
|
|
Net sales (US$ millions)
|
|
368.3
|
|
|
36.3
|
|
|
|
|
|
US$ Gross profit
2
|
|
|
|
|
|
NM
|
|
||
|
US$ Gross margin (%)
2
|
|
|
|
|
|
NM
|
|
||
|
US$ Operating income
3
|
|
10.0
|
|
|
0.3
|
|
|
|
|
|
US$ Operating income margin (%)
3
|
|
2.7
|
|
|
0.8
|
|
|
1.9 pts
|
|
|
|
|
|
|
|
|
|
|||
|
1
|
Also includes cement bonded board net sales.
|
|
2
|
The change in gross profit and gross margin is not presented due to the impact from the acquisition of Fermacell during the first quarter of fiscal year 2019.
|
|
3
|
Includes Fermacell transaction and integration costs of US$21.8 million, as well as, a US$7.3 million inventory fair value adjustment resulting from acquisition accounting adjustments in fiscal year 2019.
|
|
US$ Millions
|
|
FY19
|
|
FY18
|
|
Change
|
|||
|
Net sales
|
|
14.6
|
|
|
14.7
|
|
|
(1
|
%)
|
|
Gross profit
|
|
|
|
|
|
NM
|
|
||
|
Gross profit margin (%)
|
|
|
|
|
|
NM
|
|
||
|
Operating loss
|
|
(30.9
|
)
|
|
(8.6
|
)
|
|
|
|
|
Product line discontinuation
|
|
(24.1
|
)
|
|
—
|
|
|
|
|
|
US$ Millions
|
|
FY19
|
|
FY18
|
|
Change %
|
|||||
|
Segment R&D expenses
|
|
$
|
(26.7
|
)
|
|
$
|
(25.4
|
)
|
|
(5
|
)
|
|
Segment R&D SG&A expenses
|
|
(2.3
|
)
|
|
(2.4
|
)
|
|
4
|
|
||
|
Total R&D operating loss
|
|
$
|
(29.0
|
)
|
|
$
|
(27.8
|
)
|
|
(4
|
)
|
|
|
|
|
|
|
|
|
|||||
|
US$ Millions
|
|
FY19
|
|
FY18
|
|
Change %
|
|||||
|
General Corporate SG&A expenses
|
|
$
|
(57.3
|
)
|
|
$
|
(56.4
|
)
|
|
(2
|
)
|
|
Fermacell acquisition costs
1
|
|
—
|
|
|
(10.0
|
)
|
|
|
|||
|
Asbestos:
|
|
|
|
|
|
|
|||||
|
Asbestos adjustments
|
|
(22.0
|
)
|
|
(156.4
|
)
|
|
86
|
|
||
|
AICF SG&A expenses
2
|
|
(1.5
|
)
|
|
(1.9
|
)
|
|
21
|
|
||
|
General Corporate operating loss
|
|
$
|
(80.8
|
)
|
|
$
|
(224.7
|
)
|
|
64
|
|
|
|
|
|
|
|
|
|
|||||
|
1
|
Relates to professional, legal and other fees incurred in FY2018 prior to the close of the Fermacell acquisition.
|
|
2
|
Relates to non-claims related operating costs incurred by AICF, which we consolidate into our financial results due to our pecuniary and contractual interests in AICF.
|
|
FY19
|
FY18
|
||||||
|
31 March 2018
|
|
0.7681
|
|
31 March 2017
|
|
0.7644
|
|
|
31 March 2019
|
|
0.7096
|
|
31 March 2018
|
|
0.7681
|
|
|
Change ($)
|
|
(0.0585
|
)
|
Change ($)
|
|
0.0037
|
|
|
Change (%)
|
|
(8
|
)
|
Change (%)
|
|
—
|
|
|
US$ Millions
|
|
FY19
|
|
FY18
|
||||
|
Increase in actuarial estimate
|
|
$
|
(72.7
|
)
|
|
$
|
(151.4
|
)
|
|
Effect of foreign exchange rate movements
|
|
49.5
|
|
|
(5.3
|
)
|
||
|
(Loss) gain on foreign currency forward contracts
|
|
(0.8
|
)
|
|
1.4
|
|
||
|
Adjustments in insurance receivable
|
|
2.0
|
|
|
—
|
|
||
|
Asbestos research and education contribution
|
|
—
|
|
|
(1.1
|
)
|
||
|
Asbestos adjustments
|
|
$
|
(22.0
|
)
|
|
$
|
(156.4
|
)
|
|
|
|
FY19
|
|
FY18
|
|
Change %
|
|||
|
Claims received
|
|
568
|
|
|
562
|
|
|
(1
|
)
|
|
Actuarial estimate for the period
|
|
576
|
|
|
576
|
|
|
—
|
|
|
Difference in claims received to actuarial estimate
|
|
8
|
|
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Average claim settlement
1
(A$)
|
|
262,000
|
|
|
253,000
|
|
|
(4
|
)
|
|
Actuarial estimate for the period
2
|
|
290,000
|
|
|
283,000
|
|
|
(2
|
)
|
|
Difference in claims paid to actuarial estimate
|
|
28,000
|
|
|
30,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
1
|
Average claim settlement is derived as the total amount paid divided by the number of non-nil claim settlements.
|
|
2
|
This actuarial estimate is a function of the assumed experience by disease type and the relative mix of settlements assumed by disease type. Any variances in the assumed mix of settlements by disease type will have an impact on the average claim settlement experience.
|
|
•
|
Claims received were
1%
below actuarial estimates and
1%
higher than fiscal year 2018;
|
|
•
|
Mesothelioma claims reported were 4% lower than actuarial expectations and 5% lower than fiscal year 2018;
|
|
•
|
The average claim settlement was
10%
below actuarial expectations;
|
|
•
|
Average claim settlement sizes were lower for most disease types, including mesothelioma claims for most age groups, compared to actuarial expectations; and
|
|
•
|
The decrease in the average claim settlement for fiscal year 2019 versus actuarial estimates was largely attributable to lower average claim settlement for non-mesothelioma claims.
|
|
US$ Millions
|
|
FY18
|
|
FY17
|
|
Change %
|
|||||
|
Net sales
|
|
$
|
2,054.5
|
|
|
$
|
1,921.6
|
|
|
7
|
|
|
Cost of goods sold
|
|
(1,324.3
|
)
|
|
(1,246.9
|
)
|
|
(6
|
)
|
||
|
Gross profit
|
|
730.2
|
|
|
674.7
|
|
|
8
|
|
||
|
|
|
|
|
|
|
|
|||||
|
Selling, general and administrative expenses
|
|
(311.3
|
)
|
|
(291.6
|
)
|
|
(7
|
)
|
||
|
Research and development expenses
|
|
(33.3
|
)
|
|
(30.3
|
)
|
|
(10
|
)
|
||
|
Asbestos adjustments
|
|
(156.4
|
)
|
|
40.4
|
|
|
|
|
||
|
Operating income
|
|
229.2
|
|
|
393.2
|
|
|
(42
|
)
|
||
|
|
|
|
|
|
|
|
|||||
|
Net interest expense
|
|
(29.5
|
)
|
|
(27.5
|
)
|
|
(7
|
)
|
||
|
Loss on early debt extinguishment
1
|
|
(26.1
|
)
|
|
—
|
|
|
|
|||
|
Other income
|
|
0.7
|
|
|
1.3
|
|
|
(46
|
)
|
||
|
Income before income taxes
|
|
174.3
|
|
|
367.0
|
|
|
(53
|
)
|
||
|
Income tax expense
|
|
(28.2
|
)
|
|
(90.5
|
)
|
|
69
|
|
||
|
Net income
|
|
$
|
146.1
|
|
|
$
|
276.5
|
|
|
(47
|
)
|
|
|
|
|
|
|
|
|
|||||
|
1
|
In December 2017, we redeemed our 5.875% senior notes due 2023 and recorded a loss on early debt extinguishment in connection with this redemption. Readers are referred to Note 10 of our 31 March 2019 consolidated financial statements for further information related to long-term debt.
|
|
|
|
FY18
|
|
FY17
|
|
Change
|
|||
|
Volume (mmsf)
|
|
2,238.8
|
|
|
2,215.4
|
|
|
1
|
%
|
|
Average net sales price per unit (per msf)
|
|
US$698
|
|
US$665
|
|
5
|
%
|
||
|
|
|
|
|
|
|
|
|||
|
Fiber cement net sales (US$ millions)
|
|
1,578.1
|
|
|
1,493.4
|
|
|
6
|
%
|
|
Gross profit
|
|
|
|
|
|
8
|
%
|
||
|
Gross margin (%)
|
|
|
|
|
|
0.6 pts
|
|||
|
Operating income (US$ millions)
|
|
381.9
|
|
|
343.9
|
|
|
11
|
%
|
|
Operating income margin (%)
|
|
24.2
|
|
|
23.0
|
|
|
1.2 pts
|
|
|
Higher average net sales price
|
2.9
|
pts
|
|
Lower start up costs
|
0.2
|
pts
|
|
Higher production costs
|
(2.5
|
pts)
|
|
Total percentage point change in gross margin
|
0.6
|
pts
|
|
|
|
FY18
|
|
FY17
|
|
Change
|
|||
|
Volume (mmsf)
|
|
494.7
|
|
|
448.2
|
|
|
10
|
%
|
|
Average net sales price per unit (per msf)
|
|
US$762
|
|
US$758
|
|
1
|
%
|
||
|
|
|
|
|
|
|
|
|||
|
Fiber cement net sales (US$ millions)
|
|
425.4
|
|
|
370.6
|
|
|
15
|
%
|
|
US$ Gross profit
|
|
|
|
|
|
14
|
%
|
||
|
US$ Gross margin (%)
|
|
|
|
|
|
(0.2 pts)
|
|
||
|
Operating income (US$ millions)
|
|
108.1
|
|
|
93.8
|
|
|
15
|
%
|
|
US$ Operating income margin (%)
|
|
25.4
|
|
|
25.3
|
|
|
0.1 pts
|
|
|
|
|
FY18
|
|
FY17
|
|
Change
|
|||
|
Volume (mmsf)
|
|
34.0
|
|
|
39.0
|
|
|
(13
|
%)
|
|
Average net sales price per unit (per msf)
|
|
US$950
|
|
US$977
|
|
(3
|
%)
|
||
|
|
|
|
|
|
|
|
|||
|
Fiber cement net sales (US$ millions)
|
|
36.3
|
|
|
41.2
|
|
|
(12
|
%)
|
|
US$ Gross profit
|
|
|
|
|
|
(16
|
%)
|
||
|
US$ Gross margin (%)
|
|
|
|
|
|
(1.6 pts)
|
|
||
|
Operating income (US$ millions)
|
|
0.3
|
|
|
1.3
|
|
|
(77
|
%)
|
|
US$ Millions
|
|
FY18
|
|
FY17
|
|
Change
|
|||||
|
Net sales
|
|
$
|
14.7
|
|
|
$
|
16.4
|
|
|
(10
|
%)
|
|
Gross profit
|
|
|
|
|
|
NM
|
|
||||
|
Gross profit margin (%)
|
|
|
|
|
|
(12.6 pts)
|
|
||||
|
Operating loss
|
|
$
|
(8.6
|
)
|
|
$
|
(6.7
|
)
|
|
(28
|
%)
|
|
US$ Millions
|
|
FY18
|
|
FY17
|
|
Change %
|
|||||
|
Segment R&D expenses
|
|
$
|
(25.4
|
)
|
|
$
|
(22.6
|
)
|
|
(12
|
)
|
|
Segment R&D SG&A expenses
|
|
(2.4
|
)
|
|
(2.9
|
)
|
|
17
|
|
||
|
Total R&D operating loss
|
|
$
|
(27.8
|
)
|
|
$
|
(25.5
|
)
|
|
(9
|
)
|
|
|
|
|
|
|
|
|
|||||
|
US$ Millions
|
|
FY18
|
|
FY17
|
|
Change %
|
|||||
|
General Corporate SG&A expenses
|
|
$
|
(56.4
|
)
|
|
$
|
(52.5
|
)
|
|
(7
|
)
|
|
Fermacell acquisition costs
1
|
|
(10.0
|
)
|
|
—
|
|
|
|
|
||
|
Asbestos:
|
|
|
|
|
|
|
|||||
|
Asbestos adjustments
|
|
(156.4
|
)
|
|
40.4
|
|
|
|
|
||
|
AICF SG&A expenses
2
|
|
(1.9
|
)
|
|
(1.5
|
)
|
|
(27
|
)
|
||
|
General Corporate operating loss
|
|
$
|
(224.7
|
)
|
|
$
|
(13.6
|
)
|
|
|
|
|
1
|
Relates to professional, legal and other fees incurred in conjunction with the acquisition of Fermacell and its subsidiaries.
|
|
2
|
Relates to non-claims related operating costs incurred by AICF, which we consolidate into our financial results due to our pecuniary and contractual interests in AICF.
|
|
FY18
|
FY17
|
||||||
|
31 March 2017
|
|
0.7644
|
|
31 March 2016
|
|
0.7657
|
|
|
31 March 2018
|
|
0.7681
|
|
31 March 2017
|
|
0.7644
|
|
|
Change ($)
|
|
0.0037
|
|
Change ($)
|
|
(0.0013
|
)
|
|
Change (%)
|
|
—
|
|
Change (%)
|
|
—
|
|
|
US$ Millions
|
|
FY18
|
|
FY17
|
||||
|
(Increase) decrease in actuarial estimate
|
|
$
|
(151.4
|
)
|
|
$
|
38.6
|
|
|
Effect of foreign exchange rate movements
|
|
(3.9
|
)
|
|
1.8
|
|
||
|
Asbestos research and education contribution
|
|
(1.1
|
)
|
|
—
|
|
||
|
Asbestos adjustments
|
|
$
|
(156.4
|
)
|
|
$
|
40.4
|
|
|
|
|
FY18
|
|
FY17
|
|
Change %
|
|||
|
Claims received
|
|
562
|
|
|
557
|
|
|
(1
|
)
|
|
Actuarial estimate for the period
|
|
576
|
|
|
625
|
|
|
8
|
|
|
Difference in claims received to actuarial estimate
|
|
14
|
|
|
68
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Average claim settlement
1
(A$)
|
|
253,000
|
|
|
224,000
|
|
|
(13
|
)
|
|
Actuarial estimate for the period
2
|
|
283,000
|
|
|
327,000
|
|
|
13
|
|
|
Difference in claims paid to actuarial estimate
|
|
30,000
|
|
|
103,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
1
|
Average claims settlement is derived as the total amount paid divided by the number of non-nil claim settlements.
|
|
2
|
This actuarial estimate is a function of the assumed experience by disease type and the relative mix of settlements assumed by disease type. Any variances in the assumed mix of settlements by disease type will have an impact on the average claim settlement experience.
|
|
•
|
Claims received during fiscal year 2018 were
2%
below actuarial estimates;
|
|
•
|
Claims received during fiscal year 2018 were
1%
higher
than fiscal year 2017;
|
|
•
|
Mesothelioma claims reported for fiscal year 2018 were 5% above both actuarial expectations and fiscal year 2017;
|
|
•
|
The average claim settlement for fiscal year 2018 was
11%
below actuarial expectations;
|
|
•
|
Average claim settlement sizes were lower for most disease types, including for mesothelioma and asbestosis, compared to actuarial expectations for fiscal year 2018; and
|
|
•
|
The decrease in average claim settlement for fiscal year 2018 versus actuarial estimates was largely attributable to lower average claim settlement sizes for non-large mesothelioma claims, together with favorable large claims experience during fiscal year 2018.
|
|
|
|
US Cents/
Security
|
|
Total US$
(millions)
|
|
Announcement
Date
|
|
Record Date
|
|
Payment Date
|
|
FY 2019 second half dividend
|
|
0.26
|
|
115.0
|
|
21 May 2019
|
|
6 June 2019
|
|
2 August 2019
|
|
FY 2019 first half dividend
|
|
0.10
|
|
43.6
|
|
8 November 2018
|
|
12 December 2018
|
|
22 February 2019
|
|
FY 2018 second half dividend
|
|
0.30
|
|
128.5
|
|
22 May 2018
|
|
7 June 2018
|
|
3 August 2018
|
|
FY 2018 first half dividend
|
|
0.10
|
|
46.2
|
|
9 November 2017
|
|
13 December 2017
|
|
23 February 2018
|
|
FY 2017 second half dividend
|
|
0.28
|
|
131.3
|
|
18 May 2017
|
|
8 June 2017
|
|
4 August 2017
|
|
FY 2017 first half dividend
|
|
0.10
|
|
46.6
|
|
17 November 2016
|
|
21 December 2016
|
|
24 February 2017
|
|
FY 2016 second half dividend
|
|
0.29
|
|
130.2
|
|
19 May 2016
|
|
9 June 2016
|
|
5 August 2016
|
|
•
|
invest in R&D and capacity expansion to support organic growth;
|
|
•
|
provide ordinary dividend payments within the payout ratio of 50-70% of net income excluding asbestos;
|
|
•
|
maintain flexibility to manage through market cycles; and
|
|
•
|
consider flexibility for accretive and strategic inorganic growth and/or other shareholder returns when appropriate.
|
|
|
Payments Due During Fiscal Year Ending 31 March
|
|||||||||||||||||||
|
US$ Millions
|
|
Total
|
|
less than 1
year
|
|
1 - 3 years
|
|
3 - 5 years
|
|
more than 5
years
|
||||||||||
|
Asbestos Liability
1
|
|
$
|
1,089.6
|
|
|
$
|
110.5
|
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|||
|
Long-Term Debt Obligations
2
|
|
1,399.4
|
|
|
—
|
|
|
—
|
|
|
150.0
|
|
|
1,249.4
|
|
|||||
|
Estimated interest payments on Long-Term Debt
3
|
|
376.6
|
|
|
62.6
|
|
|
125.6
|
|
|
125.6
|
|
|
62.8
|
|
|||||
|
Long-Term Debt – AICF loan facility
4
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
|
Estimated interest payments on Long-Term Debt – AICF loan facility
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
|
Operating Lease Obligations
|
|
66.2
|
|
|
18.4
|
|
|
27.0
|
|
|
12.6
|
|
|
8.2
|
|
|||||
|
Purchase Obligations
5
|
|
15.4
|
|
|
5.6
|
|
|
0.8
|
|
|
0.8
|
|
|
8.2
|
|
|||||
|
Total
|
|
$
|
2,947.2
|
|
|
$
|
197.1
|
|
|
$
|
153.4
|
|
|
$
|
289.0
|
|
|
$
|
1,328.6
|
|
|
1
|
The amount of the asbestos liability reflects the terms of the AFFA, which has been calculated by reference to (but is not exclusively based upon) the most recent actuarial estimate of the projected future asbestos-related cash flows prepared by KPMGA. The asbestos liability also includes an allowance for the future claims-handling costs of AICF. We anticipate that we will make a contribution of approximately US$100.9 million to AICF on 1 July 2019. This amount represents 35% of our free cash flow of US
$288.4
million as defined by the AFFA. Our free cash flow, as defined by the AFFA, is our operating cash flow per US GAAP in effect during 2004. To reconcile our current year operating cash flow of US$
287.6
million to 2004 US GAAP, a US$0.8 million adjustment is required. The table above does not include a breakdown of payments subsequent to fiscal year ending 31 March 2020 as such amounts are not reasonably estimable. See Note 12 to our consolidated financial statements for further information regarding our future obligations under the AFFA.
|
|
2
|
The amount of US$1,380.3 million disclosed on our consolidated balance sheet at 31 March 2019 reflects the gross balance of outstanding debt held by the Company, as noted in the table above, net of US$19.1 million of debt issuance costs.
|
|
3
|
Interest amounts are estimates based on debt remaining unchanged from the 31 March 2019 balance and interest rates remaining consistent with the rates at 31 March 2019. Interest paid includes interest in relation to our bank debt facilities and bonds, as well as the net amount paid relating to interest rate swap agreements. The interest on our bank debt facilities is variable based on a market rate and includes margins agreed to with the various lending banks. Also included in estimated interest payments are commitment fees related to the undrawn amounts of our bank debt facilities. The interest on our interest rate swaps and bond is set at a fixed rate. There are several variables that can affect the amount of interest we may pay in future years, including: (i) new bank debt facilities or bond issuance with rates or margins different from historical rates; (ii) expiration of existing bank debt facilities resulting in a change in the average interest rate; (iii) fluctuations in the market interest rate; (iv) new interest rate swap agreements; and (v) expiration of existing interest rate swap agreements. We have not included estimated interest payments subsequent to fiscal year ending 31 March 2024 as such amounts are not reasonably estimable.
|
|
4
|
JHI plc and its wholly-owned subsidiaries are not a party to, guarantor of, or security provided in respect of the AICF loan facility. However, because we consolidate AICF due to our pecuniary and contractual interest in AICF, any drawings, repayments or payments of accrued interest by AICF under the AICF loan facility impact our consolidated financial position, results of operations and cash flows. At 31 March 2019, AICF had an outstanding balance under the AICF Loan Facility of nil.
|
|
5
|
Purchase Obligations are defined as agreements to purchase goods or services that are enforceable and legally-binding on us and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transactions.
|
|
|
|
|
|
Page
|
|
(Millions of US dollars)
|
31 March
2019
|
|
31 March
2018
|
||||
|
Assets
|
|
|
|
||||
|
Current assets:
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
78.7
|
|
|
$
|
281.6
|
|
|
Restricted cash and cash equivalents
|
5.1
|
|
|
5.0
|
|
||
|
Restricted cash and cash equivalents - Asbestos
|
39.8
|
|
|
26.6
|
|
||
|
Restricted short-term investments - Asbestos
|
17.7
|
|
|
38.4
|
|
||
|
Accounts and other receivables, net of provision for doubtful trade debts of US$2.9 million and US$1.3 million as of 31 March 2019 and 31 March 2018
|
254.6
|
|
|
202.7
|
|
||
|
Inventories
|
317.4
|
|
|
255.7
|
|
||
|
Prepaid expenses and other current assets
|
31.3
|
|
|
25.4
|
|
||
|
Insurance receivable - Asbestos
|
7.5
|
|
|
5.1
|
|
||
|
Workers’ compensation - Asbestos
|
2.0
|
|
|
2.1
|
|
||
|
Total current assets
|
754.1
|
|
|
842.6
|
|
||
|
Property, plant and equipment, net
|
1,388.4
|
|
|
992.1
|
|
||
|
Goodwill
|
201.1
|
|
|
4.9
|
|
||
|
Intangible assets, net
|
174.4
|
|
|
12.3
|
|
||
|
Insurance receivable - Asbestos
|
43.7
|
|
|
52.8
|
|
||
|
Workers’ compensation - Asbestos
|
25.8
|
|
|
28.8
|
|
||
|
Deferred income taxes
|
1,092.9
|
|
|
29.9
|
|
||
|
Deferred income taxes - Asbestos
|
349.3
|
|
|
382.9
|
|
||
|
Other assets
|
2.9
|
|
|
4.7
|
|
||
|
Total assets
|
$
|
4,032.6
|
|
|
$
|
2,351.0
|
|
|
Liabilities and Shareholders’ Equity (Deficit)
|
|
|
|
||||
|
Current liabilities:
|
|
|
|
||||
|
Accounts payable and accrued liabilities
|
$
|
255.5
|
|
|
$
|
193.3
|
|
|
Accrued payroll and employee benefits
|
84.9
|
|
|
61.8
|
|
||
|
Accrued product warranties
|
6.8
|
|
|
7.3
|
|
||
|
Income taxes payable
|
13.4
|
|
|
3.2
|
|
||
|
Asbestos liability
|
110.5
|
|
|
114.1
|
|
||
|
Workers’ compensation - Asbestos
|
2.0
|
|
|
2.1
|
|
||
|
Other liabilities
|
9.9
|
|
|
12.8
|
|
||
|
Total current liabilities
|
483.0
|
|
|
394.6
|
|
||
|
Long-term debt
|
1,380.3
|
|
|
884.4
|
|
||
|
Deferred income taxes
|
80.4
|
|
|
66.4
|
|
||
|
Accrued product warranties
|
39.8
|
|
|
45.5
|
|
||
|
Income taxes payable
|
25.2
|
|
|
25.9
|
|
||
|
Asbestos liability
|
979.1
|
|
|
1,101.0
|
|
||
|
Workers’ compensation - Asbestos
|
25.8
|
|
|
28.8
|
|
||
|
Other liabilities
|
44.6
|
|
|
25.9
|
|
||
|
Total liabilities
|
3,058.2
|
|
|
2,572.5
|
|
||
|
Commitments and contingencies (Note 14)
|
|
|
|
||||
|
Shareholders’ equity (deficit):
|
|
|
|
||||
|
Common stock, Euro 0.59 par value, 2.0 billion shares authorized; 442,269,905 shares issued and outstanding at 31 March 2019 and 441,524,118 shares issued and outstanding at 31 March 2018
|
230.0
|
|
|
229.5
|
|
||
|
Additional paid-in capital
|
197.6
|
|
|
185.6
|
|
||
|
Accumulated equity (deficit)
|
577.1
|
|
|
(635.3
|
)
|
||
|
Accumulated other comprehensive loss
|
(30.3
|
)
|
|
(1.3
|
)
|
||
|
Total shareholders’ equity (deficit)
|
974.4
|
|
|
(221.5
|
)
|
||
|
Total liabilities and shareholders’ equity (deficit)
|
$
|
4,032.6
|
|
|
$
|
2,351.0
|
|
|
|
|
|
James Hardie Industries plc
- Consolidated Statements of Operations and Comprehensive Income
|
120
|
|
|
|
|
|
Years Ended 31 March
|
||||||||||
|
(Millions of US dollars, except per share data)
|
2019
|
|
2018
|
|
2017
|
||||||
|
Net sales
|
$
|
2,506.6
|
|
|
$
|
2,054.5
|
|
|
$
|
1,921.6
|
|
|
Cost of goods sold
|
(1,675.6
|
)
|
|
(1,324.3
|
)
|
|
(1,246.9
|
)
|
|||
|
Gross profit
|
831.0
|
|
|
730.2
|
|
|
674.7
|
|
|||
|
Selling, general and administrative expenses
|
(403.6
|
)
|
|
(311.3
|
)
|
|
(291.6
|
)
|
|||
|
Research and development expenses
|
(37.9
|
)
|
|
(33.3
|
)
|
|
(30.3
|
)
|
|||
|
Asset impairments
|
(15.9
|
)
|
|
—
|
|
|
—
|
|
|||
|
Asbestos adjustments
|
(22.0
|
)
|
|
(156.4
|
)
|
|
40.4
|
|
|||
|
Operating income
|
351.6
|
|
|
229.2
|
|
|
393.2
|
|
|||
|
Interest expense, net of capitalized interest
|
(54.2
|
)
|
|
(32.9
|
)
|
|
(28.5
|
)
|
|||
|
Interest income
|
4.1
|
|
|
3.4
|
|
|
1.0
|
|
|||
|
Loss on early debt extinguishment
|
(1.0
|
)
|
|
(26.1
|
)
|
|
—
|
|
|||
|
Other income
|
0.1
|
|
|
0.7
|
|
|
1.3
|
|
|||
|
Income before income taxes
|
300.6
|
|
|
174.3
|
|
|
367.0
|
|
|||
|
Income tax expense
|
(71.8
|
)
|
|
(28.2
|
)
|
|
(90.5
|
)
|
|||
|
Net income
|
$
|
228.8
|
|
|
$
|
146.1
|
|
|
$
|
276.5
|
|
|
Income per share:
|
|
|
|
|
|
||||||
|
Basic
|
$
|
0.52
|
|
|
$
|
0.33
|
|
|
$
|
0.62
|
|
|
Diluted
|
$
|
0.52
|
|
|
$
|
0.33
|
|
|
$
|
0.62
|
|
|
Weighted average common shares outstanding (Millions):
|
|
|
|
|
|
||||||
|
Basic
|
441.9
|
|
|
441.2
|
|
|
442.7
|
|
|||
|
Diluted
|
443.0
|
|
|
442.3
|
|
|
443.9
|
|
|||
|
Comprehensive income, net of tax:
|
|
|
|
|
|
||||||
|
Net income
|
$
|
228.8
|
|
|
$
|
146.1
|
|
|
$
|
276.5
|
|
|
Cash flow hedges
|
(0.1
|
)
|
|
—
|
|
|
—
|
|
|||
|
Currency translation adjustments
|
(28.9
|
)
|
|
0.9
|
|
|
(3.0
|
)
|
|||
|
Comprehensive income
|
$
|
199.8
|
|
|
$
|
147.0
|
|
|
$
|
273.5
|
|
|
|
Years Ended 31 March
|
||||||||||
|
(Millions of US dollars)
|
2019
|
|
2018
|
|
2017
|
||||||
|
Cash Flows From Operating Activities
|
|
|
|
|
|
||||||
|
Net income
|
$
|
228.8
|
|
|
$
|
146.1
|
|
|
$
|
276.5
|
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
||||||
|
Depreciation and amortization
|
119.4
|
|
|
92.0
|
|
|
83.2
|
|
|||
|
Deferred income taxes
|
12.7
|
|
|
(76.8
|
)
|
|
26.0
|
|
|||
|
Stock-based compensation
|
12.5
|
|
|
11.1
|
|
|
9.3
|
|
|||
|
Asbestos adjustments
|
22.0
|
|
|
156.4
|
|
|
(40.4
|
)
|
|||
|
Excess tax benefits from share-based awards
|
—
|
|
|
(0.8
|
)
|
|
(3.0
|
)
|
|||
|
Asset impairments
|
15.9
|
|
|
—
|
|
|
—
|
|
|||
|
Loss on early debt extinguishment
|
1.0
|
|
|
26.1
|
|
|
—
|
|
|||
|
Other, net
|
16.3
|
|
|
12.6
|
|
|
15.0
|
|
|||
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
||||||
|
Accounts and other receivables
|
(18.1
|
)
|
|
(2.0
|
)
|
|
(28.4
|
)
|
|||
|
Inventories
|
(28.6
|
)
|
|
(51.7
|
)
|
|
(9.7
|
)
|
|||
|
Prepaid expenses and other assets
|
(1.7
|
)
|
|
(2.8
|
)
|
|
(2.1
|
)
|
|||
|
Insurance receivable - Asbestos
|
4.8
|
|
|
7.3
|
|
|
93.3
|
|
|||
|
Accounts payable and accrued liabilities
|
(12.9
|
)
|
|
14.2
|
|
|
39.6
|
|
|||
|
Claims and handling costs paid - Asbestos
|
(108.8
|
)
|
|
(104.4
|
)
|
|
(91.8
|
)
|
|||
|
Income taxes payable
|
8.8
|
|
|
26.9
|
|
|
(2.7
|
)
|
|||
|
Other accrued liabilities
|
15.5
|
|
|
47.8
|
|
|
17.7
|
|
|||
|
Net cash provided by operating activities
|
$
|
287.6
|
|
|
$
|
302.0
|
|
|
$
|
382.5
|
|
|
Cash Flows From Investing Activities
|
|
|
|
|
|
||||||
|
Purchases of property, plant and equipment
|
$
|
(301.1
|
)
|
|
$
|
(203.7
|
)
|
|
$
|
(101.9
|
)
|
|
Proceeds from sale of property, plant and equipment
|
—
|
|
|
7.9
|
|
|
—
|
|
|||
|
Capitalized interest
|
(5.4
|
)
|
|
(4.8
|
)
|
|
(2.0
|
)
|
|||
|
Acquisition of business, net of cash acquired
|
(558.7
|
)
|
|
—
|
|
|
—
|
|
|||
|
Acquisition of assets
|
—
|
|
|
—
|
|
|
(5.1
|
)
|
|||
|
Purchase of restricted short-term investments - Asbestos
|
(89.1
|
)
|
|
(78.4
|
)
|
|
—
|
|
|||
|
Proceeds from restricted short-term investments - Asbestos
|
106.3
|
|
|
40.0
|
|
|
—
|
|
|||
|
Net cash used in investing activities
|
$
|
(848.0
|
)
|
|
$
|
(239.0
|
)
|
|
$
|
(109.0
|
)
|
|
Cash Flows From Financing Activities
|
|
|
|
|
|
||||||
|
Proceeds from credit facilities
|
$
|
230.0
|
|
|
$
|
380.0
|
|
|
$
|
395.0
|
|
|
Repayments of credit facilities
|
(180.0
|
)
|
|
(455.0
|
)
|
|
(410.0
|
)
|
|||
|
Proceeds from 364-day term loan facility
|
492.4
|
|
|
—
|
|
|
—
|
|
|||
|
Repayments of 364-day term loan facility
|
(458.8
|
)
|
|
—
|
|
|
—
|
|
|||
|
Proceeds from senior unsecured notes
|
458.8
|
|
|
800.0
|
|
|
77.3
|
|
|||
|
Debt issuance costs
|
(6.1
|
)
|
|
(15.7
|
)
|
|
(1.7
|
)
|
|||
|
Repayment of senior unsecured notes
|
—
|
|
|
(400.0
|
)
|
|
—
|
|
|||
|
Call redemption premium paid to note holders
|
—
|
|
|
(19.5
|
)
|
|
—
|
|
|||
|
Proceeds from issuance of shares
|
—
|
|
|
0.2
|
|
|
0.3
|
|
|||
|
Excess tax benefits from share-based awards
|
—
|
|
|
—
|
|
|
3.0
|
|
|||
|
Common stock repurchased and retired
|
—
|
|
|
—
|
|
|
(99.8
|
)
|
|||
|
Dividends paid
|
(172.1
|
)
|
|
(177.5
|
)
|
|
(176.8
|
)
|
|||
|
Proceeds from NSW Loan - Asbestos
|
—
|
|
|
—
|
|
|
77.0
|
|
|||
|
Repayments of NSW Loan - Asbestos
|
—
|
|
|
(51.9
|
)
|
|
(74.3
|
)
|
|||
|
Net cash provided by (used in) financing activities
|
$
|
364.2
|
|
|
$
|
60.6
|
|
|
$
|
(210.0
|
)
|
|
Effects of exchange rate changes on cash and cash equivalents, restricted cash and restricted cash - Asbestos
|
$
|
6.6
|
|
|
$
|
(3.2
|
)
|
|
$
|
0.2
|
|
|
Net (decrease) increase in cash and cash equivalents, restricted cash and restricted cash - Asbestos
|
(189.6
|
)
|
|
120.4
|
|
|
63.7
|
|
|||
|
Cash and cash equivalents, restricted cash and restricted cash - Asbestos at beginning of period
|
313.2
|
|
|
192.8
|
|
|
129.1
|
|
|||
|
Cash and cash equivalents, restricted cash and restricted cash - Asbestos at end of period
|
$
|
123.6
|
|
|
$
|
313.2
|
|
|
$
|
192.8
|
|
|
|
|
|
|
|
|
||||||
|
Supplemental Disclosure of Cash Flow Activities
|
|
|
|
|
|
||||||
|
Cash paid during the year for interest
|
$
|
57.0
|
|
|
$
|
26.3
|
|
|
$
|
26.2
|
|
|
Cash paid during the year for income taxes, net
|
$
|
26.3
|
|
|
$
|
49.1
|
|
|
$
|
51.5
|
|
|
Cash paid to AICF
|
$
|
103.0
|
|
|
$
|
102.2
|
|
|
$
|
91.1
|
|
|
|
|
|
James Hardie Industries plc –
Consolidated Statements of Changes in Shareholders’ Equity (Deficit)
|
122
|
|
|
|
|
(Millions of US dollars)
|
Common
Stock
|
|
Additional
Paid-in
Capital
|
|
Accumulated
(Deficit) Equity
|
|
Treasury
Stock
|
|
Accumulated
Other
Comprehensive Income (Loss)
|
|
Total
|
||||||||||||
|
Balances as of 31 March 2016
|
$
|
231.4
|
|
|
$
|
164.4
|
|
|
$
|
(621.8
|
)
|
|
$
|
—
|
|
|
$
|
0.8
|
|
|
$
|
(225.2
|
)
|
|
Net income
|
—
|
|
|
—
|
|
|
276.5
|
|
|
—
|
|
|
—
|
|
|
276.5
|
|
||||||
|
Other comprehensive loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(3.0
|
)
|
|
(3.0
|
)
|
||||||
|
Stock-based compensation
|
0.9
|
|
|
8.4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
9.3
|
|
||||||
|
Tax benefit from stock options exercised
|
—
|
|
|
3.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.0
|
|
||||||
|
Equity awards exercised
|
—
|
|
|
0.3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.3
|
|
||||||
|
Dividends declared
|
—
|
|
|
—
|
|
|
(173.3
|
)
|
|
—
|
|
|
—
|
|
|
(173.3
|
)
|
||||||
|
Treasury stock purchased
|
—
|
|
|
—
|
|
|
—
|
|
|
(99.8
|
)
|
|
—
|
|
|
(99.8
|
)
|
||||||
|
Treasury stock retired
|
(3.2
|
)
|
|
(2.3
|
)
|
|
(94.3
|
)
|
|
99.8
|
|
|
—
|
|
|
—
|
|
||||||
|
Balances as of 31 March 2017
|
$
|
229.1
|
|
|
$
|
173.8
|
|
|
$
|
(612.9
|
)
|
|
$
|
—
|
|
|
$
|
(2.2
|
)
|
|
$
|
(212.2
|
)
|
|
Net income
|
—
|
|
|
—
|
|
|
146.1
|
|
|
—
|
|
|
—
|
|
|
146.1
|
|
||||||
|
Other comprehensive income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.9
|
|
|
0.9
|
|
||||||
|
Stock-based compensation
|
0.4
|
|
|
11.6
|
|
|
(0.9
|
)
|
|
—
|
|
|
—
|
|
|
11.1
|
|
||||||
|
Equity awards exercised
|
—
|
|
|
0.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.2
|
|
||||||
|
Dividends declared
|
—
|
|
|
—
|
|
|
(167.6
|
)
|
|
—
|
|
|
—
|
|
|
(167.6
|
)
|
||||||
|
Balances as of 31 March 2018
|
$
|
229.5
|
|
|
$
|
185.6
|
|
|
$
|
(635.3
|
)
|
|
$
|
—
|
|
|
$
|
(1.3
|
)
|
|
$
|
(221.5
|
)
|
|
Net income
|
—
|
|
|
—
|
|
|
228.8
|
|
|
—
|
|
|
—
|
|
|
228.8
|
|
||||||
|
Other comprehensive loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(29.0
|
)
|
|
(29.0
|
)
|
||||||
|
Stock-based compensation
|
0.5
|
|
|
12.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
12.5
|
|
||||||
|
Adoption of ASU 2016-16
|
—
|
|
|
—
|
|
|
1,160.3
|
|
|
—
|
|
|
—
|
|
|
1,160.3
|
|
||||||
|
Dividends declared
|
—
|
|
|
—
|
|
|
(176.7
|
)
|
|
—
|
|
|
—
|
|
|
(176.7
|
)
|
||||||
|
Balances as of 31 March 2019
|
$
|
230.0
|
|
|
$
|
197.6
|
|
|
$
|
577.1
|
|
|
$
|
—
|
|
|
$
|
(30.3
|
)
|
|
$
|
974.4
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
124
|
|
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
125
|
|
|
|
|
|
Years
|
|
Buildings
|
10 to 50
|
|
Buildings Improvements
|
3 to 25
|
|
Leasehold Improvements
|
5 to 40
|
|
Machinery and Equipment
|
1 to 30
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
126
|
|
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
127
|
|
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
128
|
|
|
|
|
Level 1
|
Quoted market prices in active markets for identical assets and liabilities that the Company has the ability to access at the measurement date;
|
|
Level 2
|
Observable market-based inputs or unobservable inputs that are corroborated by market data for the asset or liability at the measurement date;
|
|
Level 3
|
Unobservable inputs that are not corroborated by market data used when there is minimal market activity for the asset or liability at the measurement date.
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
129
|
|
|
|
|
|
Years Ended 31 March
|
|||||||
|
(Millions of shares)
|
2019
|
|
2018
|
|
2017
|
|||
|
Basic common shares outstanding
|
441.9
|
|
|
441.2
|
|
|
442.7
|
|
|
Dilutive effect of stock awards
|
1.1
|
|
|
1.1
|
|
|
1.2
|
|
|
Diluted common shares outstanding
|
443.0
|
|
|
442.3
|
|
|
443.9
|
|
|
|
|
|
|
|
|
|||
|
(US dollars)
|
2019
|
|
2018
|
|
2017
|
|||
|
Net income per share - basic
|
0.52
|
|
|
0.33
|
|
|
0.62
|
|
|
Net income per share - diluted
|
0.52
|
|
|
0.33
|
|
|
0.62
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
130
|
|
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
131
|
|
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
132
|
|
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
133
|
|
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
134
|
|
|
|
|
|
Year ended 31 March 2018
|
||||||||||
|
(Millions of US dollars)
|
As reported
|
|
ASU 2016-18
Adjustment
|
|
As adjusted
|
||||||
|
Cash and cash equivalents at the beginning of the period
|
$
|
78.9
|
|
|
$
|
113.9
|
|
|
$
|
192.8
|
|
|
Cash and cash equivalents at the end of the period
|
281.6
|
|
|
31.6
|
|
|
313.2
|
|
|||
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
||||||
|
Restricted cash - Asbestos
|
95.2
|
|
|
(95.2
|
)
|
|
—
|
|
|||
|
Payment to AICF
|
(102.2
|
)
|
|
102.2
|
|
|
—
|
|
|||
|
Asbestos liability
|
(104.4
|
)
|
|
104.4
|
|
|
—
|
|
|||
|
Asbestos claims paid
|
—
|
|
|
(104.4
|
)
|
|
(104.4
|
)
|
|||
|
Net cash provided by operating activities
|
295.0
|
|
|
7.0
|
|
|
302.0
|
|
|||
|
Purchase of investments - Asbestos
|
—
|
|
|
(78.4
|
)
|
|
(78.4
|
)
|
|||
|
Proceeds from investments - Asbestos
|
—
|
|
|
40.0
|
|
|
40.0
|
|
|||
|
Net cash used in investing activities
|
(200.6
|
)
|
|
(38.4
|
)
|
|
(239.0
|
)
|
|||
|
Repayments of NSW Loan - Asbestos
|
—
|
|
|
(51.9
|
)
|
|
(51.9
|
)
|
|||
|
Net cash used in financing activities
|
112.5
|
|
|
(51.9
|
)
|
|
60.6
|
|
|||
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
||||||
|
Effects of exchange rate changes on cash
|
(4.2
|
)
|
|
1.0
|
|
|
(3.2
|
)
|
|||
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
135
|
|
|
|
|
|
Year ended 31 March 2017
|
||||||||||
|
(Millions of US dollars)
|
As reported
|
|
ASU 2016-18
Adjustment
|
|
As adjusted
|
||||||
|
Cash and cash equivalents at the beginning of the period
|
$
|
107.1
|
|
|
$
|
22.0
|
|
|
$
|
129.1
|
|
|
Cash and cash equivalents at the end of the period
|
78.9
|
|
|
113.9
|
|
|
192.8
|
|
|||
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
||||||
|
Restricted cash - Asbestos
|
0.9
|
|
|
(0.9
|
)
|
|
—
|
|
|||
|
Payment to AICF
|
(91.1
|
)
|
|
91.1
|
|
|
—
|
|
|||
|
Asbestos liability
|
(92.0
|
)
|
|
92.0
|
|
|
—
|
|
|||
|
Asbestos claims paid
|
—
|
|
|
(91.8
|
)
|
|
(91.8
|
)
|
|||
|
Net cash provided by operating activities
|
292.1
|
|
|
90.4
|
|
|
382.5
|
|
|||
|
Proceeds from NSW Loan - Asbestos
|
—
|
|
|
77.0
|
|
|
77.0
|
|
|||
|
Repayments of NSW Loan - Asbestos
|
—
|
|
|
(74.3
|
)
|
|
(74.3
|
)
|
|||
|
Net cash used in financing activities
|
(212.7
|
)
|
|
2.7
|
|
|
(210.0
|
)
|
|||
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
||||||
|
Effects of exchange rate changes on cash
|
1.4
|
|
|
(1.2
|
)
|
|
0.2
|
|
|||
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
136
|
|
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
137
|
|
|
|
|
|
Year Ended 31 March 2019
|
||||||||||||||||||
|
(Millions of US dollars)
|
North America
Fiber Cement
|
|
Asia Pacific
Fiber Cement
|
|
Europe Building
Products
|
|
Other
Businesses
|
|
Consolidated
|
||||||||||
|
Fiber cement revenues
|
$
|
1,676.9
|
|
|
$
|
446.8
|
|
|
$
|
35.8
|
|
|
$
|
—
|
|
|
$
|
2,159.5
|
|
|
Fiber gypsum revenues
|
—
|
|
|
—
|
|
|
332.5
|
|
|
—
|
|
|
332.5
|
|
|||||
|
Other revenues
|
—
|
|
|
—
|
|
|
—
|
|
|
14.6
|
|
|
14.6
|
|
|||||
|
Total revenues
|
$
|
1,676.9
|
|
|
$
|
446.8
|
|
|
$
|
368.3
|
|
|
$
|
14.6
|
|
|
$
|
2,506.6
|
|
|
|
Year Ended 31 March 2018
|
||||||||||||||||||
|
(Millions of US dollars)
|
North America
Fiber Cement
|
|
Asia Pacific
Fiber Cement
|
|
Europe Building
Products
|
|
Other
Businesses
|
|
Consolidated
|
||||||||||
|
Fiber cement revenues
|
$
|
1,578.1
|
|
|
$
|
425.4
|
|
|
$
|
36.3
|
|
|
$
|
—
|
|
|
$
|
2,039.8
|
|
|
Fiber gypsum revenues
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
|
Other revenues
|
—
|
|
|
—
|
|
|
—
|
|
|
14.7
|
|
|
14.7
|
|
|||||
|
Total revenues
|
$
|
1,578.1
|
|
|
$
|
425.4
|
|
|
$
|
36.3
|
|
|
$
|
14.7
|
|
|
$
|
2,054.5
|
|
|
|
Year Ended 31 March 2017
|
||||||||||||||||||
|
(Millions of US dollars)
|
North America
Fiber Cement
|
|
Asia Pacific
Fiber Cement
|
|
Europe Building
Products
|
|
Other
Businesses
|
|
Consolidated
|
||||||||||
|
Fiber cement revenues
|
$
|
1,493.4
|
|
|
$
|
370.6
|
|
|
$
|
41.2
|
|
|
$
|
—
|
|
|
$
|
1,905.2
|
|
|
Fiber gypsum revenues
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||
|
Other revenues
|
—
|
|
|
—
|
|
|
—
|
|
|
16.4
|
|
|
16.4
|
|
|||||
|
Total revenues
|
$
|
1,493.4
|
|
|
$
|
370.6
|
|
|
$
|
41.2
|
|
|
$
|
16.4
|
|
|
$
|
1,921.6
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
138
|
|
|
|
|
|
31 March
|
||||||
|
(Millions of US dollars)
|
2019
|
|
2018
|
||||
|
Cash and cash equivalents
|
$
|
78.7
|
|
|
$
|
281.6
|
|
|
Restricted cash
|
5.1
|
|
|
5.0
|
|
||
|
Restricted cash - Asbestos
|
39.8
|
|
|
26.6
|
|
||
|
Total cash and cash equivalents, restricted cash and restricted cash - Asbestos
|
$
|
123.6
|
|
|
$
|
313.2
|
|
|
|
31 March
|
||||||
|
(Millions of US dollars)
|
2019
|
|
2018
|
||||
|
Trade receivables
|
$
|
245.5
|
|
|
$
|
196.9
|
|
|
Other receivables and advances
|
12.0
|
|
|
7.1
|
|
||
|
Provision for doubtful trade debts
|
(2.9
|
)
|
|
(1.3
|
)
|
||
|
Total accounts and other receivables
|
$
|
254.6
|
|
|
$
|
202.7
|
|
|
|
31 March
|
||||||||||
|
(Millions of US dollars)
|
2019
|
|
2018
|
|
2017
|
||||||
|
Balance at beginning of period
|
$
|
1.3
|
|
|
$
|
0.9
|
|
|
$
|
1.1
|
|
|
Adjustment to provision
|
2.8
|
|
|
0.6
|
|
|
(0.1
|
)
|
|||
|
Write-offs, net of recoveries
|
(1.2
|
)
|
|
(0.2
|
)
|
|
(0.1
|
)
|
|||
|
Balance at end of period
|
$
|
2.9
|
|
|
$
|
1.3
|
|
|
$
|
0.9
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
139
|
|
|
|
|
|
31 March
|
||||||
|
(Millions of US dollars)
|
2019
|
|
2018
|
||||
|
Finished goods
|
$
|
235.0
|
|
|
$
|
190.3
|
|
|
Work-in-process
|
7.3
|
|
|
8.1
|
|
||
|
Raw materials and supplies
|
88.8
|
|
|
65.3
|
|
||
|
Provision for obsolete finished goods and raw materials
|
(13.7
|
)
|
|
(8.0
|
)
|
||
|
Total inventories
|
$
|
317.4
|
|
|
$
|
255.7
|
|
|
(Millions of US dollars)
|
Goodwill
1
|
|
Trade names
2
|
|
Other
3
|
||||||
|
Balance - 31 March 2018
|
$
|
4.9
|
|
|
$
|
—
|
|
|
$
|
7.4
|
|
|
Acquired during the period
|
220.0
|
|
|
126.8
|
|
|
—
|
|
|||
|
Impairment
|
(4.6
|
)
|
|
—
|
|
|
—
|
|
|||
|
Foreign exchange impact
|
(19.2
|
)
|
|
(10.7
|
)
|
|
—
|
|
|||
|
Balance - 31 March 2019
|
$
|
201.1
|
|
|
$
|
116.1
|
|
|
$
|
7.4
|
|
|
1
|
At 31 March 2019, Goodwill of US
$200.8
million and US
$0.3
million was included in the Europe Building Products segment and Asia Pacific Fiber Cement segment, respectively. At 31 March 2018, Goodwill of US
$4.6
million and US
$0.3
million was included in the Other Businesses segment and the Asia Pacific Fiber Cement segment, respectively. During the year ended 31 March 2019, the Company recorded a US
$4.6 million
goodwill impairment charge in the Other Businesses segment due to the Company's decision to cease production of its fiberglass windows business. The Company did not record any goodwill impairment charges for the years ended 31 March 2018 and 2017.
|
|
2
|
Trade names are included in the Europe Building Products segment at 31 March 2019.
|
|
3
|
Other indefinite-lived intangible assets are included in the North America Fiber Cement segment at 31 March 2019 and 2018
.
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
140
|
|
|
|
|
(Millions of US dollars)
|
Gross Carrying Amount
|
|
Accumulated Amortization
|
|
Net Carrying Amount
|
||||||
|
Customer relationships:
|
|
|
|
|
|
||||||
|
Balance - 31 March 2018
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Acquired during the period
|
57.8
|
|
|
—
|
|
|
57.8
|
|
|||
|
Amortization
|
—
|
|
|
(4.8
|
)
|
|
(4.8
|
)
|
|||
|
Foreign exchange impact
|
(5.8
|
)
|
|
0.5
|
|
|
(5.3
|
)
|
|||
|
Balance - 31 March 2019
|
$
|
52.0
|
|
|
$
|
(4.3
|
)
|
|
$
|
47.7
|
|
|
(Millions of US dollars)
|
Gross Carrying Amount
|
|
Accumulated Amortization and Impairment
|
|
Net Carrying Amount
|
||||||
|
Other intangibles:
|
|
|
|
|
|
||||||
|
Balance - 31 March 2018
|
$
|
9.7
|
|
|
$
|
(4.8
|
)
|
|
$
|
4.9
|
|
|
Acquired during the period
|
2.4
|
|
|
—
|
|
|
2.4
|
|
|||
|
Amortization
|
—
|
|
|
(1.3
|
)
|
|
(1.3
|
)
|
|||
|
Impairment
|
—
|
|
|
(2.6
|
)
|
|
(2.6
|
)
|
|||
|
Foreign exchange impact
|
(0.3
|
)
|
|
0.1
|
|
|
(0.2
|
)
|
|||
|
Balance - 31 March 2019
|
$
|
11.8
|
|
|
$
|
(8.6
|
)
|
|
$
|
3.2
|
|
|
(In Years)
|
31 March 2019
|
|
31 March 2018
|
|
|
Customer Relationships
|
12.0
|
|
—
|
|
|
Other Intangibles
|
7.5
|
|
6.1
|
|
|
Total
|
11.7
|
|
6.1
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
141
|
|
|
|
|
Years ended 31 March (Millions of US dollars):
|
|
||
|
2020
|
$
|
3.2
|
|
|
2021
|
2.8
|
|
|
|
2022
|
3.6
|
|
|
|
2023
|
4.4
|
|
|
|
2024
|
4.7
|
|
|
|
(Millions of US dollars)
Cost or valuation:
|
Land
|
|
Buildings
|
|
Machinery
and Equipment |
|
Construction
in Progress 1 |
|
Total
|
||||||||||
|
At 31 March 2017
|
$
|
69.5
|
|
|
$
|
344.5
|
|
|
$
|
1,175.7
|
|
|
$
|
56.6
|
|
|
$
|
1,646.3
|
|
|
Additions
2
|
—
|
|
|
7.9
|
|
|
83.8
|
|
|
126.1
|
|
|
217.8
|
|
|||||
|
Disposals
3
|
(1.4
|
)
|
|
(5.6
|
)
|
|
(24.3
|
)
|
|
(3.6
|
)
|
|
(34.9
|
)
|
|||||
|
Exchange differences
|
0.1
|
|
|
—
|
|
|
0.9
|
|
|
(0.2
|
)
|
|
0.8
|
|
|||||
|
At 31 March 2018
|
$
|
68.2
|
|
|
$
|
346.8
|
|
|
$
|
1,236.1
|
|
|
$
|
178.9
|
|
|
$
|
1,830.0
|
|
|
Additions
|
1.6
|
|
58.9
|
|
203.6
|
|
76.7
|
|
340.8
|
|
|||||||||
|
Acquisitions
|
19.2
|
|
44.1
|
|
|
159.5
|
|
|
7.5
|
|
|
230.3
|
|
||||||
|
Transfers
4
|
—
|
|
|
(6.0
|
)
|
|
2.2
|
|
|
(6.5
|
)
|
|
(10.3
|
)
|
|||||
|
Disposals
3
|
(0.2
|
)
|
|
(5.9
|
)
|
|
(48.1
|
)
|
|
(1.2
|
)
|
|
(55.4
|
)
|
|||||
|
Exchange differences
|
(5.0
|
)
|
|
(5.1
|
)
|
|
(45.7
|
)
|
|
1.8
|
|
|
(54.0
|
)
|
|||||
|
At 31 March 2019
|
$
|
83.8
|
|
|
$
|
432.8
|
|
|
$
|
1,507.6
|
|
|
$
|
257.2
|
|
|
$
|
2,281.4
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Accumulated depreciation:
|
|
|
|
|
|
|
|
|
|
||||||||||
|
At 31 March 2017
|
$
|
—
|
|
|
$
|
(128.0
|
)
|
|
$
|
(639.3
|
)
|
|
$
|
—
|
|
|
$
|
(767.3
|
)
|
|
Charge for the year
|
—
|
|
|
(11.3
|
)
|
|
(77.6
|
)
|
|
—
|
|
|
(88.9
|
)
|
|||||
|
Disposals
3
|
—
|
|
|
1.9
|
|
|
16.6
|
|
|
—
|
|
|
18.5
|
|
|||||
|
Exchange differences
|
—
|
|
|
—
|
|
|
(0.2
|
)
|
|
—
|
|
|
(0.2
|
)
|
|||||
|
At 31 March 2018
|
$
|
—
|
|
|
$
|
(137.4
|
)
|
|
$
|
(700.5
|
)
|
|
$
|
—
|
|
|
$
|
(837.9
|
)
|
|
Charge for the year
|
—
|
|
|
(14.6
|
)
|
|
(95.0
|
)
|
|
—
|
|
|
(109.6
|
)
|
|||||
|
Transfers
4
|
—
|
|
|
0.8
|
|
|
3.7
|
|
|
—
|
|
|
4.5
|
|
|||||
|
Disposals
3
|
—
|
|
|
4.1
|
|
|
23.3
|
|
|
—
|
|
|
27.4
|
|
|||||
|
Exchange differences
|
—
|
|
|
3.2
|
|
|
19.4
|
|
|
—
|
|
|
22.6
|
|
|||||
|
At 31 March 2019
|
$
|
—
|
|
|
$
|
(143.9
|
)
|
|
$
|
(749.1
|
)
|
|
$
|
—
|
|
|
$
|
(893.0
|
)
|
|
Net book amount:
|
|
|
|
|
|
|
|
|
|
||||||||||
|
At 31 March 2018
|
$
|
68.2
|
|
|
$
|
209.4
|
|
|
$
|
535.6
|
|
|
$
|
178.9
|
|
|
$
|
992.1
|
|
|
At 31 March 2019
|
$
|
83.8
|
|
|
$
|
288.9
|
|
|
$
|
758.5
|
|
|
$
|
257.2
|
|
|
$
|
1,388.4
|
|
|
1
|
Construction in progress is presented net of assets transferred into service.
|
|
2
|
Additions include
US$5.4 million
and
US$4.8 million
of capitalized interest for the years ended 31 March 2019 and 2018, respectively.
|
|
3
|
The
US$28.0 million
net book value of disposals in fiscal year 2019 includes
US$13.7 million
of usage of replacement parts,
US$6.1 million
of impairment due to the Company's decision to cease production of its fiberglass windows business,
US$2.6 million
of impairment related to the discontinuance of its MCT product line,
US$0.4 million
of impairment charges on individual assets and
US$5.2 million
of disposals of assets no longer in use. The
US$16.4 million
net book value of disposals in fiscal year 2018 includes
US$13.9 million
of usage of replacement parts and
US$0.7 million
of impairment charges on individual assets. The remaining net book value of disposals of
US$1.8 million
is related to the disposal of assets no longer in use.
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
142
|
|
|
|
|
4
|
Transfers include the net book value of
Property, plant and equipment, net
associated with our fiberglass windows business, which was classified as held for sale at 31 March 2019. This net book value of
US$5.8 million
was removed from
Property, plant and equipment, net
and was included in the
Prepaid expenses and other current assets
on the consolidated balance sheets at 31 March 2019.
|
|
|
31 March
|
||||||
|
(Millions of US dollars)
|
2019
|
|
2018
|
||||
|
Trade creditors
|
$
|
142.4
|
|
|
$
|
111.8
|
|
|
Accrued interest
|
8.8
|
|
|
12.5
|
|
||
|
Other creditors and accruals
|
104.3
|
|
|
69.0
|
|
||
|
Total accounts payable and accrued liabilities
|
$
|
255.5
|
|
|
$
|
193.3
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
143
|
|
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
144
|
|
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
145
|
|
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
146
|
|
|
|
|
|
31 March
|
||||||||||
|
(Millions of US dollars)
|
2019
|
|
2018
|
|
2017
|
||||||
|
Balance at beginning of period
|
$
|
52.8
|
|
|
$
|
46.6
|
|
|
$
|
45.3
|
|
|
(Decrease) increase for product warranties accrual
|
(0.8
|
)
|
|
13.1
|
|
|
17.0
|
|
|||
|
Acquired during the period
|
0.5
|
|
|
—
|
|
|
—
|
|
|||
|
Settlements made in cash or in kind
|
(5.9
|
)
|
|
(6.9
|
)
|
|
(15.7
|
)
|
|||
|
Balance at end of period
|
$
|
46.6
|
|
|
$
|
52.8
|
|
|
$
|
46.6
|
|
|
|
Years Ended 31 March
|
||||||||||
|
(Millions of US dollars)
|
2019
|
|
2018
|
|
2017
|
||||||
|
Change in estimates:
|
|
|
|
|
|
||||||
|
Change in actuarial estimate - asbestos liability
|
$
|
(73.8
|
)
|
|
$
|
(152.1
|
)
|
|
$
|
44.7
|
|
|
Change in actuarial estimate - insurance receivable
|
—
|
|
|
1.2
|
|
|
(8.2
|
)
|
|||
|
Change in estimate - AICF claims-handling costs
|
1.1
|
|
|
(0.5
|
)
|
|
2.1
|
|
|||
|
Subtotal - Change in estimates
|
(72.7
|
)
|
|
(151.4
|
)
|
|
38.6
|
|
|||
|
Effect of foreign exchange on Asbestos net liabilities
|
49.5
|
|
|
(5.3
|
)
|
|
2.8
|
|
|||
|
(Loss) gain on foreign currency forward contracts
|
(0.8
|
)
|
|
1.4
|
|
|
(1.0
|
)
|
|||
|
Adjustments in insurance receivable
|
2.0
|
|
|
—
|
|
|
—
|
|
|||
|
Asbestos research and education contribution
|
—
|
|
|
(1.1
|
)
|
|
—
|
|
|||
|
Total Asbestos Adjustments
|
$
|
(22.0
|
)
|
|
$
|
(156.4
|
)
|
|
$
|
40.4
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
147
|
|
|
|
|
|
Year Ended 31 March 2019
|
||||
|
(Millions of US and Australian dollars, respectively)
|
US$
|
|
A$
|
||
|
Central Estimate – Discounted and Inflated
|
1,325.9
|
|
|
1,868.4
|
|
|
Central Estimate – Undiscounted but Inflated
|
1,574.3
|
|
|
2,218.5
|
|
|
Central Estimate – Undiscounted and Uninflated
|
993.3
|
|
|
1,399.8
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
148
|
|
|
|
|
|
|
For the Years Ended 31 March
|
|||||||||||||
|
|
|
2019
|
|
|
2018
|
|
|
2017
|
|
|
2016
|
|
|
2015
|
|
|
Number of open claims at beginning of period
|
|
336
|
|
|
352
|
|
|
426
|
|
|
494
|
|
|
466
|
|
|
Number of new claims
|
|
568
|
|
|
562
|
|
|
557
|
|
|
577
|
|
|
665
|
|
|
Number of closed claims
|
|
572
|
|
|
578
|
|
|
631
|
|
|
645
|
|
|
637
|
|
|
Number of open claims at end of period
|
|
332
|
|
|
336
|
|
|
352
|
|
|
426
|
|
|
494
|
|
|
Average settlement amount per settled claim
|
|
A$262,108
|
|
A$253,431
|
|
A$223,535
|
|
A$248,138
|
|
A$254,209
|
|||||
|
Average settlement amount per case closed
|
|
A$234,156
|
|
A$217,038
|
|
A$167,563
|
|
A$218,900
|
|
A$217,495
|
|||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Average settlement amount per settled claim
|
|
US$191,236
|
|
US$196,093
|
|
US$168,300
|
|
US$182,763
|
|
US$222,619
|
|||||
|
Average settlement amount per case closed
|
|
US$170,842
|
|
US$167,934
|
|
US$126,158
|
|
US$161,229
|
|
US$190,468
|
|||||
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
149
|
|
|
|
|
|
|
31 March
|
||||||
|
(Millions of US dollars)
|
|
2019
|
|
2018
|
||||
|
Asbestos liability – current
|
|
$
|
(110.5
|
)
|
|
$
|
(114.1
|
)
|
|
Asbestos liability – non-current
|
|
(979.1
|
)
|
|
(1,101.0
|
)
|
||
|
Asbestos liability – Total
|
|
(1,089.6
|
)
|
|
(1,215.1
|
)
|
||
|
Insurance receivable – current
|
|
7.5
|
|
|
5.1
|
|
||
|
Insurance receivable – non-current
|
|
43.7
|
|
|
52.8
|
|
||
|
Insurance receivable – Total
|
|
51.2
|
|
|
57.9
|
|
||
|
Workers’ compensation asset – current
|
|
2.0
|
|
|
2.1
|
|
||
|
Workers’ compensation asset – non-current
|
|
25.8
|
|
|
28.8
|
|
||
|
Workers’ compensation liability – current
|
|
(2.0
|
)
|
|
(2.1
|
)
|
||
|
Workers’ compensation liability – non-current
|
|
(25.8
|
)
|
|
(28.8
|
)
|
||
|
Workers’ compensation – Total
|
|
—
|
|
|
—
|
|
||
|
Other net liabilities
|
|
(2.1
|
)
|
|
(2.2
|
)
|
||
|
Restricted cash and cash equivalents of AICF
|
|
39.8
|
|
|
26.6
|
|
||
|
Restricted short-term investments of AICF
|
|
17.7
|
|
|
38.4
|
|
||
|
Net Unfunded AFFA liability
|
|
$
|
(983.0
|
)
|
|
$
|
(1,094.4
|
)
|
|
Deferred income taxes – non-current
|
|
349.3
|
|
|
382.9
|
|
||
|
Income tax payable
|
|
25.3
|
|
|
21.1
|
|
||
|
Net Unfunded AFFA liability, net of tax
|
|
$
|
(608.4
|
)
|
|
$
|
(690.4
|
)
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
150
|
|
|
|
|
(Millions of US dollars)
|
Asbestos
Liability
|
|
Insurance
Receivables
|
|
Restricted
Cash and Investments
|
|
Other
Assets
and Liabilities
|
|
Net Unfunded AFFA Liability
|
|
Deferred Tax
Assets
|
|
Income
Tax
Payable
|
|
Net Unfunded AFFA Liability, net of tax
|
||||||||||||||||
|
Opening Balance - 31 March 2018
|
$
|
(1,215.1
|
)
|
|
$
|
57.9
|
|
|
$
|
65.0
|
|
|
$
|
(2.2
|
)
|
|
$
|
(1,094.4
|
)
|
|
$
|
382.9
|
|
|
$
|
21.1
|
|
|
$
|
(690.4
|
)
|
|
Asbestos claims paid
1
|
107.6
|
|
|
—
|
|
|
(107.6
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
|
Payment received in accordance with AFFA
2
|
—
|
|
|
—
|
|
|
103.0
|
|
|
—
|
|
|
103.0
|
|
|
—
|
|
|
—
|
|
|
103.0
|
|
||||||||
|
AICF claims-handling costs incurred (paid)
|
1.2
|
|
|
—
|
|
|
(1.2
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
|
AICF operating costs paid - non claims-handling
|
—
|
|
|
—
|
|
|
(1.5
|
)
|
|
—
|
|
|
(1.5
|
)
|
|
—
|
|
|
—
|
|
|
(1.5
|
)
|
||||||||
|
Change in actuarial estimate
|
(73.9
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(73.9
|
)
|
|
—
|
|
|
—
|
|
|
(73.9
|
)
|
||||||||
|
Change in claims handling cost estimate
|
1.1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1.1
|
|
|
—
|
|
|
—
|
|
|
1.1
|
|
||||||||
|
Impact on deferred income tax due to change in actuarial estimate
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
21.2
|
|
|
—
|
|
|
21.2
|
|
||||||||
|
Insurance recoveries
|
—
|
|
|
(2.5
|
)
|
|
4.8
|
|
|
—
|
|
|
2.3
|
|
|
—
|
|
|
—
|
|
|
2.3
|
|
||||||||
|
Movement in income tax payable
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(26.0
|
)
|
|
5.2
|
|
|
(20.8
|
)
|
||||||||
|
Other movements
|
—
|
|
|
—
|
|
|
1.6
|
|
|
—
|
|
|
1.6
|
|
|
(0.2
|
)
|
|
(0.3
|
)
|
|
1.1
|
|
||||||||
|
Effect of foreign exchange
|
89.5
|
|
|
(4.2
|
)
|
|
(6.6
|
)
|
|
0.1
|
|
|
78.8
|
|
|
(28.6
|
)
|
|
(0.7
|
)
|
|
49.5
|
|
||||||||
|
Closing Balance - 31 March 2019
|
$
|
(1,089.6
|
)
|
|
$
|
51.2
|
|
|
$
|
57.5
|
|
|
$
|
(2.1
|
)
|
|
$
|
(983.0
|
)
|
|
$
|
349.3
|
|
|
$
|
25.3
|
|
|
$
|
(608.4
|
)
|
|
1
|
Claims paid of US
$107.6
million reflects A
$147.5
million converted at the average exchange rate for the period based on the assumption that these transactions occurred evenly throughout the period.
|
|
2
|
The payment received in accordance with AFFA of US
$103.0
million reflects the US dollar equivalent of the A
$138.4
million payment, translated at the exchange rate set
five
days before the day of payment.
|
|
Payment Date
|
Payment Amount A$ Millions
|
Payment Amount US$ Millions
|
Operating Cash flow US$ Millions
|
Free Cash Flow US$ Millions
|
||||
|
2 July 2018
|
138.4
|
|
103.0
|
|
295.0
|
|
294.2
|
|
|
3 July 2017
|
135.1
|
|
102.2
|
|
292.1
|
|
292.1
|
|
|
1 July 2016
|
120.7
|
|
91.1
|
|
260.4
|
|
260.4
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
151
|
|
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
152
|
|
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
153
|
|
|
|
|
|
|
|
|
|
Fair Value as of
|
||||||||||||||||||
|
(Millions of US dollars)
|
Notional Amount
|
|
31 March 2019
|
|
31 March 2018
|
||||||||||||||||||
|
|
31 March 2019
|
|
31 March 2018
|
|
Assets
|
|
Liabilities
|
|
Assets
|
|
Liabilities
|
||||||||||||
|
Derivatives not accounted for as hedges
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Interest rate swap contracts
|
$
|
75.0
|
|
|
$
|
100.0
|
|
|
$
|
0.3
|
|
|
$
|
—
|
|
|
$
|
0.4
|
|
|
$
|
—
|
|
|
Foreign currency forward contracts
|
—
|
|
|
0.8
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Total
|
$
|
75.0
|
|
|
$
|
100.8
|
|
|
$
|
0.3
|
|
|
$
|
—
|
|
|
$
|
0.4
|
|
|
$
|
—
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
154
|
|
|
|
|
Years ending 31 March
(Millions of US dollars):
|
2020
|
2021
|
2022
|
2023
|
2024
|
Thereafter
|
Total
|
||||||||||||||
|
Operating leases
1
|
$
|
18.4
|
|
$
|
15.3
|
|
$
|
11.7
|
|
$
|
7.5
|
|
$
|
5.1
|
|
$
|
8.2
|
|
$
|
66.2
|
|
|
Purchase commitments
2
|
0.4
|
|
0.4
|
|
0.4
|
|
0.4
|
|
0.4
|
|
8.2
|
|
10.2
|
|
|||||||
|
Capital commitments
3
|
5.2
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
5.2
|
|
|||||||
|
|
|||||||||||||||||||||
|
1
Future lease payments for non-cancellable operating leases having a remaining term in excess of one year at 31 March 2019. As the lessee, the Company principally enters into property, building and equipment leases.
|
|||||||||||||||||||||
|
2
Represents unconditional purchase obligations that include agreements to purchase goods or services, primarily gypsum, that are enforceable and legally binding on us and that specify all significant terms, including fixed or minimum quantities to be purchased, fixed, minimum or variable price provisions, and approximate timing of the transaction. Purchase obligations exclude agreements that are cancellable without penalty.
|
|||||||||||||||||||||
|
3
Represents total outstanding purchase obligations under purchase orders as of 31 March 2019 in connection with future capital expenditures in connection with our capacity expansion projects.
|
|||||||||||||||||||||
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
155
|
|
|
|
|
|
|
Years Ended 31 March
|
||||||||||
|
(Millions of US dollars)
|
|
2019
|
|
2018
|
|
2017
|
||||||
|
Income before income taxes:
|
|
|
|
|
|
|
||||||
|
Domestic
|
|
$
|
196.4
|
|
|
$
|
155.1
|
|
|
$
|
172.2
|
|
|
Foreign
|
|
104.2
|
|
|
19.2
|
|
|
194.8
|
|
|||
|
Income before income taxes:
|
|
$
|
300.6
|
|
|
$
|
174.3
|
|
|
$
|
367.0
|
|
|
Income tax expense:
|
|
|
|
|
|
|
||||||
|
Current:
|
|
|
|
|
|
|
||||||
|
Domestic
|
|
$
|
(26.6
|
)
|
|
$
|
(14.8
|
)
|
|
$
|
(15.2
|
)
|
|
Foreign
|
|
(6.5
|
)
|
|
(69.4
|
)
|
|
(36.0
|
)
|
|||
|
Current income tax expense
|
|
(33.1
|
)
|
|
(84.2
|
)
|
|
(51.2
|
)
|
|||
|
Deferred:
|
|
|
|
|
|
|
||||||
|
Domestic
|
|
(1.3
|
)
|
|
(1.8
|
)
|
|
(4.0
|
)
|
|||
|
Foreign
|
|
(37.4
|
)
|
|
57.8
|
|
|
(35.3
|
)
|
|||
|
Deferred income tax (expense) benefit
|
|
(38.7
|
)
|
|
56.0
|
|
|
(39.3
|
)
|
|||
|
Total income tax expense
|
|
$
|
(71.8
|
)
|
|
$
|
(28.2
|
)
|
|
$
|
(90.5
|
)
|
|
|
|
Years Ended 31 March
|
||||||||||
|
(Millions of US dollars)
|
|
2019
|
|
2018
|
|
2017
|
||||||
|
Income tax expense computed at the statutory tax rates
|
|
$
|
(48.9
|
)
|
|
$
|
(24.6
|
)
|
|
$
|
(84.4
|
)
|
|
US state income taxes, net of the federal benefit
|
|
(3.1)
|
|
(4.3
|
)
|
|
(3.0
|
)
|
||||
|
Asbestos - effect of foreign exchange
|
|
14.9
|
|
(1.8
|
)
|
|
0.8
|
|
||||
|
Expenses not deductible
|
|
(4.9)
|
|
(4.7
|
)
|
|
(2.5
|
)
|
||||
|
US manufacturing deduction
|
|
—
|
|
|
2.5
|
|
|
2.2
|
|
|||
|
Foreign taxes on domestic income
|
|
(34.5
|
)
|
|
(34.2
|
)
|
|
(2.1
|
)
|
|||
|
Amortization of intangibles
|
|
—
|
|
|
12.4
|
|
|
2.8
|
|
|||
|
Taxes on foreign income
|
|
4.5
|
|
|
(3.0
|
)
|
|
(5.4
|
)
|
|||
|
Net deferred tax liability revaluation
|
|
0.2
|
|
|
27.7
|
|
|
—
|
|
|||
|
Other items
|
|
—
|
|
|
1.8
|
|
|
1.1
|
|
|||
|
Total income tax expense
|
|
$
|
(71.8
|
)
|
|
$
|
(28.2
|
)
|
|
$
|
(90.5
|
)
|
|
Effective tax rate
|
|
23.9
|
%
|
|
16.2
|
%
|
|
24.7
|
%
|
|||
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
156
|
|
|
|
|
|
|
31 March
|
||||||
|
(Millions of US dollars)
|
|
2019
|
|
2018
|
||||
|
Deferred tax assets:
|
|
|
|
|
||||
|
Intangible assets
|
|
$
|
1,209.8
|
|
|
$
|
—
|
|
|
Asbestos liability
|
|
349.3
|
|
|
382.9
|
|
||
|
Other provisions and accruals
|
|
55.6
|
|
|
37.7
|
|
||
|
Net operating loss carryforwards
|
|
69.9
|
|
|
25.5
|
|
||
|
Foreign and research tax credit carryforwards
|
|
115.5
|
|
|
126.1
|
|
||
|
Total deferred tax assets
|
|
1,800.1
|
|
|
572.2
|
|
||
|
Valuation allowance
|
|
(267.6
|
)
|
|
(129.6
|
)
|
||
|
Total deferred tax assets net of valuation allowance
|
|
1,532.5
|
|
|
442.6
|
|
||
|
Deferred tax liabilities:
|
|
|
|
|
||||
|
Depreciable and amortizable assets
|
|
(132.2
|
)
|
|
(81.6
|
)
|
||
|
Other
|
|
(38.5
|
)
|
|
(14.6
|
)
|
||
|
Total deferred tax liabilities
|
|
(170.7
|
)
|
|
(96.2
|
)
|
||
|
Total deferred taxes, net
|
|
$
|
1,361.8
|
|
|
$
|
346.4
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
157
|
|
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
158
|
|
|
|
|
(Millions of US Dollars)
|
|
Unrecognized
tax benefits
|
|
Interest and
Penalties
|
||||
|
Balance at 31 March 2016
|
|
$
|
0.7
|
|
|
$
|
—
|
|
|
Additions for tax positions of the current year
|
|
0.1
|
|
|
—
|
|
||
|
Reductions in tax positions of prior year
|
|
(0.1
|
)
|
|
—
|
|
||
|
Balance at 31 March 2017
|
|
$
|
0.7
|
|
|
$
|
—
|
|
|
Additions for tax positions of the current year
|
|
—
|
|
|
—
|
|
||
|
Reductions in tax positions of prior year
|
|
—
|
|
|
—
|
|
||
|
Balance at 31 March 2018
|
|
$
|
0.7
|
|
|
$
|
—
|
|
|
Additions for tax positions of the current year
|
|
0.1
|
|
|
0.1
|
|
||
|
Reductions in tax positions of prior year
|
|
—
|
|
|
—
|
|
||
|
Reductions applicable to lapse of statute of limitations
|
|
(0.2
|
)
|
|
—
|
|
||
|
Balance at 31 March 2019
|
|
$
|
0.6
|
|
|
$
|
0.1
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
159
|
|
|
|
|
|
Years Ended 31 March
|
||||||||||
|
(Millions of US dollars)
|
2019
|
|
2018
|
|
2017
|
||||||
|
Liability Awards (Income) Expense
|
$
|
(0.6
|
)
|
|
$
|
5.6
|
|
|
$
|
5.4
|
|
|
Equity Awards Expense
|
12.5
|
|
|
11.1
|
|
|
9.3
|
|
|||
|
Total stock-based compensation expense
|
$
|
11.9
|
|
|
$
|
16.7
|
|
|
$
|
14.7
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
160
|
|
|
|
|
|
Shares
Available for
Grant
|
|
|
Balance at 31 March 2017
|
27,238,814
|
|
|
Granted
|
(1,779,904
|
)
|
|
Balance at 31 March 2018
|
25,458,910
|
|
|
Granted
|
(1,714,094
|
)
|
|
Balance at 31 March 2019
|
23,744,816
|
|
|
|
Outstanding Options
|
||||
|
|
Number
|
|
Weighted
Average
Exercise
Price (A$)
|
||
|
Balance at 31 March 2017
|
48,896
|
|
|
6.38
|
|
|
Exercised
|
(48,896
|
)
|
|
6.38
|
|
|
Balance at 31 March 2018
|
—
|
|
|
|
|
|
Exercised
|
—
|
|
|
|
|
|
Balance at 31 March 2019
|
—
|
|
|
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
161
|
|
|
|
|
|
Restricted
Stock Units
|
|
Weighted
Average Fair
Value at Grant
Date (A$)
|
||
|
Non-vested at 31 March 2017
|
3,340,245
|
|
|
14.80
|
|
|
Granted
|
1,779,904
|
|
|
14.04
|
|
|
Vested
|
(615,334
|
)
|
|
12.05
|
|
|
Forfeited
|
(367,223
|
)
|
|
14.12
|
|
|
Non-vested at 31 March 2018
|
4,137,592
|
|
|
14.63
|
|
|
Granted
|
1,714,094
|
|
|
14.12
|
|
|
Vested
|
(745,787
|
)
|
|
15.53
|
|
|
Forfeited
|
(844,391
|
)
|
|
13.71
|
|
|
Non-vested at 31 March 2019
|
4,261,508
|
|
|
14.47
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
162
|
|
|
|
|
Vesting Condition:
|
Market
|
|
Market
|
|
Market
|
|||
|
|
FY19
|
|
FY19
|
|
FY18
|
|||
|
Date of grant
|
6 Sep 2018
|
|
|
17 Aug 2018
|
|
|
21 Aug 2017
|
|
|
Dividend yield (per annum)
|
3.0
|
%
|
|
3.0
|
%
|
|
3.0
|
%
|
|
Expected volatility
|
26.8
|
%
|
|
28.1
|
%
|
|
30.1
|
%
|
|
Risk free interest rate
|
2.7
|
%
|
|
2.7
|
%
|
|
1.5
|
%
|
|
Expected life in years
|
2.9
|
|
|
3.0
|
|
|
3.3
|
|
|
JHX stock price at grant date (A$)
|
20.87
|
|
|
22.00
|
|
|
17.91
|
|
|
Number of restricted stock units
|
49,381
|
|
|
663,738
|
|
|
932,393
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
163
|
|
|
|
|
(Millions of US dollars)
|
US
Cents/Security
|
|
US$ Millions
Total Amount
|
|
Announcement Date
|
|
Record Date
|
|
Payment Date
|
|
FY 2019 first half dividend
|
0.10
|
|
43.6
|
|
8 November 2018
|
|
12 December 2018
|
|
22 February 2019
|
|
FY 2018 second half dividend
|
0.30
|
|
128.5
|
|
22 May 2018
|
|
7 June 2018
|
|
3 August 2018
|
|
FY 2018 first half dividend
|
0.10
|
|
46.2
|
|
9 November 2017
|
|
13 December 2017
|
|
23 February 2018
|
|
FY 2017 second half dividend
|
0.28
|
|
131.3
|
|
18 May 2017
|
|
8 June 2017
|
|
4 August 2017
|
|
FY 2017 first half dividend
|
0.10
|
|
46.6
|
|
17 November 2016
|
|
21 December 2016
|
|
24 February 2017
|
|
FY 2016 second half dividend
|
0.29
|
|
130.2
|
|
19 May 2016
|
|
9 June 2016
|
|
5 August 2016
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
164
|
|
|
|
|
|
|
Net Sales to Customers
Years Ended 31 March
|
||||||||||
|
(Millions of US dollars)
|
|
2019
|
|
2018
|
|
2017
|
||||||
|
North America Fiber Cement
|
|
$
|
1,676.9
|
|
|
$
|
1,578.1
|
|
|
$
|
1,493.4
|
|
|
Asia Pacific Fiber Cement
|
|
446.8
|
|
|
425.4
|
|
|
370.6
|
|
|||
|
Europe Building Products
|
|
368.3
|
|
|
36.3
|
|
|
41.2
|
|
|||
|
Other Businesses
|
|
14.6
|
|
|
14.7
|
|
|
16.4
|
|
|||
|
Worldwide total
|
|
$
|
2,506.6
|
|
|
$
|
2,054.5
|
|
|
$
|
1,921.6
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
||||||
|
|
|
Income Before Income Taxes
Years Ended 31 March
|
||||||||||
|
(Millions of US dollars)
|
|
2019
|
|
2018
|
|
2017
|
||||||
|
North America Fiber Cement
1,10
|
|
$
|
382.5
|
|
|
$
|
381.9
|
|
|
$
|
343.9
|
|
|
Asia Pacific Fiber Cement
1
|
|
99.8
|
|
|
108.1
|
|
|
93.8
|
|
|||
|
Europe Building Products
1,7
|
|
10.0
|
|
|
0.3
|
|
|
1.3
|
|
|||
|
Other Businesses
10
|
|
(30.9
|
)
|
|
(8.6
|
)
|
|
(6.7
|
)
|
|||
|
Research and Development
1
|
|
(29.0
|
)
|
|
(27.8
|
)
|
|
(25.5
|
)
|
|||
|
Segments total
|
|
432.4
|
|
|
453.9
|
|
|
406.8
|
|
|||
|
General Corporate
2,6
|
|
(80.8
|
)
|
|
(224.7
|
)
|
|
(13.6
|
)
|
|||
|
Total operating income
|
|
351.6
|
|
|
229.2
|
|
|
393.2
|
|
|||
|
Net interest expense
3
|
|
(50.1
|
)
|
|
(29.5
|
)
|
|
(27.5
|
)
|
|||
|
Loss on early debt extinguishment
|
|
(1.0
|
)
|
|
(26.1
|
)
|
|
—
|
|
|||
|
Other income
|
|
0.1
|
|
|
0.7
|
|
|
1.3
|
|
|||
|
Worldwide total
|
|
$
|
300.6
|
|
|
$
|
174.3
|
|
|
$
|
367.0
|
|
|
|
|
Total Identifiable Assets
31 March
|
||||||
|
(Millions of US dollars)
|
|
2019
|
|
2018
|
||||
|
North America Fiber Cement
|
|
$
|
1,280.2
|
|
|
$
|
1,070.7
|
|
|
Asia Pacific Fiber Cement
|
|
328.8
|
|
|
328.8
|
|
||
|
Europe Building Products
|
|
717.7
|
|
|
22.8
|
|
||
|
Other Businesses
|
|
10.9
|
|
|
30.1
|
|
||
|
Research and Development
|
|
8.1
|
|
|
7.5
|
|
||
|
Segments total
|
|
2,345.7
|
|
|
1,459.9
|
|
||
|
General Corporate
4,5
|
|
1,686.9
|
|
|
891.1
|
|
||
|
Worldwide total
|
|
$
|
4,032.6
|
|
|
$
|
2,351.0
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
165
|
|
|
|
|
|
|
Net Sales to Customers
Years Ended 31 March
|
||||||||||
|
(Millions of US dollars)
|
|
2019
|
|
2018
|
|
2017
|
||||||
|
North America
9
|
|
$
|
1,691.5
|
|
|
$
|
1,592.8
|
|
|
$
|
1,509.9
|
|
|
Australia
|
|
315.1
|
|
|
301.1
|
|
|
252.5
|
|
|||
|
Germany
|
|
137.1
|
|
|
2.1
|
|
|
2.7
|
|
|||
|
New Zealand
|
|
79.1
|
|
|
76.8
|
|
|
73.3
|
|
|||
|
Other Countries
8
|
|
283.8
|
|
|
81.7
|
|
|
83.2
|
|
|||
|
Worldwide total
|
|
$
|
2,506.6
|
|
|
$
|
2,054.5
|
|
|
$
|
1,921.6
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
Total Identifiable Assets
31 March
|
||||||||
|
(Millions of US dollars)
|
|
|
|
2019
|
|
2018
|
||||||
|
North America
9
|
|
|
|
$
|
1,294.6
|
|
|
$
|
1,103.6
|
|
||
|
Australia
|
|
|
|
235.4
|
|
|
242.6
|
|
||||
|
Germany
|
|
|
|
512.3
|
|
|
0.5
|
|
||||
|
New Zealand
|
|
|
|
39.2
|
|
|
34.8
|
|
||||
|
Other Countries
8
|
|
|
|
264.2
|
|
|
78.4
|
|
||||
|
Segments total
|
|
|
|
2,345.7
|
|
|
1,459.9
|
|
||||
|
General Corporate
4,5
|
|
|
|
1,686.9
|
|
|
891.1
|
|
||||
|
Worldwide total
|
|
|
|
$
|
4,032.6
|
|
|
$
|
2,351.0
|
|
||
|
1
|
Research and development expenditures are expensed as incurred and are summarized by segment in the following table:
|
|
|
|
Years Ended 31 March
|
||||||||||
|
(Millions of US dollars)
|
|
2019
|
|
2018
|
|
2017
|
||||||
|
North America Fiber Cement
|
|
$
|
6.5
|
|
|
$
|
6.1
|
|
|
$
|
6.2
|
|
|
Asia Pacific Fiber Cement
|
|
2.1
|
|
|
1.8
|
|
|
1.5
|
|
|||
|
Europe Building Products
|
|
2.6
|
|
|
—
|
|
|
—
|
|
|||
|
Research and Development
a
|
|
26.7
|
|
|
25.4
|
|
|
22.6
|
|
|||
|
|
|
$
|
37.9
|
|
|
$
|
33.3
|
|
|
$
|
30.3
|
|
|
2
|
The principal components of General Corporate costs are officer and employee compensation and related benefits, professional and legal fees, administrative costs, and rental expense on the Company’s corporate offices. Also included in General Corporate costs are the following:
|
|
|
|
Years Ended 31 March
|
||||||||||
|
(Millions of US dollars)
|
|
2019
|
|
2018
|
|
2017
|
||||||
|
Asbestos adjustments
|
|
$
|
(22.0
|
)
|
|
$
|
(156.4
|
)
|
|
$
|
40.4
|
|
|
AICF SG&A expenses
|
|
(1.5
|
)
|
|
(1.9
|
)
|
|
(1.5
|
)
|
|||
|
Gain on sale of Fontana building
|
|
—
|
|
|
3.4
|
|
|
—
|
|
|||
|
Fermacell acquisition costs
|
|
—
|
|
|
10.0
|
|
|
—
|
|
|||
|
3
|
The Company does not report net interest expense for each operating segment as operating segments are not held directly accountable for interest expense. Included in net interest expense is net AICF interest (income) expense of US
$(2.0) million
, US
$(1.9) million
and US
$1.1 million
in fiscal years 2019, 2018 and 2017, respectively.
|
|
4
|
Included in General Corporate costs are deferred tax assets for each operating segment that are not held directly accountable for deferred income taxes.
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
166
|
|
|
|
|
5
|
Asbestos-related assets at 31 March 2019 and 2018 are US
$486.8 million
and US
$537.7 million
, respectively, and are included in the General Corporate costs.
|
|
6
|
Included in the General Corporate costs are New Zealand weathertightness legal costs of US
$3.3
million,
nil
and
nil
for the years ended 31 March 2019, 2018 and 2017, respectively.
|
|
7
|
Included in the Europe Building Products segment are Fermacell transaction and integration costs of US
$21.8 million
and the amortization of the inventory fair value adjustment of US
$7.3 million
for the year ended 31 March 2019. As this inventory was sold during the first quarter of fiscal year 2019, the entire adjustment was recognized into cost of goods sold during the same period.
|
|
8
|
Included are all other countries that account for less than 5% of net sales and total identifiable assets individually, primarily in the Philippines, Switzerland and other European countries.
|
|
9
|
The amounts disclosed for North America are substantially all related to the USA.
|
|
10
|
The following table summarizes asset impairment costs by segment:
|
|
|
|
Years Ended 31 March
|
||||||||||
|
(Millions of US dollars)
|
|
2019
|
|
2018
|
|
2017
|
||||||
|
North America Fiber Cement
a
|
|
$
|
3.0
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Other Businesses
b
|
|
12.9
|
|
|
—
|
|
|
—
|
|
|||
|
|
|
$
|
15.9
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
||||||
|
a
For the year ended 31 March 2019, the Company recorded impairment charges of US$2.6 million and US$0.4 million to
Property, plant and equipment, net
and
Intangible assets, net,
respectively, related to the discontinuance of its MCT product line.
|
||||||||||||
|
b
For the year ended 31 March 2019, the Company recorded impairment charges of US$4.6 million, US$6.1 million and US$2.2 million to the
Goodwill, Property, Plant and equipment, net
and
Intangible assets, net
, respectively, due to the Company's decision to cease production of its fiberglass windows business in the second quarter of fiscal year 2019.
|
||||||||||||
|
|
|
Years Ended 31 March
|
|||||||||||||||||||
|
(Millions of US dollars)
|
|
2019
|
|
2018
|
|
2017
|
|||||||||||||||
|
Customer A
|
|
$
|
260.5
|
|
|
10.4
|
%
|
|
$
|
246.9
|
|
|
12.0
|
%
|
|
$
|
226.0
|
|
|
10.3
|
%
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
167
|
|
|
|
|
(Millions of US dollars)
|
|
Cash Flow
Hedges
|
|
Foreign
Currency
Translation
Adjustments
|
|
Total
|
||||||
|
Balance at 31 March 2018
|
|
$
|
0.3
|
|
|
$
|
(1.6
|
)
|
|
$
|
(1.3
|
)
|
|
Other comprehensive loss
|
|
(0.1
|
)
|
|
(28.9
|
)
|
|
(29.0
|
)
|
|||
|
Balance at 31 March 2019
|
|
$
|
0.2
|
|
|
$
|
(30.5
|
)
|
|
$
|
(30.3
|
)
|
|
(Millions of US dollars)
|
|
||
|
Cash and cash equivalents
|
$
|
76.9
|
|
|
Accounts and other receivable
|
43.7
|
|
|
|
Inventories
|
39.7
|
|
|
|
Other assets
|
4.1
|
|
|
|
Property, plant and equipment
|
230.3
|
|
|
|
Intangible assets
|
187.0
|
|
|
|
Accounts payable
|
(40.5
|
)
|
|
|
Other liabilities
|
(41.2
|
)
|
|
|
Deferred tax liabilities
|
(84.4
|
)
|
|
|
Net assets acquired
|
$
|
415.6
|
|
|
Goodwill
|
220.0
|
|
|
|
Total consideration
|
$
|
635.6
|
|
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
168
|
|
|
|
|
(Millions of US dollars)
|
Estimated remaining useful life (years)
|
Fair Value
|
||
|
Trade name
|
Indefinite
|
$
|
126.8
|
|
|
Customer relationships
|
13
|
57.8
|
|
|
|
Other intangible assets
|
2 - 13
|
2.4
|
|
|
|
Total
|
|
$
|
187.0
|
|
|
|
Years Ended 31 March
|
||||||
|
|
2019
|
|
2018
|
||||
|
(Millions of US dollars)
|
(Unaudited)
|
|
(Unaudited)
|
||||
|
Net sales
|
$
|
2,506.6
|
|
|
$
|
2,367.0
|
|
|
Income before income taxes
|
329.7
|
|
|
203.6
|
|
||
|
|
Years Ended 31 March
|
||||||
|
|
2019
|
|
2018
|
||||
|
(Millions of US dollars)
|
(Unaudited)
|
|
(Unaudited)
|
||||
|
Net sales
|
$
|
368.3
|
|
|
$
|
348.8
|
|
|
Income before income taxes
|
39.1
|
|
|
29.0
|
|
||
|
|
|
|
James Hardie Industries plc –
Notes to Consolidated Financial Statements (Continued)
|
169
|
|
|
|
|
|
US$ Millions
|
||||||||||
|
Description of Service
|
FY19
|
|
FY18
|
|
FY17
|
||||||
|
Audit fees
1
|
$
|
5.7
|
|
|
$
|
4.3
|
|
|
$
|
3.9
|
|
|
Audit-related fees
2
|
—
|
|
|
—
|
|
|
—
|
|
|||
|
Tax fees
|
—
|
|
|
—
|
|
|
—
|
|
|||
|
All other fees
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
1
|
Audit Fees include the aggregate fees for professional services rendered by our independent registered public accounting firm. Professional services include the audit of our annual financial statements and services that are normally provided in connection with statutory and regulatory filings.
|
|
2
|
Audit-Related Fees include the aggregate fees billed for assurance and related services rendered by our independent registered public accounting firm. Our independent registered public accounting firm did not engage any temporary employees to conduct any portion of the audit of our consolidated financial statements for the fiscal years ended 31 March 2019, 2018 and 2017.
|
|
•
|
changing political and economic conditions;
|
|
•
|
changing laws and policies;
|
|
•
|
the general hazards associated with the assertion of sovereign rights over certain areas in which we conduct our business; and
|
|
•
|
laws limiting or conditioning the right and ability of subsidiaries and joint ventures to pay dividends or remit earnings to affiliated companies.
|
|
•
|
employees may voluntarily or involuntarily exit the Company because of the acquisitions;
|
|
•
|
our management team may have its attention diverted while trying to integrate the acquired businesses;
|
|
•
|
we may encounter obstacles when incorporating the acquired operations into our operations and management and in achieving intended levels of manufacturing quality;
|
|
•
|
differences in business backgrounds, corporate cultures and management philosophies;
|
|
•
|
the ability to integrate or create and enforce uniform standards, controls, procedures, policies and information systems, including without limitation, technological, accounting and record keeping systems;
|
|
•
|
potential unknown liabilities or contingencies and unforeseen increased expenses or delays associated with the acquisition, specifically with respect to licensors, customers, employees,
|
|
•
|
the recording of goodwill and intangible assets that will be subject to impairment testing on a regular basis and potential periodic impairment charges;
|
|
•
|
we may discover previously undetected operational or other issues; and
|
|
•
|
the acquired operations may not otherwise perform as expected or provide expected results.
|
|
•
|
make it more difficult for us to satisfy our debt service obligations or refinance our indebtedness;
|
|
•
|
increase our vulnerability to adverse economic and general industry conditions, including interest rate fluctuations, because a portion of our borrowings are and will continue to be at variable rates of interest;
|
|
•
|
require us to dedicate a substantial portion of our cash flow from operations to payments on our debt, which would reduce the availability of our cash flow from operations to fund working capital, capital expenditures or other general corporate purposes;
|
|
•
|
limit our flexibility in planning for, or reacting to, changes in our business and industry;
|
|
•
|
place us at a disadvantage compared to competitors that may have proportionately less debt;
|
|
•
|
limit our ability to obtain additional debt or equity financing due to applicable financial and restrictive covenants in our debt agreements; and
|
|
•
|
increase our cost of borrowing.
|
|
|
Fiscal Years Ended 31 March
|
|||||||
|
|
2019
|
|
2018
|
|
2017
|
|||
|
Fiber Cement United States and Canada
|
2,592
|
|
|
2,659
|
|
|
2,390
|
|
|
Europe Building Products
1
|
994
|
|
|
80
|
|
|
81
|
|
|
Fiber Cement Australia
|
603
|
|
|
539
|
|
|
484
|
|
|
Fiber Cement New Zealand
|
186
|
|
|
170
|
|
|
155
|
|
|
Fiber Cement Philippines
|
304
|
|
|
261
|
|
|
223
|
|
|
Other Businesses – United States
|
19
|
|
|
35
|
|
|
29
|
|
|
Research & Development, including Technology
|
159
|
|
|
156
|
|
|
156
|
|
|
General Corporate
|
59
|
|
|
60
|
|
|
59
|
|
|
Total Employees
|
4,916
|
|
|
3,960
|
|
|
3,577
|
|
|
1
|
On 3 April 2018, we completed the Fermacell acquisition. As such, the total number of employees fiscal year ended 31 March 2019 for Europe Building Products represent the actual number of people employed for the fiscal year ended 31 March 2019 and not the average number of people employed.
|
|
|
|
|
Common Stock (in the form of CUFS)
|
Australian Securities Exchange
|
|
ADSs
|
New York Stock Exchange
|
|
JHI plc CUFS on ASX
|
|
JHI plc ADS on NYSE
1
|
||||||||||
|
Period
|
High (A$)
|
|
Low (A$)
|
|
Period
|
High (US$)
|
|
Low (US$)
|
||||
|
Fiscal year ended:
|
|
|
|
|
Fiscal year ended:
|
|
|
|
||||
|
31 March 2019
|
24.19
|
|
|
14.38
|
|
|
31 March 2019
|
18.66
|
|
|
10.00
|
|
|
31 March 2018
|
23.85
|
|
|
17.03
|
|
|
31 March 2018
|
18.79
|
|
|
13.55
|
|
|
31 March 2017
|
23.09
|
|
|
17.63
|
|
|
31 March 2017
|
17.30
|
|
|
13.45
|
|
|
31 March 2016
|
20.04
|
|
|
14.15
|
|
|
31 March 2016
|
72.19
|
|
|
10.19
|
|
|
31 March 2015
|
15.67
|
|
|
11.16
|
|
|
31 March 2015
|
68.51
|
|
|
48.39
|
|
|
Fiscal quarter ended:
|
|
|
|
|
Fiscal quarter ended:
|
|
|
|
||||
|
31 March 2019
|
18.92
|
|
|
14.71
|
|
|
31 March 2019
|
13.24
|
|
|
10.51
|
|
|
31 December 2018
|
20.86
|
|
|
14.38
|
|
|
31 December 2018
|
15.42
|
|
|
10.00
|
|
|
30 September 2018
|
23.90
|
|
|
20.53
|
|
|
30 September 2018
|
17.38
|
|
|
14.74
|
|
|
30 June 2018
|
24.19
|
|
|
21.50
|
|
|
30 June 2018
|
18.66
|
|
|
15.99
|
|
|
31 March 2018
|
23.85
|
|
|
21.07
|
|
|
31 March 2018
|
18.79
|
|
|
16.87
|
|
|
31 December 2017
|
22.63
|
|
|
17.27
|
|
|
31 December 2017
|
17.69
|
|
|
13.62
|
|
|
30 September 2017
|
20.50
|
|
|
17.03
|
|
|
30 September 2017
|
15.84
|
|
|
13.55
|
|
|
30 June 2017
|
23.20
|
|
|
19.25
|
|
|
30 June 2017
|
17.28
|
|
|
14.36
|
|
|
Month ended:
|
|
|
|
|
Month ended:
|
|
|
|
||||
|
30 April 2019
|
19.54
|
|
|
17.75
|
|
|
30 April 2019
|
13.76
|
|
|
12.77
|
|
|
31 March 2019
|
18.92
|
|
|
17.42
|
|
|
31 March 2019
|
13.20
|
|
|
12.45
|
|
|
28 February 2019
|
18.38
|
|
|
14.78
|
|
|
28 February 2019
|
13.24
|
|
|
10.97
|
|
|
31 January 2019
|
15.93
|
|
|
14.71
|
|
|
31 January 2019
|
11.71
|
|
|
10.51
|
|
|
31 December 2018
|
16.27
|
|
|
14.38
|
|
|
31 December 2018
|
12.50
|
|
|
10.00
|
|
|
30 November 2018
|
20.09
|
|
|
14.90
|
|
|
30 November 2018
|
14.96
|
|
|
10.83
|
|
|
1
|
Effective 18 September 2015, the beneficial ownership ratio under our ADS program was changed from five CUFS to each ADS to one CUFS to each ADS.
|
|
Service
|
Fees
|
|
Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property
|
Up to US$0.05 per ADS issued
|
|
Cancellation of ADSs
|
Up to US$0.05 per ADS issued
|
|
Distribution of cash dividends or other cash distributions
|
Up to US$0.05 per ADS issued
|
|
Operational and maintenance costs
|
An annual fee of US $0.05 per ADS held on the applicable record date established by the depositary
|
|
•
|
taxes and other governmental charges;
|
|
•
|
registration fees as may from time to time be in effect for the registration of transfers of CUFS generally on the CHESS;
|
|
•
|
expenses for cable, telex and fax transmissions and delivery services;
|
|
•
|
expenses incurred for converting foreign currency into US dollars;
|
|
•
|
fees and expenses incurred in connection with compliance with exchange control regulations and other regulatory requirements applicable to CUFS, deposited securities, ADSs and ADRs; and
|
|
•
|
fees and expenses incurred in connection with the delivery or servicing of CUFS on deposit.
|
|
•
|
the power to delegate their powers to the CEO, any director, any person or persons employed by us or any of our subsidiaries or to a committee of the Board;
|
|
•
|
the power to appoint attorneys to act on our behalf;
|
|
•
|
the power to borrow money on our behalf and to mortgage or charge our undertaking, property, assets, and uncalled capital as security for such borrowings; and
|
|
•
|
the power to do anything that is necessary or desirable for us to participate in any computerized, electronic or other system for the facilitation of the transfer of CUFS or the operation of our registers that may be owned, operated or sponsored by the ASX.
|
|
Provision
|
|
Details
|
|
Power to vote on proposals, arrangements or contracts in which the director is materially interested
|
|
The Company’s Articles of Association provide that a director cannot vote on any resolution concerning a matter in which he has, directly or indirectly, an interest which is material or a duty which conflicts or may conflict with the interests of the Company. A director cannot be counted in the quorum present at a meeting in relation to any such resolution on which the director is not entitled to vote.
Under Irish law, directors who have a personal interest in a contract or a proposed contract with the Company are required to declare the nature of their interest at a meeting of the directors of the Company. The Company is required to maintain a register of such declared interests which must be made available for inspection by the shareholders at general meetings.
|
|
Power to vote on compensation
|
|
The maximum aggregate ordinary remuneration of the non-executive directors is US$2,800,000 per annum and can be increased from time to time by an ordinary resolution. Changes to non-executive director remuneration are recommended by the Remuneration Committee and are approved at a properly convened meeting of the Board (which consists of nine non-executive directors and the CEO).
There is no requirement for our shareholders to approve the remuneration policy. The Company currently intends to continue voluntarily producing a remuneration report.
These provisions are subject to the relevant listing rules of the ASX regarding director remuneration.
|
|
Age limit for retirement or non-retirement
|
|
Our Articles of Association do not include any provisions regarding the mandatory retirement age of a director.
|
|
Number of shares for director’s qualification
|
|
No director will require a share qualification in order to act as a director.
|
|
•
|
in the case of the ASX, shareholder approval for the issue of equity securities which exceed 15% of the number of equity securities on issue (as determined in accordance with the ASX listing rules and subject to the various exemptions set out therein); and
|
|
•
|
in the case of the NYSE, shareholder approval for the issuance of shares that have or will have upon issuance voting power equal to or in excess of 20% of the voting power outstanding before the issuance of such shares (subject to certain exceptions).
|
|
•
|
by instructing CDN, as legal owner of our shares represented by CUFS, how to vote the shares represented by the holder’s CUFS;
|
|
•
|
by directing CDN to appoint itself (or another person) as the nominated proxy pursuant to a voting instruction form provided by the Company; or
|
|
•
|
by converting the holder’s CUFS into our shares and voting the shares at the meeting, which must be undertaken prior to the meeting. However, in order to sell their shares on the ASX thereafter, it will first be necessary to convert them back to CUFS.
|
|
•
|
any person acquires, whether by a series of transactions over a period of time or not, shares or other securities which (taken together with shares or other securities held or acquired by persons acting in concert) carry 30% or more of the voting rights of a relevant company; or
|
|
•
|
any person, who together with persons acting in concert, holds not less than 30% of the voting rights and such person or any person acting in concert with them acquires, in any period of 12 months, additional shares or other securities of more than 0.05% of the total voting rights of the relevant company, such person must extend offers to the holders of any class of equity securities (whether voting or non-voting) and to holders of any class of transferable voting capital in respect of all such equity securities and transferable voting capital.
|
|
•
|
all holders of the securities of an offeree of the same class must be afforded equivalent treatment; moreover, if a person acquires control of a company, the other holders of securities must be protected;
|
|
•
|
the holders of the securities of an offeree must have sufficient time and information to enable them to reach a properly informed decision on the offer; where it advises the holders of securities, the board of the offeree must give its views on the effects of implementation of the offer on employment, conditions of employment and the locations of the offeree’s places of business;
|
|
•
|
the board of an offeree must act in the interests of the company as a whole and must not deny the holders of securities the opportunity to decide on the merits of the offer;
|
|
•
|
false markets must not be created in the securities of the offeree, of the offeror or of any other company concerned by the offer in such a way that the rise or fall of the prices of the securities becomes artificial and the normal functioning of the markets is distorted;
|
|
•
|
an offeror must announce an offer only after ensuring that he or she can fulfill in full any cash consideration, if such is offered, and after taking all reasonable measures to secure the implementation of any other type of consideration;
|
|
•
|
an offeree must not be hindered in the conduct of its affairs for longer than is reasonable by an offer for its securities; and
|
|
•
|
a substantial acquisition of securities (whether such acquisition is to be effected by one transaction or a series of transactions) shall take place only at an acceptable speed and shall be subject to adequate and timely disclosure.
|
|
•
|
such person’s interest was below 3% of our issued share capital prior to such acquisition and equals or exceeds 3% after such acquisition;
|
|
•
|
such person’s interest was equal to or above 3% of our issued share capital before an acquisition or disposition and increases or decreases through an integer of a percentage as a result of such acquisition or disposition (e.g., from 3.8% to 4.3% or from 5.2% to 4.9%); and
|
|
•
|
where such person’s interest was equal to or above 3% of our issued share capital before a disposition and falls below 3% as a result of such disposition.
|
|
•
|
an individual shareholder resident for tax purposes in either a member state of the EU (apart from Ireland) or in a country with which Ireland has a double tax treaty, and the individual is neither resident nor ordinarily resident in Ireland;
|
|
•
|
a corporate shareholder not resident for tax purposes in Ireland nor ultimately controlled, directly or indirectly, by persons so resident and which is resident for tax purposes in either a member state of the EU (apart from Ireland) or a country with which Ireland has a double tax treaty;
|
|
•
|
a corporate shareholder that is not resident for tax purposes in Ireland and which is ultimately controlled, directly or indirectly, by persons resident in either a member state of the EU (apart from Ireland) or in a country with which Ireland has a double tax treaty;
|
|
•
|
a corporate shareholder that is not resident for tax purposes in Ireland and whose principal class of shares (or those of its 75% parent) is substantially and regularly traded on a recognized stock exchange in either a member state of the EU (including Ireland where the Company trades only on the Irish stock exchange) or in a country with which Ireland has a double tax treaty or on an exchange approved by the Irish Minister for Finance; or
|
|
•
|
a corporate shareholder that is not resident for tax purposes in Ireland and is wholly-owned, directly or indirectly, by two or more companies the principal class of shares of each of which is substantially and regularly traded on a recognized stock exchange in either a member state of the EU (including Ireland where the Company trades only on the Irish stock exchange) or in a country with which Ireland has a double tax treaty or on an exchange approved by the Irish Minister for Finance; and
|
|
•
|
provided that, in all cases noted above, the shareholder has made the appropriate non-resident declaration to us prior to payment of the dividend.
|
|
•
|
to the extent that the property of which the gift or inheritance consists is situated in Ireland at the date of the gift or inheritance;
|
|
•
|
where the person making the gift or inheritance is or was resident or ordinarily resident in Ireland at the date of the disposition under which the gift or inheritance is taken; or
|
|
•
|
where the person receiving the gift or inheritance is resident or ordinarily resident in Ireland at the date of the gift or inheritance.
|
|
•
|
furnish our shareholders with annual reports containing consolidated financial statements examined by an independent registered public accounting firm; and
|
|
•
|
furnish quarterly reports for the first three quarters of each fiscal year containing unaudited consolidated financial information in filings with the SEC under Form 6-K.
|
|
|
|
US$
|
|
A$
|
|
Euros
|
|
NZ$
|
|
Other
1
|
|||||
|
Net sales
|
|
63.9
|
%
|
|
12.6
|
%
|
|
14.6
|
%
|
|
3.2
|
%
|
|
5.7
|
%
|
|
Expenses
2
|
|
63.4
|
%
|
|
12.2
|
%
|
|
16.6
|
%
|
|
3.3
|
%
|
|
4.5
|
%
|
|
Liabilities (excluding borrowings)
2
|
|
17.6
|
%
|
|
69.5
|
%
|
|
11.1
|
%
|
|
0.9
|
%
|
|
0.9
|
%
|
|
|
|
US$
|
|
A$
|
|
Euros
|
|
NZ$
|
|
Other
1
|
|||||
|
Net sales
|
|
77.5
|
%
|
|
14.7
|
%
|
|
1.8
|
%
|
|
3.7
|
%
|
|
2.3
|
%
|
|
Expenses
2
|
|
71.9
|
%
|
|
20.8
|
%
|
|
2.0
|
%
|
|
3.3
|
%
|
|
2.0
|
%
|
|
Liabilities (excluding borrowings)
2
|
|
20.8
|
%
|
|
76.4
|
%
|
|
1.0
|
%
|
|
1.1
|
%
|
|
0.7
|
%
|
|
1
|
Comprised of Philippine pesos and Canadian dollars.
|
|
2
|
Liabilities include A$ denominated asbestos liability, which was initially recorded in the fourth quarter of fiscal year 2006. Expenses include cost of goods sold, SG&A expenses, R&D expenses and adjustments to the asbestos liability. See “Section 3 – Risk Factors,” and Note 12 of our consolidated financial statements further information regarding the asbestos liability.
|
|
Geographic Region
|
|
31 March
2019
|
|
31 March
2018
|
||
|
Australia
|
|
62.79
|
%
|
|
49.03
|
%
|
|
United States
|
|
18.12
|
%
|
|
29.31
|
%
|
|
United Kingdom
|
|
3.92
|
%
|
|
4.14
|
%
|
|
Europe (excluding the United Kingdom)
|
|
5.39
|
%
|
|
4.85
|
%
|
|
Asia
|
|
2.94
|
%
|
|
4.22
|
%
|
|
Other
|
|
6.84
|
%
|
|
8.45
|
%
|
|
Size of Holding Range
|
|
CUFS
|
|
Options
|
||||||
|
Holders
|
|
Holdings
|
|
Holders
|
|
Holdings
|
||||
|
1-1,000
|
|
12,294
|
|
|
5,134,448
|
|
|
-
|
|
-
|
|
1,001-5,000
|
|
6,009
|
|
|
13,126,992
|
|
|
-
|
|
-
|
|
5,001-10,000
|
|
795
|
|
|
5,618,022
|
|
|
-
|
|
-
|
|
10,001-100,000
|
|
468
|
|
|
10,433,689
|
|
|
-
|
|
-
|
|
100,001 and over
|
|
63
|
|
|
407,956,754
|
|
|
-
|
|
-
|
|
Totals
|
|
19,629
|
|
|
442,269,905
|
|
|
-
|
|
-
|
|
CUFS holder
|
|
Shares
Beneficially
Owned
|
|
Percentage
of Shares
Outstanding
|
||
|
Commonwealth Bank of Australia
1
|
|
31,083,296
|
|
|
7.03
|
%
|
|
Blackrock Group
2
|
|
24,729,809
|
|
|
5.59
|
%
|
|
OppenheimerFunds, Inc.
3
|
|
23,564,091
|
|
|
5.33
|
%
|
|
The Vanguard Group, Inc.
4
|
|
23,463,934
|
|
|
5.31
|
%
|
|
FMR LLC
5
|
|
22,010,117
|
|
|
4.98
|
%
|
|
Challenger Limited
6
|
|
18,918,753
|
|
|
4.28
|
%
|
|
Schroders plc.
7
|
|
14,529,189
|
|
|
3.29
|
%
|
|
T. Rowe Price Associates, Inc.
8
|
|
13,291,605
|
|
|
3.01
|
%
|
|
1
|
Commonwealth Bank of Australia and its affiliates most recently became a substantial shareholder on 15 August 2014, and through subsequent sales and purchases currently holds 31,083,296 shares as of 21 February 2019, as reported to the Company on 25 February 2019.
|
|
2
|
BlackRock Group most recently became a substantial shareholder on 16 October 2014, and through subsequent sales and purchases currently holds 24,729,809 shares as of 31 December 2018, as reported on a Schedule 13G filed with the SEC on 5 February 2019.
|
|
3
|
OppenheimerFunds, Inc., more recently became a substantial shareholder on 30 June 2016, with a current holding of 23,564,091 shares, as reported to the Company on 20 July 2016.
|
|
4
|
The Vanguard Group, Inc. became a substantial shareholder on 17 August 2018, and through subsequent purchases currently holds 23,463,934 shares as of 31 December 2018, as reported on a Schedule 13G filed with the SEC on 11 February 2019.
|
|
5
|
FMR LLC and its affiliates more recently became a substantial shareholder on 30 January 2019, and through subsequent purchases currently holds 22,010,117 shares as of 31 December 2018, as reported on a Schedule 13G filed with the SEC on 13 February 2019.
|
|
6
|
Challenger Limited became a substantial shareholder on 23 May 2018, and through subsequent purchases currently holds 18,918,753 shares, as reported to the Company on 23 October 2018.
|
|
7
|
Schroders plc. became a substantial shareholder on 1 June 2015 with a current holding of 14,529,189 shares, as reported to the Company on 21 December 2015 on Form TR-1.
|
|
8
|
T. Rowe Price Associates, Inc. became a substantial shareholder on 4 April 2019, with a current holding of 13,291,605 shares, as reported to the Company on 11 April 2019.
|
|
Name
|
|
CUFS Holdings
|
|
Percentage
|
|
Rank
|
|||
|
HSBC Custody Nominees (Australia) Limited
|
|
152,425,939
|
|
|
34.46
|
%
|
|
1
|
|
|
J P Morgan Nominees Australia Pty Limited
|
|
110,384,165
|
|
|
24.96
|
%
|
|
2
|
|
|
Citicorp Nominees Pty Limited
|
|
34,611,986
|
|
|
7.83
|
%
|
|
3
|
|
|
National Nominees Limited
|
|
26,704,615
|
|
|
6.04
|
%
|
|
4
|
|
|
BNP Paribas Nominees Pty Ltd
|
|
25,863,800
|
|
|
5.85
|
%
|
|
5
|
|
|
Citicorp Nominees Pty Limited
|
|
12,088,042
|
|
|
2.73
|
%
|
|
6
|
|
|
BNP Paribas Noms Pty Ltd
|
|
10,914,829
|
|
|
2.47
|
%
|
|
7
|
|
|
Australia Foundation Investment Company Limited
|
|
4,400,000
|
|
|
0.99
|
%
|
|
8
|
|
|
HSBC Custody Nominees (Australia) Limited
|
|
3,455,987
|
|
|
0.78
|
%
|
|
9
|
|
|
BNP Paribas Nominees Pty Ltd
|
|
1,785,000
|
|
|
0.40
|
%
|
|
10
|
|
|
Australian Foundation Investment Company Limited
|
|
1,665,000
|
|
|
0.38
|
%
|
|
11
|
|
|
BNP Paribas Nominees Pty Ltd
|
|
1,407,840
|
|
|
0.32
|
%
|
|
12
|
|
|
Argo Investments Limited
|
|
1,400,000
|
|
|
0.32
|
%
|
|
13
|
|
|
Avanteos Investments Limited
|
|
1,377,083
|
|
|
0.31
|
%
|
|
14
|
|
|
AMP Life Limited
|
|
1,178,069
|
|
|
0.27
|
%
|
|
15
|
|
|
BNP Paribas Noms (NZ) Ltd
|
|
1,158,261
|
|
|
0.26
|
%
|
|
16
|
|
|
Netwealth Investments Limited
|
|
1,134,015
|
|
|
0.26
|
%
|
|
17
|
|
|
UBS Nominees Pty Ltd
|
|
1,059,980
|
|
|
0.24
|
%
|
|
18
|
|
|
HSBC Custody Nominees (Australia) Limited
|
|
834,788
|
|
|
0.19
|
%
|
|
19
|
|
|
Djerriwarrh Investments Limited
|
|
792,000
|
|
|
0.18
|
%
|
|
20
|
|
|
TOTAL
|
|
394,641,399
|
|
|
89.23
|
%
|
|
|
|
|
2001 Plan
|
|
2001 Equity Incentive Plan
|
|
ADR
|
|
American Depositary Receipt
|
|
ADS
|
|
American Depositary Share
|
|
AFFA
|
|
Amended and Restated Final Funding Agreement, as amended from time to time
|
|
AGM
|
|
Annual General Meeting
|
|
AICF
|
|
Asbestos Injuries Compensation Fund
|
|
ASC
|
|
Accounting Standards Codification
|
|
ASIC
|
|
Australian Securities and Investments Commission
|
|
ASU
|
|
Accounting Standards Update
|
|
ASX
|
|
Australian Securities Exchange
|
|
ATO
|
|
Australian Taxation Office
|
|
CDN
|
|
CHESS Depositary Nominees Pty Ltd
|
|
CEO
|
|
Chief Executive Officer
|
|
CFO
|
|
Chief Financial Officer
|
|
CHESS
|
|
Clearing House Electronic Subregister System
|
|
Commonwealth
|
|
The Commonwealth of Australia
|
|
CP Plan
|
|
Company Performance Plan
|
|
CUFS
|
|
CHESS Units of Foreign Securities
|
|
ESG
|
|
Environment, Social & Governance
|
|
EPS
|
|
Earnings Per Share
|
|
FASB
|
|
Financial Accounting Standards Board
|
|
GDPR
|
|
General Data Protection Regulation
|
|
GEM
|
|
Global Exchange Market
|
|
IP Plan
|
|
Individual Performance Plan
|
|
IRS
|
|
United States Internal Revenue Service
|
|
KPMGA
|
|
KPMG Actuarial
|
|
LIBOR
|
|
London Interbank Offered Rate
|
|
LOB
|
|
Limitation on Benefits
|
|
LTI
|
|
Long-Term Incentive
|
|
LTIP
|
|
Long-Term Incentive Plan 2006
|
|
NBSK
|
|
Northern Bleached Softwood Kraft, the Company’s benchmark grade of pulp relative to our US business
|
|
NSW
|
|
New South Wales
|
|
NYSE
|
|
New York Stock Exchange
|
|
OSB
|
|
Oriented Strand Board
|
|
OSHA
|
|
United States Occupational Safety and Health Administration
|
|
PDG
|
|
Primary Demand Growth
|
|
PEL
|
|
Permissible Exposure Limit
|
|
R&D
|
|
Research and Development
|
|
ROCE
|
|
Return on Capital Employed
|
|
RSU
|
|
Restricted Stock Unit
|
|
SEC
|
|
United States Securities and Exchange Commission
|
|
SG&A
|
|
Selling, General and Administrative
|
|
STI
|
|
Short-Term Incentive
|
|
TCJ Act
|
|
US Tax Cuts and Jobs Act
|
|
TSR
|
|
Total Shareholder Return
|
|
and Comprehensive Income (Loss)
(US GAAP)
|
|
Remuneration Report (non US GAAP)
|
|
|
|
|
|
Net sales
|
|
Net sales
|
|
Cost of goods sold
|
|
Cost of goods sold
|
|
Gross profit
|
|
Gross profit
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
Selling, general and administrative expenses
|
|
Research and development expenses
|
|
Research and development expenses
|
|
Asbestos adjustments
|
|
Asbestos adjustments
|
|
Operating income (loss)
|
|
EBIT*
|
|
|
|
|
|
Sum of interest expense and interest income
|
|
Net interest income (expense)*
|
|
Other income (expense)
|
|
Other income (expense)
|
|
Income (loss) before income taxes
|
|
Operating profit (loss) before income taxes*
|
|
|
|
|
|
Income tax (expense) benefit
|
|
Income tax (expense) benefit
|
|
|
|
|
|
Net income (loss)
|
|
Net operating profit (loss)*
|
|
|
||
|
*- Represents non-US GAAP descriptions used by Australian companies.
|
||
|
•
|
Adjusted operating income;
|
|
•
|
Adjusted net income; and
|
|
•
|
Adjusted diluted earnings per share
|
|
|
Fiscal Years Ended 31 March
|
|||||||||||
|
(Millions of US dollars)
|
|
2019
|
|
2018
|
|
2017
|
||||||
|
Operating income
|
|
$
|
351.6
|
|
|
$
|
229.2
|
|
|
$
|
393.2
|
|
|
Excluding:
|
|
|
|
|
|
|
||||||
|
Asbestos:
|
|
|
|
|
|
|
||||||
|
Asbestos adjustments
|
|
22.0
|
|
|
156.4
|
|
|
(40.4
|
)
|
|||
|
AICF SG&A expenses
|
|
1.5
|
|
|
1.9
|
|
|
1.5
|
|
|||
|
Fermacell acquisition costs
|
|
—
|
|
|
10.0
|
|
|
—
|
|
|||
|
Product line discontinuation
|
|
29.5
|
|
|
—
|
|
|
—
|
|
|||
|
Adjusted operating income
|
|
$
|
404.6
|
|
|
$
|
397.5
|
|
|
$
|
354.3
|
|
|
|
Fiscal Year Ended 31 March
|
|||||||||||
|
(Millions of US dollars)
|
|
2019
|
|
2018
|
|
2,017
|
||||||
|
Net income
|
|
$
|
228.8
|
|
|
$
|
146.1
|
|
|
$
|
276.5
|
|
|
Excluding:
|
|
|
|
|
|
|
||||||
|
Asbestos:
|
|
|
|
|
|
|
||||||
|
Asbestos adjustments
|
|
22.0
|
|
|
156.4
|
|
|
(40.4
|
)
|
|||
|
AICF SG&A expenses
|
|
1.5
|
|
|
1.9
|
|
|
1.5
|
|
|||
|
AICF interest (income) expense, net
|
|
(2.0
|
)
|
|
(1.9
|
)
|
|
1.1
|
|
|||
|
Loss on early debt extinguishment
|
|
1.0
|
|
|
26.1
|
|
|
—
|
|
|||
|
Fermacell acquisition costs
|
|
—
|
|
|
10.0
|
|
|
—
|
|
|||
|
Product line discontinuation
|
|
29.5
|
|
|
—
|
|
|
—
|
|
|||
|
Tax adjustments
1
|
|
19.7
|
|
|
(47.3
|
)
|
|
9.9
|
|
|||
|
Adjusted net income
|
|
$
|
300.5
|
|
|
$
|
291.3
|
|
|
$
|
248.6
|
|
|
|
|
|
|
|
|
|
||||||
|
1
Includes tax adjustments related to amortization benefit of certain US intangible assets, asbestos, product line discontinuation, loss on early debt extinguishment, and other tax adjustments
|
||||||||||||
|
|
Fiscal Year Ended 31 March
|
|||||||||||
|
(Millions of US dollars)
|
|
2019
|
|
2018
|
|
2017
|
||||||
|
Adjusted net income
|
|
$
|
300.5
|
|
|
$
|
291.3
|
|
|
$
|
248.6
|
|
|
Weighted average common shares outstanding - Diluted (millions)
|
|
443.0
|
|
|
442.3
|
|
|
443.9
|
|
|||
|
Adjusted diluted earnings per share (US cents)
|
|
68
|
|
|
66
|
|
|
56
|
|
|||
|
Exhibit
Number
|
|
Exhibit Description
|
|
|
Memorandum of Association of James Hardie Industries plc, as amended (filed as Exhibit 99.4 to the Company’s Report on Form 6-K filed 14 August 2018 (Commission File Number 001-15240) and incorporated by reference herein)
|
|
|
|
Articles of Association of James Hardie Industries plc (filed as Exhibit 99.4 to the Company’s Report on Form 6-K filed 14 August 2018 (Commission File Number 001-15240) and incorporated by reference herein)
|
|
|
|
Amended and Restated Deposit Agreement, by and among James Hardie Industries plc, Deutsche Bank Trust Company Americas, as depositary, and the holders and beneficial owners of American depositary shares evidenced by American depositary receipts issued thereunder (filed as Exhibit 99.A to the Company’s Registration Statement on Form F-6 filed on 25 September 2014 (Commission File Number 333-198928) and incorporated by reference herein)
|
|
|
|
Form of Amendment No. 1 to Amended and Restated Deposit Agreement (filed as Exhibit 99(A)(2) to the Company’s Post-Effective Amendment No. 1 to Form F-6 filed on 03 September 2015 (Commission File Number 333-198928) and incorporated by reference herein)
|
|
|
|
Guarantee Trust Deed, dated 19 December 2006, by and between James Hardie Industries N.V. and AET Structured Finance Services Pty Limited (filed as Exhibit 4.12 to the Company’s Post-Effective No. 1 to Form F-4 filed on 17 June 2010 (Commission File Number 333-165531) and incorporated by reference herein)
|
|
|
|
Performing Subsidiary Undertaking and Guarantee Trust Deed, dated 19 December 2006, by and between James Hardie 117 Pty Limited and AET Structured Finance Services Pty Limited (filed as Exhibit 4.14 to the Company’s Post-Effective No. 1 to Form F-4 filed on 17 June 2010 (Commission File Number 333-165531) and incorporated by reference herein)
|
|
|
|
Intercreditor Deed, dated 19 December 2006, by and among The State of New South Wales, James Hardie Industries N.V., Asbestos Injuries Compensation Fund Limited and AET Structured Finance Services Pty Limited (filed as Exhibit 10.34 to the Company’s Post-Effective No. 1 to Form F-4 filed on 17 June 2010 (Commission File Number 333-165531) and incorporated by reference herein)
|
|
|
|
Letter Agreement, dated 21 March 2007, amending the Intercreditor Deed, dated 19 December 2006, by and among The State of New South Wales, James Hardie Industries N.V., Asbestos Injuries Compensation Fund Limited and AET Structured Finance Services Pty Limited (filed as Exhibit 10.35 to the Company’s Post-Effective No. 1 to Form F-4 filed on 17 June 2010 (Commission File Number 333-165531) and incorporated by reference herein)
|
|
|
|
Performing Subsidiary Intercreditor Deed, dated 19 December 2006, by and among The State of New South Wales, James Hardie 117 Pty Limited, Asbestos Injuries Compensation Fund Limited and AET Structured Finance Services Pty Limited (filed as Exhibit 10.37 to the Company’s Post-Effective No. 1 to Form F-4 filed on 17 June 2010 (Commission File Number 333-165531) and incorporated by reference herein)
|
|
|
|
Letter Agreement, dated 21 March 2007, amending the Performing Subsidiary Intercreditor Deed, dated 19 December 2006, by and among The State of New South Wales, James Hardie 117 Pty Limited, Asbestos Injuries Compensation Fund Limited and AET Structured Finance Services Pty Limited (filed as Exhibit 10.38 to the Company’s Post-Effective No. 1 to Form F-4 filed on 17 June 2010 (Commission File Number 333-165531) and incorporated by reference herein)
|
|
|
|
Amending Deed to Guarantee Trust Deed, dated 6 October 2009, by and between James Hardie Industries N.V. and AET Structured Finance Services Pty Limited (filed as Exhibit 2.10 to the Company’s Annual Report on Form 20-F filed on 30 June 2010 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Amending Deed to Performing Subsidiary Undertaking and Guarantee Trust Deed, dated 6 October 2009, by and between James Hardie 117 Pty Limited and AET Structured Finance Services Pty Limited (filed as Exhibit 2.12 to the Company’s Annual Report on Form 20-F filed on 30 June 2010 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Amending Deed (Intercreditor Deed), dated 23 June 2009, by and among The State of New South Wales, James Hardie Industries N.V., Asbestos Injuries Compensation Fund Limited and AET Structured Finance Services Pty Limited (filed as Exhibit 4.36 to the Company’s Annual Report on Form 20-F filed on 30 June 2010 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
Exhibit
Number
|
|
Exhibit Description
|
|
|
Amending Deed (Performing Subsidiary Intercreditor Deed), dated 23 June 2009, by and among The State of New South Wales, James Hardie 117 Pty Limited, Asbestos Injuries Compensation Fund Limited and AET Structured Finance Services Pty Limited (filed as Exhibit 4.39 to the Company’s Annual Report on Form 20-F filed on 30 June 2010 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Indenture, dated 13 December 2017, by and among James Hardie International Finance Designated Activity Company, the guarantors named therein and Deutsche Bank Trust Company Americas (filed as Exhibit 2.13 to the Company’s Annual Report on Form 20-F filed on 22 May 2018 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Form of 4.750% Senior Note due 2025 (filed as Exhibit 2.14 to the Company’s Annual Report on Form 20-F filed on 22 May 2018 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Form of 5.000% Senior Note due 2028 (filed as Exhibit 2.15 to the Company’s Annual Report on Form 20-F filed on 22 May 2018 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Amended and Restated Credit and Guaranty Agreement, dated 13 December 2017, by and among James Hardie International Finance Designated Activity Company and James Hardie Building Products Inc., as borrowers, James Hardie International Group Limited and James Hardie Technology Limited, as guarantors, James Hardie Industries plc, as parent, HSBC Bank USA, National Association, as administrative agent, and the other lender parties thereto (filed as Exhibit 2.16 to the Company’s Annual Report on Form 20-F filed on 22 May 2018 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
364-Day Term Loan and Guaranty Agreement, dated 13 December 2017, by and among James Hardie International Finance Designated Activity Company and James Hardie Building Products Inc., as borrowers, James Hardie International Group Limited and James Hardie Technology Limited, as guarantors, James Hardie Industries plc, as parent, HSBC Bank USA, National Association, as administrative agent, and the other lender parties thereto (filed as Exhibit 2.17 to the Company’s Annual Report on Form 20-F filed on 22 May 2018 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Indenture, dated 4 October 2018, among James Hardie International Finance Designated Activity Company, the guarantors listed therein, Deutsche Bank Trust Company Americas, as Trustee and Registrar and Deutsche Bank AG, London Branch, as Paying Agent and Transfer Agent (filed as Exhibit 99.8 to the Company’s Report on Form 6-K filed 8 November 2018 (Commission File Number 001-15240 and incorporated by reference herein)
|
|
|
|
Form of 3.625% Senior Notes due 2026 ((filed as Exhibit 99.8 to the Company’s Report on Form 6-k filed 8 November 2018 (Commission File Number 001-15240 and incorporated by reference herein)
|
|
|
|
Amended and Restated James Hardie Industries SE 2001 Equity Incentive Plan (filed as Exhibit 4.1 to the Company’s Annual Report on Form 20-F filed on 2 July 2012 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Amended and Restated James Hardie Industries plc Long Term Incentive Plan 2006 (filed as Exhibit 99.5 to the Company’s Report on Form 6-K filed 14 August 2018 (Commission File Number 001-15240 and incorporated by reference herein)
|
|
|
|
Form of Joint and Several Indemnity Agreement among James Hardie N.V., James Hardie (USA) Inc. and certain indemnitees thereto (filed as Exhibit 4.15 to the Company’s Annual Report on Form 20-F filed on 7 July 2005 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Form of Joint and Several Indemnity Agreement among James Hardie Industries N.V., James Hardie Inc. and certain indemnitees thereto (filed as Exhibit 4.16 to the Company’s Annual Report on Form 20-F filed on 7 July 2005 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Form of Deed of Access, Insurance and Indemnity between James Hardie Industries N.V. and supervisory board directors and managing board directors (filed as Exhibit 4.9 to the Company’s Annual Report on Form 20-F filed on 8 July 2008 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
Exhibit
Number
|
|
Exhibit Description
|
|
|
Form of Indemnity Agreement between James Hardie Building Products, Inc. and supervisory board directors, managing board directors and certain executive officers (filed as Exhibit 4.10 to the Company’s Annual Report on Form 20-F filed on 8 July 2008 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Form of Irish law-governed Deed of Access, Insurance and Indemnity between James Hardie Industries SE, a European Company registered in Ireland, and its directors, company secretary and certain senior employees thereto (filed as Exhibit 10.10 to the Company’s Registration Statement on Form F-4 filed on 23 June 2009 (Commission File 333-160177) and incorporated by reference herein)
|
|
|
|
Form of Deed of Access, Insurance and Indemnity between James Hardie Industries plc, and certain indemnitees thereto (filed as Exhibit 4.9 to the Company’s Annual Report on Form 20-F filed on 21 May 2015 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Deed of Release - Unions and Banton, dated 21 December 2005, by and among James Hardie Industries N.V., Australian Council of Trade Unions, Unions New South Wales, and Bernard Douglas Banton (filed as Exhibit 4.23 to the Company’s Annual Report on Form 20-F filed on 29 September 2006 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Deed of Release, dated 22 June 2006, by and between James Hardie Industries N.V. and The State of New South Wales (filed as Exhibit 4.25 to the Company’s Annual Report on Form 20-F filed on 29 September 2006 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Amended and Restated Final Funding Agreement, dated 21 November 2006, by and among James Hardie Industries N.V., James Hardie 117 Pty Ltd, The State of New South Wales and Asbestos Injuries Compensation Fund Limited in its capacity as trustee of the Asbestos Injuries Compensation Fund (filed as Exhibit 99.4 to the Company’s Report on Form 6-K filed on 05 January 2007 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Asbestos Injuries Compensation Fund Amended and Restated Trust Deed, dated 14 December 2006, by and between James Hardie Industries N.V. and Asbestos Injuries Compensation Fund Limited (filed as Exhibit 4.22 to the Company’s Annual Report on Form 20-F filed on 6 July 2007 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Second Irrevocable Power of Attorney, dated 14 December 2006, by and between Asbestos Injuries Compensation Fund Limited and The State of New South Wales (filed as Exhibit 4.26 to the Company’s Annual Report on Form 20-F filed on 6 July 2007 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Deed of Accession, dated 14 December 2006, by and among Asbestos Injuries Compensation Fund Limited, James Hardie Industries N.V., James Hardie 117 Pty Limited and The State of New South Wales (filed as Exhibit 4.27 to the Company’s Annual Report on Form 20-F filed on 6 July 2007 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Amendment to Amended and Restated Final Funding Agreement, dated 6 August 2007, by and among, James Hardie Industries NV, James Hardie 117 Pty Limited, The State of New South Wales and Asbestos Injuries Compensation Fund Limited in its capacity as trustee of the Asbestos Injuries Compensation Fund (filed as Exhibit 4.22 to the Company’s Annual Report on Form 20-F filed on 8 July 2008 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Deed Poll, dated 11 June 2008, amendment of the Asbestos Injuries Compensation Fund Amended and Restated Trust Deed (filed as Exhibit 4.27 to the Company’s Annual Report on Form 20-F filed on 8 July 2008 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Amendment to Amended and Restated Final Funding Agreement, dated 8 November 2007, by and among, James Hardie Industries NV, James Hardie 117 Pty Limited, The State of New South Wales and Asbestos Injuries Compensation Fund Limited in its capacity as trustee of the Asbestos Injuries Compensation Fund (filed as Exhibit 4.23 to the Company’s Annual Report on Form 20-F filed on 8 July 2008 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
Exhibit
Number
|
|
Exhibit Description
|
|
|
Amendment to Amended and Restated Final Funding Agreement, dated 11 June 2008, by and among, James Hardie Industries NV, James Hardie 117 Pty Limited, The State of New South Wales and Asbestos Injuries Compensation Fund Limited in its capacity as trustee of the Asbestos Injuries Compensation Fund (filed as Exhibit 4.24 to the Company’s Annual Report on Form 20-F filed on 8 July 2008 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Amended and Restated Final Funding Agreement - Address for Service of Notice on Trustee, dated 13 June 2008 (filed as Exhibit 4.25 to the Company’s Annual Report on Form 20-F filed on 8 July 2008 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Amendment to Amended and Restated Final Funding Agreement, dated 17 July 2008, by and among, James Hardie Industries NV, James Hardie 117 Pty Limited, The State of New South Wales and Asbestos Injuries Compensation Fund Limited in its capacity as trustee of the Asbestos Injuries Compensation Fund (filed as Exhibit 10.27 to the Company’s Registration Statement on Form F-4 filed on 23 June 2009 (Commission File 333-160177) and incorporated by reference herein)
|
|
|
|
Deed of Confirmation, dated 23 June 2009, by and among James Hardie Industries N.V, James Hardie 117 Pty Limited, The State of New South Wales and Asbestos Injuries Compensation Fund Limited in its capacity as trustee of the Asbestos Injuries Compensation Fund (filed as Exhibit 10.37 to the Company’s Registration Statement on Form F-4/A filed on 10 July 2009 (Commission File 333-160177) and incorporated by reference herein)
|
|
|
|
Amending Agreement (Parent Guarantee), dated 23 June 2009, by and among Asbestos Injuries Compensation Fund Limited, The State of New South Wales and James Hardie Industries N.V. (filed as Exhibit 4.30 to the Company’s Annual Report on Form 20-F filed on 30 June 2010 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Deed to amend the Amended and Restated Final Funding Agreement and facilitate the Authorized Loan Facility, dated 9 December 2010, by and among James Hardie Industries SE, James Hardie 117 Pty Limited, The State of New South Wales and Asbestos Injuries Compensation Fund Limited in its capacity as trustee of each of the Compensation Funds (filed as Exhibit 4.25 to the Company’s Annual Report on Form 20-F filed on 29 June 2011 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
AICF facility agreement, dated 9 December 2010, by and among Asbestos Injuries Compensation Fund Limited, ABN 60 Pty Limited, Amaca Pty Ltd, Amaba Pty Ltd and The State of New South Wales (filed as Exhibit 4.40 to the Company’s Annual Report on Form 20-F filed on 29 June 2011 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Fixed and Floating Charge, dated 9 December 2010, by and among Asbestos Injuries Compensation Fund Limited, ABN 60 Pty Limited, Amaca Pty Ltd, Amaba Pty Ltd and The State of New South Wales (filed as Exhibit 4.41 to the Company’s Annual Report on Form 20-F filed on 29 June 2011 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Deed to amend the Amended and Restated Final Funding Agreement, dated 29 February 2012, by and among James Hardie Industries SE, James Hardie 117 Pty Limited, The State of New South Wales and Asbestos Injuries Compensation Fund Limited in its capacity as trustee of each of the Compensation Funds (filed as Exhibit 4.27 to the Company’s Annual Report on Form 20-F filed on 2 July 2012 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Deed to amend the Amended and Restated Final Funding Agreement, dated 28 March 2012, by and among James Hardie Industries SE, James Hardie 117 Pty Limited, The State of New South Wales and Asbestos Injuries Compensation Fund Limited in its capacity as trustee of each of the Compensation Funds (filed as Exhibit 4.28 to the Company’s Annual Report on Form 20-F filed on 2 July 2012 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Summary of Amendments to Amended and Restated Final Funding Agreement, dated 20 December 2013, by and among, James Hardie Industries NV, James Hardie 117 Pty Limited, The State of New South Wales and Asbestos Injuries Compensation Fund Limited in its capacity as trustee of the Asbestos Injuries Compensation Fund (filed as Exhibit 4.37 to the Company’s Annual Report on Form 20-F filed on 26 June 2014 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
Exhibit
Number
|
|
Exhibit Description
|
|
|
Deed of Amendment, dated 27 February 2015, by and among Asbestos Injuries Compensation Fund Limited, ABN 60 Pty Limited, Amaca Pty Ltd, Amaba Pty Ltd and The State of New South Wales (filed as Exhibit 4.32 to the Company’s Annual Report on Form 20-F filed on 21 May 2015 (Commission File Number 001-15240) and incorporated by reference herein)
|
|
|
|
|
Sale and Purchase Agreement related to XI (DL) Holdings GmbH, dated 7 November 2017, by and among Xella International S.A., as seller, Platin 1391. GmbH (now known as James Hardie Germany GmbH) as purchaser, and James Hardie International Group Limited, as guarantor (filed as Exhibit 4.30 to the Company’s Annual Report on Form 20-F filed on 22 May 2018 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
Deed of Amendment, Amended and Restated Final Funding Agreement, dated 19 December 2017, by and among James Hardie Industries plc, James Hardie 117 Pty Limited, The State of New South Wales and Asbestos Injuries Compensation Fund Limited in its capacity as trustee for each of the Compensation Fund (filed as Exhibit 4.31 to the Company’s Annual Report on Form 20-F filed on 22 May 2018 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Amendment to Sale and Purchase Agreement, dated 13 December 2017, by and among Xella International S.A., as seller, Platin 1391. GmbH (now known as James Hardie Germany GmbH) as purchaser, and James Hardie International Group Limited, as guarantor (filed as Exhibit 4.32 to the Company’s Annual Report on Form 20-F filed on 22 May 2018 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
Second Amendment and Accession Agreement to the Sale and Purchase Agreement related to XI (DL) Holdings GmbH, dated 3 April 2018, by and among Xella International S.A., James Hardie Germany GmbH, James Hardie International Group Limited and James Hardie International Finance Designated Activity Company (filed as Exhibit 4.33 to the Company’s Annual Report on Form 20-F filed on 22 May 2018 (Commission File 001-15240) and incorporated by reference herein)
|
|
|
|
List of significant subsidiaries of James Hardie Industries plc
|
|
|
|
Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
|
Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
|
|
Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
|
|
Consent of Ernst & Young LLP, independent registered public accounting firm
|
|
|
|
Consent of KPMG Actuarial
|
|
|
101.INS*
|
|
XBRL Instance Document
|
|
101.SCH*
|
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL*
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.DEF*
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB*
|
|
XBRL Taxonomy Extension Labels Linkbase Document
|
|
Exhibit
Number
|
|
Exhibit Description
|
|
101.PRE*
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
|
|
|
|
|
|
|
JAMES HARDIE INDUSTRIES plc
|
||
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ JACK TRUONG
|
|
|
|
|
|
Jack Truong
|
|
Date: 21
May 2019
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
JAMES HARDIE INDUSTRIES plc
|
||
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ MICHAEL N. HAMMES
|
|
|
|
|
|
Michael N. Hammes
|
|
Date: 21
May 2019
|
|
|
|
Chairman
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|